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ABSTRACT 
Brian C. Ferslew:  Importance of Hepatic Transporters, Including Basolateral Efflux Proteins, in Drug 
Disposition: Impact of Phospholipidosis and Non-Alcoholic Steatohepatitis  
 (Under the direction of Kim L.R. Brouwer) 
 
 The objective of this dissertation project was to develop preclinical and clinical tools to assess the 
impact of liver pathology on transporter-mediated systemic and hepatic exposure to medications.  A 
translational approach utilizing established pre-clinical hepatic transport systems, mathematical modeling, 
and a pivotal in vivo human study was employed.  A novel application of rat sandwich-cultured 
hepatocytes (SCH) was developed to evaluate the impact of drug-induced phospholipidosis on the 
vectorial transport of probe substrates for hepatic basolateral and canalicular transport proteins.  Results 
indicated that rat SCH treated with prototypical hepatic phospholipidosis inducers are a sensitive and 
selective model for drug-induced phospholipidosis; both organic anion transporting polypeptide-mediated 
uptake and bile salt export pump-mediated biliary excretion were reduced after the onset of 
phospholipidosis.  Enalapril currently is being investigated for its anti-fibrotic effects in the treatment of 
patients with non-alcoholic steatohepatitis (NASH).  Although the basolateral uptake transporters 
responsible for enalapril entry into the hepatocyte are well characterized, less is known about 
translocation of enalaprilat (the active metabolite) across the basolateral membrane into the systemic 
circulation.  Studies were conducted using membrane vesicles prepared from transporter-expressing cells 
and a novel human SCH efflux protocol to assess the involvement of two hepatic basolateral efflux 
transporters known to be up-regulated in inflammatory liver disease [i.e., multidrug resistance-associated 
protein (MRP)3 and MRP4]; enalaprilat is transported across the basolateral membrane, in part, by 
MRP4.  A novel clinical protocol was developed using morphine glucuronides as a probe for MRP3 
function to determine the impact of altered hepatic transporter expression on drug disposition in patients 
iv 
 
with NASH.  A physiologically-based mathematical model was constructed to inform study design.  
Systemic concentrations of morphine glucuronides were increased significantly in patients with NASH 
compared to healthy subjects, as predicted by the model.  This work provides a mechanistic 
understanding of the impact that hepatic transporter function has on the disposition of drugs and 
endogenous compounds under normal conditions and in response to altered liver function due to drug-
induced phospholipidosis or liver disease, specifically non-alcoholic steatohepatitis.  This knowledge is 
fundamental to safe and efficacious dosing of medications that depend on these transporters for 
disposition and/or elimination. 
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CHAPTER 1.  Introduction: Drug Transport in the Liver 
 
Hepatic Physiology: Liver Structure and Function 
The liver is a major organ involved in drug metabolism and excretion. The hepatocyte, the 
predominant cell type in the liver, is responsible for selective uptake, metabolism via phase I enzymes 
(e.g. cytochrome P450 [CYP], flavin-containing monooxygenase [FMO], carboxylesterase [CES]) and/or 
phase II conjugation systems, and excretion of numerous drugs, xenobiotics and endogenous compounds. 
It is now appreciated that many compounds cannot cross cellular plasma membranes by simple diffusion, 
and that transport proteins may be required for clearance of drugs from hepatic sinusoidal blood or 
excretion of parent compound and/or metabolite(s) from the hepatocyte into bile. Hepatocytes are 
polarized cells that extend in chord-like arrays throughout the liver, and are characterized by plasma 
membrane domains with distinct physiological functions: the sinusoidal (basolateral) domain has 
specialized proteins responsible for the exchange of compounds with the sinusoidal plasma in the space of 
Disse, while the canalicular (apical) domain has distinct proteins responsible for excretion of compounds 
into the lumen of the bile canaliculi. (Figure 1.1) Several members of the solute carrier (SLC) and ATP-
binding cassette (ABC) transport protein superfamilies are involved in the uptake and efflux across the 
basolateral and apical membranes of hepatocytes. Members of the SLC family are typically uptake 
transporters that use ion gradients resulting from secondary or tertiary active transport processes to drive 
translocation of drugs across membranes. Members of the ABC superfamily function primarily as active 
efflux pumps that are driven by energy provided by the direct hydrolysis of ATP to move compounds out  
 
This work has been published in Drug Transporters: Molecular Characterization and Role in Drug 
Disposition, Second Edition and is presented in the style of that book. Edited by Guofeng You and 
Marilyn E. Morris. © 2014 John Wiley & Sons, Inc. Published 2014 by John Wiley & Sons, Inc. 
Reprinted with permission of John Wiley and Sons.  All rights reserved 
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of the hepatocyte. Human transport genes/proteins are identified by upper case letters (e.g ABCC2, 
MRP2), whereas genes/proteins from preclinical species are identified by lowercase letters (e.g. Abcc2, 
Mrp2).  
In this chapter we will review the substrate specificity for uptake and efflux transporters 
expressed in the liver, and discuss the impact of driving force(s), as well as translational and 
posttranslational regulation on hepatic transport. In addition, an overview of methodology and approaches 
currently in use or under development to evaluate the function of hepatic transport proteins is provided. 
Finally, the clinical significance of altered hepatic transport with respect to disease states and/or drug 
interactions will be discussed. The major focus of this chapter is on human proteins and clinically relevant 
drug-drug interactions (DDIs). 
Hepatic Uptake Transport Proteins 
The liver is the interface between the intestine and the systemic circulation; hepatic basolateral 
uptake is the first step of hepatobiliary elimination. Members of the SLC10, SLC22 and SLCO gene 
families represent the predominant transport proteins known to mediate uptake of xeno- and endobiotics 
across the basolateral membrane of the hepatocyte. 
NTCP (SLC10A1) The sodium taurocholate cotransporting polypeptide (NTCP) is expressed exclusively 
in the liver. NTCP, which belongs to the SLC10 family, mediates Na
+
-dependent bile acid uptake into 
human liver against a 5- to 10-fold concentration gradient and with a 2:1 sodium-taurocholate (TC) 
stoichiometry. The substrate specificity of NTCP primarily comprises bile acids such as taurocholate, as 
well as conjugated di- and trihydroxy-bile acids, but this protein also transports the cholephilic 
compounds bromosulfophthalein (BSP) and estrone-3-sulfate (E1S). Statins such as fluvastatin, 
rosuvastatin, and pitavastatin have been identified as substrates of NTCP. However, recent studies 
indicate that NTCP only contributes modestly to overall statin accumulation in human hepatocytes. 
1,2
 
Interestingly, NTCP*2, a variant resulting in a protein with no ability to transport bile acids, demonstrated 
increased transport of rosuvastatin in vitro. 
2
 In addition to bile acid transport, NTCP is a functional 
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receptor for hepatitis B and hepatitis D virus, consistent with the liver tropism of hepatitis B and D virus 
and exclusive liver expression of NTCP. 
3
 
OATPs (SLCOs) Organic anion transporting polypeptides (OATPs) play an essential role in the hepatic 
uptake of many drugs, and it is now well established that these transport proteins can impact the 
pharmacokinetic and pharmacodynamic profile of drugs. The location of OATPs on the basolateral 
membrane of the hepatocyte often renders them the rate-limiting step in the hepatobiliary clearance of 
drugs, thus controlling the hepatic elimination and/or oral bioavailability of various compounds. In 
contrast to NTCP, OATPs operate in a Na
+
-independent manner, possibly as electroneutral exchangers 
with intracellular bicarbonate, glutathione, or glutathione conjugates. 
4
 Human OATPs are not exact 
orthologs of rodent Oatps, which may explain some discrepancies in the hepatic disposition of substrates 
between preclinical species and humans. OATP1B1, OATP1B3, and OATP2B1 have been identified on 
the liver basolateral membrane domain. OATP1B1 is exclusively expressed in liver; OATP1B3 is 
predominantly expressed in the liver whereas OATP2B1 is widely expressed throughout the body. 
OATP1A2 also has been identified in liver tissue; however, expression appears to be exclusively 
localized in cholangiocytes, suggesting that OATP1A2 may be involved in reabsorption of compounds 
excreted into bile. 
5
 OATPs are characterized by a largely overlapping and broad substrate spectrum (see 
Table 1.1). The importance of OATPs in the hepatic uptake of statins, DDIs and Rotor syndrome has 
received considerable attention in recent years (see Rotor Syndrome and Drug Interactions in 
Hepatobiliary Transport sections)  
OATs (SLC22) Organic anion transporters (OATs) are members of the SLC22 family. OATs mediate the 
uptake of negatively charged endogenous and xenobiotic compounds in exchange for intracellular organic 
anions including dicarboxylate, lactate or short-chain fatty acids. The majority of data regarding OAT 
transport has been generated with respect to renal drug transport due to the substantial expression of 
OATs in the kidney. Of the six human members, OAT2 (SLC22A7) is predominantly expressed on the 
basolateral membrane of hepatocytes, but also has been found on the basolateral membrane of renal 
proximal tubule cells. Endogenous substrates of human OAT2 include nucleosides and nucleotides, 
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prostaglandins, dehydroepiandrosterone sulfate (DHEAS), E1S, L-ascorbate and urate. Certain anticancer 
drugs as well as H2 receptor antagonists and antibiotics have been identified as substrates of this 
transporter (see Table 1.1). Human OAT2 has 79% sequence identity to its rat ortholog Oat2, but subtle 
differences in substrate specificity exist. OAT7 (SLC22A9) is expressed exclusively in the basolateral 
membrane of the liver and has been shown to transport sulfated hormones such as E1S and DHEAS with 
high affinity. 
6
 Unlike other OAT proteins, OAT7 does not transport para-aminohippurate, α-
ketoglutarate, prostaglandins, cyclic nucleotides, or salicylic acid.  
OCTs and OCTNs (SLC22A) Organic cation transporters (OCTs) and organic cation/carnitine 
transporters (OCTNs) are members of the SLC22 family and are polyspecific transporters that mediate the 
electrogenic and Na
+
-independent transport primarily of small (<400 Da) cations or neutral molecules. 
Human OCT1 (SLC22A1), OCT3, and OCTN2 (SLC22A5) are the isoforms expressed on the basolateral 
membrane of hepatocytes. While OCT1 is almost exclusively expressed in liver in humans, OCT3 and 
OCTN2 have a much broader tissue distribution including kidney, brain, skeletal muscle, and placenta. 
OCT1 exhibits a broad substrate spectrum that includes endogenous compounds (e.g., choline, 
acetylcholine and monoamine neurotransmitters) and drugs such as some antivirals, H2-receptor 
antagonists, and the antidiabetic metformin. Substrates for OCT3 appear to be more limited to 
endogenous substances and neurotransmitters.  
OSTα/β (SLC51A/B) The organic solute transporter (OST) α/β is a heteromeric transporter expressed in 
small intestine, kidney, testis, and adrenal gland. In the liver, OSTα/β is expressed on the basolateral 
membrane. Substrate transport is bidirectional depending on the electrochemical gradient of the 
substrate.
7
 The expression of this protein in organs involved in bile acid homeostasis together with 
regulation by the bile acid sensing farnesoid X receptor (FXR), and inherent ability to transport bile acids, 
suggest that OSTα/β may be associated with bile acid malabsorption or cholestasis. 
Hepatic Efflux Transport Proteins 
Hepatic excretion of xeno- and endobiotics from the liver may occur across the basolateral 
membrane into sinusoidal blood, or across the canalicular (apical) membrane into the bile which flows 
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through fine tubular canals between adjacent liver cells (see Figure 1.1). A list of substrates for human 
hepatic export proteins is provided (see Table 1.2). 
Canalicular Transport Proteins 
Canalicular transporters responsible for the biliary excretion of drugs and metabolites primarily 
belong to the ATP-binding cassette (ABC) family of transport proteins, which mediate ATP-dependent 
transfer of solutes. In addition, multidrug and toxin extrusion 1 (MATE1) is a protein belonging to the 
solute carrier family involved in the transport of organic cations across the canalicular membrane.   
MDR1 P-glycoprotein (ABCB1) Multidrug resistance protein 1 P-glycoprotein (P-gp) was first 
identified in multidrug-resistant (MDR) tumor cells. 
8
 P-gp represents the most widely studied ABC 
transport protein and is responsible for biliary excretion of bulky hydrophobic and cationic substrates 
including chemotherapeutic agents, cardiac glycosides, cyclosporin A and HIV protease inhibitors (PIs). 
P-gp modulators have been evaluated to increase oral bioavailability, tissue concentrations and drug 
sensitivity for a number of compounds, especially in cancer chemotherapy where overexpression of P-gp 
in the tumor is one reason for therapeutic failure. Unfortunately, this strategy has had limited success. 
9
  
MDR3 (ABCB4) Multidrug resistance protein 3 (MDR3) plays a crucial role in basic liver physiology in 
humans and rats. MDR3, a phospholipid flippase, is involved in the biliary secretion of phospholipids, 
cholesterol and cholephilic compounds, which are responsible for the formation of micelles that solubilize 
bile acids in the lumen of the bile canaliculi. 
10
 Mutations in the MDR3 gene lead to progressive familial 
intrahepatic cholestasis type 3 (PFIC3), a disease that is characterized by increased γ-
glutamyltranspeptidase levels, ductular proliferation and inflammatory infiltration that can progress to 
biliary cirrhosis.   
BSEP (ABCB11) The bile salt export pump (BSEP), mediates the biliary excretion of conjugated and 
unconjugated bile acids. Although bile acids appear to be the predominant substrates, BSEP also can 
transport the non-bile acid substrate pravastatin. 
11
 Patients with progressive familial intrahepatic 
cholestasis (PFIC) type 2 (PFIC2) have mutations in the ABCB11 gene that result in proteosomal and 
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lysosomal degradation of the misfolded proteins and a complete absence or reduced expression of 
functional BSEP on the apical membrane. 
12
 Increased intracellular concentrations of detergent-like bile 
acids secondary to inhibition of BSEP has been suggested as one mechanism for drug-induced liver 
injury. 
13
 
MRP2 (ABCC2) Multidrug resistance-associated protein 2 (MRP2) is a major xenobiotic efflux pump on 
the canalicular membrane. MRP2 plays a key role in the biliary excretion of organic anions, including 
bilirubin-diglucuronide, glutathione conjugates, sulfated bile acids, and divalent bile acid conjugates, as 
well as numerous drugs, including indomethacin, methotrexate, telmisartan, many glucuronide and sulfate 
conjugates of drugs such as acetaminophen-glucuronide and -sulfate, and even metal complexes such as 
arsenic-glutathione conjugates. The absence of functional MRP2 leads to Dubin-Johnson syndrome, 
which is associated with defective biliary excretion of bilirubin. 
14
 Animals with hereditary conjugated 
hyperbilirubinemia [MRP2-deficient rats (GY/TR
-
) and Eisai hyperbilirubinemic rats (EHBR)] exhibit 
increased expression of Mrp3, an efflux transporter on the basolateral membrane that provides a 
compensatory mechanism to enable excretion of Mrp2 substrates into the systemic circulation, thus 
helping to avoid excessive accumulation of organic anions in the hepatocyte (see Dubin-Johnson 
Syndrome section). 
15,16
 
BCRP (ABCG2) Breast cancer resistance protein (BCRP), a half-transport protein that forms a functional 
heterodimer, is expressed on the canalicular membrane of the hepatocyte and mediates the transport of 
E1S and various other sulfated steroidal compounds as well as many fluoroquinolone analogs, glyburide 
and rosuvastatin. Additionally, BCRP is involved in the development of resistance to a variety of 
anticancer agents, such as SN-38, mitoxantrone, and doxorubicin. 
17,18
 
MATEs (SLC47A) Multidrug and toxin extrusion protein 1 (MATE1), is expressed on the canalicular 
membrane of hepatocytes. In contrast to the other canalicular transporters discussed above, MATE1 
belongs to the solute carrier family and is thought to function as a proton exchanger. MATE1 substrates 
include the organic cations guanidine and thiamine, as well as numerous drugs. 
19
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Basolateral Efflux Transport Proteins 
Members of the ATP-dependent MRP subfamily of transport proteins represent the major class of 
export proteins on the hepatic basolateral membrane. MRP 1, 3, 4, 5 and 6 are involved in the cellular 
transport of both hydrophobic uncharged molecules and hydrophilic anionic compounds (see Table 1.2). 
20
 In addition to these MRPs, other transport proteins on the basolateral membrane may play a role in 
hepatic basolateral excretion. For example, the OATPs and OSTα/β have been hypothesized to function 
as basolateral export proteins under certain conditions, although the in vivo role of these transport proteins 
in basolateral excretion of drugs from the hepatocyte remains to be elucidated. 
21,22
  
MRP1 (ABCC1) Multidrug resistance-associated protein 1 (MRP1) is responsible for efflux of various 
organic anions, including glucuronide, glutathione, and sulfate-conjugated drugs, doxorubicin, etoposide 
glucuronide, glutathione-conjugated chlorambucil and E1S. Although MRP1 expression is very low on 
the basolateral membrane in the healthy human liver, it is highly inducible during severe liver injury and 
up-regulated in dividing hepatocytes; therefore, MRP1 may play a role in liver protection. 
23
 
MRP3 (ABCC3) Multidrug resistance-associated protein 3 (MRP3) is involved in the hepatic excretion of 
glucuronide conjugates (e.g. acetaminophen-glucuronide, estradiol-17β-glucuronide and morphine-3 and 
6-glucuronides) as well as bilirubin, methotrexate and some conjugated bile acids. Expression of MRP3 
in normal liver is relatively low, but MRP3 expression is increased markedly in the absence of functional 
MRP2, such as in patients with Dubin-Johnson syndrome (see Dubin-Johnson Syndrome section). 
Excretion of glucuronide conjugates across the basolateral membrane in the absence of functional MRP2 
may play a protective role by preventing the toxic accumulation of both endogenous and exogenous 
chemicals in the hepatocyte. 
MRP4 (ABCC4) Multidrug resistance-associated protein 4 (MRP4) is involved in the transport of 
adefovir, bile acids (including glycine- and taurine-conjugated forms), prostaglandins and leukotrienes. 
MRP4 expression under normal conditions is relatively low, but is induced in inflammatory, cholestatic 
and necrotic hepatic states, as well as in critical illness. 
24-25
 MRP4 function recently was postulated to 
modulate efficacy and toxicity of anticancer drugs in HIV-infected patients treated with nelfinavir.
 26
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Additional studies are required to fully elucidate the role of MRP4 in hepatic and systemic disposition of 
drugs and metabolites in healthy individuals and patients with hepatic disease.  
MRP5 and MRP6 (ABCC5 and ABCC6) Little is known about the physiologic relevance of multidrug 
resistance-associated proteins 5 and 6 (MRP5 and MRP6, respectively) in the hepatic disposition of drugs 
and metabolites in human liver. MRP5 transports adefovir, cyclic-AMP and -GMP, 6-mercaptopurine, 
folate and 6-thioguanine. In humans, inflammatory conditions secondary to acetaminophen overdose, 
resulted in induction of MRP5, as well as MRP1, MRP4, BCRP and P-gp. 
27
 MRP5 may play a crucial 
role in cellular protection, nucleotide homeostasis and signaling. MRP6 transports glutathione conjugates 
and the endothelin receptor antagonist, BQ-123, but its functional role in hepatic transport remains to be 
elucidated. 
28
  
Regulation of Hepatic Drug Transport Proteins  
Transcriptional Regulation  
Due to their role in cellular homeostasis of both endogenous and exogenous molecules, transport 
proteins are tightly regulated through multiple processes including translational and posttranslational 
mechanisms. Transcriptional regulation occurs through a large family of nuclear receptors (NRs) that are 
involved in developmental, physiological and pathophysiological responses. For example, bilirubin and 
bile acids have been shown to regulate transcription of transport proteins involved in their own 
disposition through binding to NRs. In addition to endogenous compounds, many xenobiotics interact 
with NRs and the resulting complexes bind to the regulatory region of genes, recruit co-regulators and 
regulate polymerase II binding and activity at the target promoters to modulate gene expression. The 
following sections give an overview of the general role of NRs with regard to regulation of hepatic drug 
transport proteins; Table 1.3 summarizes current knowledge about the regulation of transport proteins by 
specific NRs. At present, most of our knowledge is based on animal and in vitro models.  
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AhR Aryl hydrocarbon receptor (AhR) has a large number of known ligands, including environmental 
chemicals such as polyaromatic hydrocarbons and dioxins, as well as natural dietary compounds and 
endogenous metabolites. 
29
 
CAR Constitutive androstane receptor (CAR) is a nuclear hormone receptor that is constitutively active 
even in the absence of a ligand. However, CAR can be regulated by chemical agonists as well as inverse 
agonists. After a ligand binds, CAR translocates to the nucleus where it binds to retinoid X receptor 
(RXR) and activates genes containing a phenobarbital response element.  
FXR Farnesoid-X receptor (FXR) is an intracellular bile acid sensor that plays an important role in bile 
acid and lipid homeostasis, fat and glucose metabolism, and inflammation. One of the main functions of 
FXR in the liver is the reduction of the hepatic bile acid burden. Activation of FXR by bile acids inhibits 
bile acid synthesis through small heterodimer partner (SHP)-mediated repression of transcription of 
CYP7A1, the rate-limiting enzyme for conversion of cholesterol to bile acids. Activation of FXR in the 
intestine results in induction of fibroblast growth factor (Fgf)-15, which translocates to the liver where it 
activates hepatic FGF receptor 4, which leads to inhibition of hepatic bile acid synthesis. 
30
 In vivo models 
confirm the complimentary roles of FXR and Fgf-15 in the liver and intestine, where activation of 
intestinal FXR protects mice from cholestatic liver injury after bile duct ligation. 
31
 
Nrf2 NFE2-related factor 2 (Nrf2) is a transcription factor that is a crucial regulator of cellular redox 
homeostasis, and plays an important role in protecting cells from oxidative stress. Nrf2 normally is 
retained in the cytoplasm by associating with the actin-kelch-like-ECH-associated protein 1 (Keap1). 
However, under oxidative stress, this interaction is disrupted and Nrf2 translocates into the nucleus to 
activate antioxidant-responsive elements in the promoter of target genes. 
32
 Typical Nrf2 target genes 
include genes involved in redox homeostasis such as superoxide dismutase, catalase, or glutathione 
peroxidase. 
33
 However, there is increased recognition that Nrf2 regulates drug metabolizing enzymes and 
drug transporters. 
34
 
PXR pregnane X receptor (PXR) is activated by a variety of endogenous and dietary compounds as well 
as pharmaceuticals. PXR is the key transcriptional regulator of CYP-3A isozymes, and it also is involved 
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in the regulation of a number of transport proteins. Upon binding of ligands, PXR translocates into the 
nucleus, heterodimerizes with RXR and binds to response elements in the promoter region of target 
genes. 
35
 In addition to its role in detoxification and transport, PXR may be involved in glucose and lipid 
metabolism and the pathogenesis of metabolic diseases. 
36
 
PPARs Peroxisome proliferator-activated receptors (PPARs) are a group of NRs that are key regulators 
of glucose and lipid homeostasis, cell proliferation, differentiation, and inflammatory response. The three 
main subtypes are PPARα, PPARγ and PPARδ. Endogenous ligands include fatty acids and eicosanoids, 
while some drugs (e.g., fibrates and thiazolindinediones) as well as environmental chemicals (e.g., 
phthalates [plasticizers] and perfluorinated fatty acids) act as exogenous ligands.  
HNFs Hepatocyte nuclear factors (HNFs) are involved in regulation of the basal expression of many 
genes and are known as master transcription factors because they are able to regulate other NRs and 
transcription factors. HNFs are involved in organ development and important cellular functions such as 
metabolism of glucose, bile acids, fatty acids, and drugs. Members of the HNF family are ubiquitously 
expressed; HNF1α and 4α are liver-enriched transcription factors.  
Post-Translational Regulation 
In addition to transcriptional processes, post-translational regulation through phosphorylation, 
glycosylation, ubiquitination, SUMOylation and/or insertion/retrieval of transport proteins into/from the 
plasma membrane allows short-term regulation of membrane transport by altering the number or activity 
of transport proteins in the plasma membrane. Transport proteins stored in intracellular vesicles are 
targeted to, and fuse with, the correct plasma domain (i.e. apical or basolateral) in response to appropriate 
stimuli; when the stimulus is withdrawn or another opposing stimulus is applied, the transporters are 
removed from the membrane by endocytosis. After endocytosis, the transport proteins are degraded via 
the lysosomal or proteasomal pathway, or remain in intracellular storage vesicles until restimulation, 
when they are again expressed on the plasma membrane. In summary, the number of transport proteins on 
the cell surface is regulated by de novo synthesis, exocytotic insertion of proteins from cytoplasmatic 
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vesicles into the plasma membrane, endocytotic retrieval from the plasma membrane, and protein 
degradation. 
Apical transport proteins Because of the central role of BSEP in bile acid transport and enterohepatic 
circulation of bile acids, trafficking of this transporter has been studied extensively. Short-term regulation 
resulting in rapid insertion and retrieval into and from the canalicular membrane has been observed in 
response to various stimuli including hormones, bile salts, or oxidative stress. 
37-40
 For example, treatment 
of rats with bile acids or cAMP resulted in a microtubule-dependent mobilization of intracellularly 
sequestered Bsep to the canalicular membrane within minutes. 
41,42
 In addition, activation of p38MAP 
kinase and subsequent translocation of Bsep to the canalicular membrane has been proposed as the 
underlying mechanism for the choleretic effect observed after administration of certain bile acids such as 
tauroursodeoxycholic acid (TUDCA). 
43
 In addition to exocytosis, internalization in response to various 
stimuli has been reported. For example, activation of Ca
2+
-dependent PKC isoforms resulted in retrieval 
of Bsep from the canalicular membrane and induced cholestasis in the isolated perfused rat liver. 
44
 
Similar to BSEP, MRP2/Mrp2 internalization/insertion in the canalicular membrane has been 
demonstrated in response to various stimuli such as glutathione (GSH) depletion, lipopolysaccharide 
(LPS) administration, or cAMP treatment. 
45,46
 Infusion of taurochenodeoxycholic acid (TCDCA) in bile 
duct cannulated rats, a model of bile acid-induced cholestasis, resulted in reduced bile flow and Mrp2 
internalization. 
47
 Taurolithocholic acid (TLCA) also resulted in intracellular retrieval of Mrp2, while 
TUDCA increased Mrp2 expression and function at the canalicular membrane and counteracted the effect 
of TLCA via a PKC-dependent mechanism. 
48
  
It is now well recognized that Mrp2 localization is dependent on the interaction with the 
anchoring protein radixin 
49
, a member of the ezrin-radixin-moesin family of proteins that cross-links 
actin filaments with integral membrane proteins and transitions between an active phosphorylated, 
membrane-anchoring (p-radixin) and an inactive dephosphorylated (radixin) form. Disruption of 
interaction between MRP2/Mrp2 and radixin results in MRP2/Mrp2 internalization, as demonstrated in 
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patients with primary biliary cirrhosis, in rodent experimental cholestatic models, or in rat liver after LPS 
treatment. 
47,50,51
  
For both MRP2/Mrp2 and BSEP/Bsep, osmolarity plays an important role in regulating 
localization. In perfused rat livers, hypo-osmotic solutions increased taurocholate biliary excretion due to 
the increased translocation of Bsep to the canalicular membrane, while hyperosmolarity resulted in 
endocytic retrieval and reduced biliary excretion. 
52
 Similarly, under hyper-osmotic conditions, Mrp2 
resides intracellularly, whereas hypo-osmotic conditions result in Mrp2 translocation to the plasma 
membrane. 
53
  
Basolateral transport proteins Phosphorylation of human and rodent OATPs/Oatps affects membrane 
expression of these proteins. 
54,55
 Activation of protein kinase C (PKC) results in internalization and 
degradation of human OATP2B1. 
56
 Similarly, the phosphorylation state of Ntcp determines whether this 
protein is localized on the basolateral membrane or in an intracellular endosomal compartment. Cyclic 
AMP treatment stimulates PI3K and PKC resulting in dephosphorylation and translocation of Ntcp from 
the cytosol to the basolateral membrane. 
57,58
  In addition to cAMP, perfusion of TCDCA, but not TC or 
TUDCA, in isolated perfused rat liver studies resulted in Ntcp retrieval from the plasma membrane, 
which may be a protective mechanism to reduce the hepatic uptake of bile acids during periods of 
increased exposure to portal bile acids. 
59
 cAMP-mediated short-term regulation of MRP3/Mrp3, with 
increased plasma membrane expression and function of this protein, has been demonstrated in human and 
rat hepatocytes. 
60
  
Taken together, transcriptional and posttranslational regulation allows fine tuning of transport 
processes and adaptation to varying physiological and non-physiological conditions. Regulation processes 
vary depending on the transport protein, species, and even tissue. One challenge in interpreting the results 
of these studies is whether the data obtained in vitro can readily be translated to complex organ systems.  
Disease State Alterations in Hepatic Transport Proteins 
Genetic mutations of transport proteins can result in disease through dysfunctional excretion and 
accumulation of toxic endogenous and/or exogenous compounds. In addition, underlying disease 
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processes themselves can influence transport protein expression, localization, and function, and thus 
result in altered pharmacokinetics and/or pharmacodynamics.  
Cholestasis 
A major function of the liver is the synthesis of cholesterol and bile acids. In humans, the rate-
limiting step in formation of bile after synthesis of bile acids is the efflux across the hepatic canalicular 
membrane via BSEP. PFIC is a heterogeneous group of autosomal recessive disorders with disrupted bile 
formation resulting in cholestasis early in childhood and adolescence. PFIC can be classified into three 
different types based on the underlying mechanism of disease. PFIC type 1 is caused by a mutation in the 
gene encoding the familiar intrahepatic cholestasis 1 protein (FIC1, ATP8A1). ATP8A1 plays a role in 
maintaining the enrichment of phosphatidylserine and -ethanolamine in the inner leaflet of the canalicular 
plasma membrane. Tight regulation of phospholipid and bile acid secretion into the bile canaliculi is 
postulated to be protective against high bile acid concentrations in the canalicular lumen. FXR-mediated 
downregulation of BSEP in patients with PFIC type 1 has been shown. PFIC2 and PFIC type 3 (PFIC3) 
are caused by mutations in the genes encoding BSEP and phospholipid translocase (MDR3), respectively. 
Mutations in BSEP that are associated with decreased bile acid secretion lead to reduced bile flow and 
accumulation of bile acids in the hepatocytes, resulting in hepatocellular damage secondary to cholestasis. 
Impaired function of BSEP due to altered gene coding or gene regulation also has been implicated in 
benign recurrent intrahepatic cholestasis type 2 (BRIC2), and intrahepatic cholestasis of pregnancy. 
61,62
 
MDR3 is a phospholipid translocator expressed in the canalicular membrane of the hepatocyte. 
Phospholipids protect the endothelial cells lining the bile canaliculi from the detergent effects of secreted 
bile acids; decreased function of MDR3 results in continuous exposure to hydrophobic bile acids in 
patients with PFIC type 3 and subsequent liver damage. 
In addition to genetic defects, many forms of acquired defects in bile acid transport that have 
been described involve direct inhibition of the function or expression of the bile acid transport proteins 
resulting in cholestasis, including drug-induced cholestasis, sepsis-associated cholestasis, and intrahepatic 
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cholestasis of pregnancy. Drug-induced cholestasis may involve BSEP inhibition, which can result in 
intracellular accumulation of bile acids and subsequent liver damage.  
Endogenous compounds also have been implicated in cholestasis. Estrogen and C17-alkylated 
steroids can cause a type of cholestasis that is similar in clinical presentation to intrahepatic cholestasis of 
pregnancy (ICP). ICP usually occurs during the third trimester of pregnancy and resolves spontaneously 
after delivery. Cholestatic estrogen metabolites appear to play a major role in the pathogenesis of ICP. In 
animal models of cholestasis, E217G or the synthetic estrogen ethinylestradiol, causes internalization and 
intracellular retention of Bsep and Mrp2, which rapidly impairs the excretory function of these canalicular 
proteins. 
37,63
  
Dubin-Johnson Syndrome  
Dubin-Johnson Syndrome (DJS) is a rare autosomal recessive disease with impaired secretion of 
organic anions, characterized by chronic conjugated hyperbilirubinemia and pigmented liver due to 
hepatic accumulation of bilirubin. Although a defect in canalicular secretion of bilirubin had long been 
assumed, the underlying mechanism was identified in the late 1990s, when an ABCC2 gene mutation was 
linked to impaired expression and function of MRP2 in this disease. 
64
 Similar mutations have been found 
in the Mrp2 gene in TR
-
/GY
 
Wistar rats and EHBR (Esai hyperbilirubinemic) Sprague-Dawley rats. Both 
rat strains are deficient in the canalicular transport of anionic conjugates such as bilirubin glucuronide as 
well as glutathione and sulfate conjugates of various compounds. 
65,66
 Patients with DJS and Mrp2-
deficient rats exhibit increased hepatic basolateral expression of MRP3/Mrp3, which is hypothesized as a 
compensatory mechanism for excretion of bilirubin conjugates. In EHBR rats, the contribution of Mrp2 to 
the DJS phenotype was proven by infection with adenovirus carrying ABCC2, which compensated for the 
genetic defect and corrected the transport deficiency. 
67
  
Rotor Syndrome 
Rotor syndrome is a rare, benign autosomal recessive liver disease clinically similar to DJS. 
Rotor syndrome is characterized by conjugated hyperbilirubinemia, but in contrast to DJS, these patients 
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lack the hepatic pigment accumulation. Furthermore, in Rotor syndrome, delayed clearance of certain 
anionic drugs (e.g. BSP) and impaired hepatic uptake of diagnostic dyes (e.g. 
99m
TC-HIDA) has been 
observed. Inactivating mutations of the SLCO1B1 and SLCO1B3 genes resulting in functional deficiency 
of OATP1B1 and OATP1B3, and hence disrupted hepatic reuptake of bilirubin glucuronide, were 
identified as the underlying mechanism for this liver disease. 
68
 Transporter knockout mouse models were 
used to show that Mrp3 secreted bilirubin conjugates into the blood while Oatp1a/1b mediated their 
hepatic reuptake. Expression of human OATP1B1 or OATP1B3 in Oatp1a/1b-deficient mice restored 
bilirubin glucuronide reuptake and detoxification mechanisms. It has been suggested that hepatic 
(re)uptake represents a detoxification strategy to shuttle bilirubin conjugates to downstream hepatocytes 
to prevent local saturation of detoxification processes. 
68
 
Non-Alcoholic Steatohepatitis (NASH) 
Approximately one-third of the U.S. population suffers from non-alcoholic fatty liver disease; 10-
20 percent of these individuals present with the more progressive inflammatory form, steatohepatitis 
(NASH). 
69,70
 Driven by the dual epidemics of diabetes and obesity, the incidence of these chronic liver 
diseases is increasing at an alarming rate. In addition to the risk of disease progression from simple fatty 
liver to NASH, cirrhosis, liver failure and hepatocellular carcinoma, there are risks inherent to patients 
with milder forms of the disease. Specifically, changes in the hepatic disposition of common medications 
may reduce drug efficacy or increase toxicity. Enzymes and transporters responsible for hepatic uptake 
and metabolism are down-regulated in NASH (e.g., OATPs; CYP2C8, CYP2C19, and CYP3A4), while 
proteins excreting drugs/toxins from the liver into the blood or bile are up-regulated (e.g., MRP3, MRP4, 
P-gp and BCRP). 
71,72
 Progression of inflammation and fibrosis ultimately results in cirrhosis, which 
impairs biliary excretion of both endogenous and exogenous compounds. The in vivo functional effect of 
NASH on hepatic handling of drugs in humans remains to be investigated. Preclinical data suggest that 
NASH may shift the excretion profile of medications, potentially leading to increased systemic toxicity or 
decreased hepatic efficacy of many drugs administered to patients with NASH. 
73,74
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Inflammation and Inflammation-Induced Cholestasis 
Inflammation often contributes to the development of liver injury during cholestasis. However, 
inflammatory processes themselves can be the cause for cholestasis due to reduction in bile flow 
associated with the release of bacterial endotoxins or inflammatory cytokines. Impaired basolateral and 
canalicular bile acid and organic anion transport has been observed in the isolated perfused rat liver after 
injection of LPS. 
75
 In a rodent model of endotoxin-induced cholestasis, LPS induced an early and 
selective, but reversible retrieval of Mrp2 from the apical membrane followed by down-regulation in 
Mrp2 mRNA. 
76
 Similarly, a decrease in both Bsep mRNA and protein accounted for the reduced 
canalicular secretion of bile acids in endotoxin-treated rats. 
77,78
 
Pro-inflammatory cytokines such as tumor necrosis factor α (TNFα), interleukin (IL)-1β and IL-6 
regulate the expression of hepatic transporters in rodents and primary and sandwich-cultured human 
hepatocytes. 
79-82
 In general, bile acid transport proteins as well as basolateral uptake transport proteins 
are repressed, whereas drug efflux transporters may be unchanged, or up- or down-regulated at the 
mRNA, protein or activity level (for review see 
83
). A recent study showing differential effects of 
BSEP/Bsep expression between sandwich-cultured human and rat hepatocytes after treatment with pro-
inflammatory cytokines
79
 demonstrated the potential for species differences in response to inflammatory 
mediators, and highlighted the need to carefully consider model selection and clinical inferences. Little 
information on the effect of inflammation on transport protein function is available in humans. In patients 
with primary biliary cirrhosis and primary sclerosing cholangitis, which are associated with inflammation, 
reduced expression of NTCP, OATPs, MRP2, and BSEP was reported, whereas MRP3 and OSTα/β 
expression was increased. 
84,85
 Furthermore, disrupted canalicular localization of MRP2 in patients with 
primary biliary cirrhosis was observed. 
86
 Although not directly correlated with inflammation, 
Vanwijngaerden et al. reported increased bile acid and bilirubin concentrations in patients in the intensive 
care unit. Liver biopsies taken from these patients immediately post mortem indicated that MRP2, MRP3 
and MRP4 mRNA and protein were increased while OATP1B1 and OATP1B3 mRNA and protein were 
decreased. 
25
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Human Immunodeficiency Virus Infection (HIV) 
To our knowledge no studies have been published that directly compare hepatic transporter 
expression between HIV infected patients and healthy individuals. In 2008, Jung et al. reported that 
mRNA levels of OCT1 and OCT2 in lymph node tissue were markedly increased in patients infected with 
HIV compared to non-infected controls 
87
. Although not investigated, direct viral- or indirect 
inflammatory-mediated activation of signaling cascades may alter normal expression and function of 
hepatic transport proteins and metabolic enzymes, thereby altering systemic clearance, efficacy or toxicity 
of drugs. Altered basolateral and/or canalicular transport protein expression may be of particular 
relevance in HIV pharmacotherapy; protease inhibitors (PIs) are often OATP and MRP2/P-gp substrates, 
whereas the nucleoside analog reverse transcriptase inhibitors (NRTIs), such as lamivudine and 
zalcitabine, are OCT1 and OCT2 substrates. 
87,88
 Furthermore, since many HIV drugs are substrates or 
inhibitors of transport proteins and metabolic enzymes, HIV patients have an increased risk for drug-drug 
interactions (DDIs). The most well-known DDI associated with HIV treatment is CYP3A4 inhibition by 
ritonavir. This interaction is used clinically to “boost” the concentrations of coadministered PIs. In 
addition, ritonavir also potently inhibits P-gp, MRP2 and other drug transporters. Ritonavir-mediated 
inhibition of P-gp was proposed as the mechanism for the significant decrease in the non-renal clearance 
of digoxin in healthy volunteers. 
89
 Although many PIs and NRTIs inhibit a multitude of transporters 
including P-gp, MRP2, OATP1B1, OATP1B3, and NTCP, clinically relevant interactions with MRP2 
have not been established, potentially due to concentrations below the inhibitory level at the site of 
transport (i.e. intracellular for MRP2). 
90,91
 Certain antiretroviral agents are associated with an increased 
incidence of hepatotoxicity, which may be related, in part, to interactions with hepatic transporters. 
88,91,92
 
Chronic Hepatitis C Viral (HCV) Infection  
Chronic HCV infection results in prolonged cellular oxidative stress and production of pro-
inflammatory cytokines, which lead to progressive fibrosis. In rodent models and human derived cell 
lines, pro-inflammatory cytokines including IL-1β, TNF-α and IL-6 have been shown to modulate nuclear 
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receptor and transporter expression. 
80,93
 Multiple studies have investigated the effect of HCV and HCV-
induced inflammation on hepatic transporter expression. Liver biopsies from patients with HCV exhibited 
increased P-gp, MRP1, MRP3 and MRP4, and decreased OATP1B1, OATP1B3, MRP2 and BCRP 
mRNA and/or protein compared to uninfected controls. 
23,94,95
 Additionally, increasing fibrosis stage in 
patients with HCV infection has been inversely correlated with mRNA expression of BSEP, MDR3, 
MRP2, NTCP, OAT2, OCT1, OATP2B1 and OATP1B1. 
96
 Although mRNA and protein do not always 
correlate directly for transport proteins, altered hepatic transporter expression may be linked to decreased 
expression and presumably transcriptional activation by the nuclear receptors AhR, PXR and PPARα. 95,96 
Even though the clinical significance of altered transporter expression is unclear, the systemic clearance 
of the P-gp substrate, nelfinavir, was significantly reduced in HIV/HCV co-infected patients compared to 
HIV patients without HCV. 
97
 Further studies are needed to elucidate the pharmacokinetic and 
pharmacodynamic consequences of fibrosis, cirrhosis and altered transporter expression in the liver, as 
well as other clearance organs, due to HCV infection and treatment.  
Model Systems for Studying Hepatobiliary Drug Transport 
Several model systems have been applied successfully to the study of hepatobiliary drug 
transport, ranging from models mimicking the transporter-mediated transmembrane movement of drugs 
(e.g. membrane vesicles) to sophisticated in vitro and in vivo models (e.g. cultured hepatocytes and 
knockout animals). Significant species differences in transporter affinity and expression profiles 
98,99
 
remain a key consideration in selecting the appropriate model. The relevance of a particular model to 
human hepatobiliary drug disposition will depend largely on whether the model is derived from human 
tissue (e.g. human hepatocytes) or whether human transport proteins are expressed. Furthermore, since 
the rate-limiting step in hepatobiliary disposition differs between drugs, the relative expression levels of 
drug-metabolizing enzymes and transport proteins must be considered for each model, and data must be 
interpreted cautiously and in conjunction with complementary model systems when such expression 
levels do not reflect the in vivo situation. Table 1.4 summarizes applications as well as advantages and 
disadvantages of various hepatobiliary drug transport models.   
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In Vitro Systems 
Membrane Vesicle Systems Isolated purified canalicular (cLPM) and basolateral (bLPM) liver plasma 
membrane vesicles with functional transport properties have been used to assess the mechanisms of 
transport (driving forces, electrogenicity) and to identify substrates and inhibitors of transport proteins. 
100,101
 This classic method was used to characterize bile acid and bilirubin glucuronide transport across the 
canalicular membrane, leading to the discovery of BSEP and MRP2. 
102,103
 For efflux transporters, inside-
out vesicles are required to permit access of ATP and the drug/inhibitor of interest to the catalytic site of 
the transporter and allow direct translocation of substrates into the vesicles. LPM vesicle preparations 
contain both inside-out and right-side-out vesicles at varying ratios. Since uptake transporters generally 
do not directly require ATP, data obtained from inside-out bLPM vesicles intended for investigation of 
basolateral efflux transporters may be confounded by uptake transporters pumping in the opposite 
direction.  Finally, concurrent with the tissue of origin, vesicles made from cLPMs or bLPMs contain 
multiple ABC transport proteins making identification of specific substrates or inhibitors impossible.  
With the evolution of cloning and transfection techniques allowing expression of individual 
(human) transport proteins, tissue-based LPM vesicle assays have largely been replaced by vesicles 
prepared from vector-transfected and virus-infected cell lines (over-) expressing a single transport protein. 
Initially, baculovirus-infected Spodoptera frugiperda, Sf9 cells, were widely used, but due to notable 
differences in glycosylation patterns and cholesterol content of the isolated membranes 
104
, more human 
relevant cell lines, such as human embryonic kidney (HEK) 293, Madin-Darby canine kidney (MDCK) II 
or porcine kidney epithelial (LLC-PK1) cells are now used more frequently. Vesicles prepared from 
single-transporter expressing cell lines are suitable for high-throughput screening of substrates or 
inhibitors, yielding kinetic parameters for the transporter of interest including the Michaelis-Menten 
constant (Km), maximal transport rate (Vmax) as well as the inhibition constant (Ki). This system is ideal 
for assessing the potential for DDIs in vitro, but fails to allow comparison of the relative contribution of 
individual transporters to the overall hepatic disposition of a compound.  
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Transfected Cell Systems Mammalian cell lines (predominantly HEK293, MDCK II and LLC-PK1) 
transfected with one or more transport proteins have evolved rapidly as one of the most widely used 
techniques to generate efficient and flexible in vitro tools for identification of substrates and inhibitors of 
hepatic transport proteins in humans. 
105
 Although expression of a single uptake transporter allows kinetic 
analysis of the substrate and inhibitor spectrum of individual transport proteins, researchers continue to 
examine ways to evaluate the interplay between uptake and efflux transport proteins. Expression of at 
least two transport proteins (one for uptake and one for excretion) in polarized cell lines such as MDCKII 
or LLC-PK1 mimic the in vivo expression of uptake and excretory transporters and are a valuable tool to 
study vectorial transport. Recently, Fahrmayr et al. developed a triple-transfected cell line expressing both 
influx and efflux transporters as well as the drug-metabolizing enzyme uridine diphosphate glucuronosyl 
transferase (UGT) 1A1 to study transporter-metabolism interactions. 
106
 Disadvantages of transfected cell 
systems include altered protein trafficking and localization due to species differences or the cell type used 
for transfection. Importantly, the relative expression levels of transport proteins and metabolizing 
enzymes remain difficult to assess and standardize, resulting in a rather artificial model exhibiting 
differences in the rate-limiting steps compared to in vivo. In addition, the actual functional activity of a 
given transport protein is likely to depend on the cellular environment, which is clearly different in a 
transfected system compared to normal hepatocytes. 
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Primary Hepatocytes Freshly isolated hepatocytes are considered to be the most comprehensive cell-
based model to study hepatic drug transport. Suspended hepatocytes remain a useful and convenient 
system to characterize hepatic drug uptake mechanisms. Unfortunately, hepatocytes rapidly lose cellular 
polarity upon isolation 
108
 and internalization of canalicular transport proteins has been observed 
109
; thus, 
it is impossible to differentiate drug efflux across the basolateral versus canalicular membrane domains in 
suspended hepatocytes. Furthermore, suspended hepatocytes only remain viable for a few hours. 
Hepatocytes cultured on a single layer of an extracellular collagen matrix (“conventional configuration”) 
have been used to study hepatotoxicity, metabolism and enzyme induction. However, hepatocytes in this 
conventional configuration continue to dedifferentiate rapidly with complete loss of cell polarity and 
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many hepatocyte-specific functions. 
110
 In contrast, hepatocytes cultured between two layers of gelled 
collagen (“sandwich configuration”; sandwich-cultured hepatocytes), maintain mature hepatocyte 
morphology and long-term expression of a differentiated phenotype. 
110,111
 This includes re-establishment 
of cell polarity, formation of functional canalicular networks in culture, and maintenance of drug transport 
proteins and metabolizing enzymes, thus allowing for the study of hepatobiliary drug metabolism and 
transport. 
112
   Hepatocyte-like cells derived from the human hepatoma cell line, HepaRG, are being tested 
as an alternative to human hepatocytes. HepaRG cells express relevant transport proteins, although 
mRNA and protein expression may differ compared to human hepatocytes. 
113,114
 Further studies are 
required to determine whether HepaRG cells could be used as an accurate alternative to primary 
cultured hepatocytes for in vitro hepatobiliary transport studies. Additionally, inducible pluripotent stem 
(iPS) cells have been differentiated successfully into hepatocyte-like cells. Although the transport 
characteristics of these cells remain to be characterized, other hepatocyte specific functions, such as 
CYP450 induction have been documented. Hepatocytes derived from a specific individual may serve as a 
powerful tool to understand the mechanisms behind idiosyncratic liver injury. 
115
 More recently, three-
dimensional hepatocyte models (e.g. LiverChip
®
, Hµrel
®
) are being developed to more closely mimic in 
vivo hepatic physiology. Additional studies are needed to establish the utility of these highly complex, but 
physiologically relevant models for the study of drug disposition and transport. 
Isolated Perfused Liver Models The isolated perfused liver (primarily rat) has been used widely to 
investigate hepatobiliary transport of drugs and xenobiotics. Although time- and animal-consuming, the 
main advantage of this model system is that the normal liver physiology (including bile flow) is 
maintained throughout the time of the experiment. Moreover, the ability to sample from both perfusate 
(blood compartment) and bile makes this model system particularly useful for mechanistic studies 
(including pharmacokinetic modeling) without potentially confounding factors from other tissues and 
clearance organs that exist in vivo. Perfused liver studies may be performed in situ or ex vivo using a 
single-pass or recirculating technique. In the single-pass technique, the outflow from the perfusion does 
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not re-enter the system, allowing steady-state conditions to be achieved rapidly. Data from single-pass 
liver perfusion allows calculation of the steady-state extraction of the parent compound as well as 
determination of basolateral and canalicular excretion of parent and formed metabolites. Large amounts 
of perfusate are required, making this technique less feasible when only a small quantity of drug is 
available. Alternatively, recirculating perfusions do not require as much perfusate; however, this method 
only allows calculation of total hepatic clearance because the parent and formed metabolites are 
continuously returned to the liver and clearance into bile is the only permanent elimination route from the 
system. Additionally, since metabolites are only cleared from the system through the bile, they may 
accumulate in the perfusate or liver tissue and potentially result in artificially magnified drug-metabolite 
transporter or metabolism interactions. An attractive feature of both perfusion techniques is the ability to 
assess the effects of in vivo pretreatments (e.g. with inducing agents or disease-inducing diets) on 
hepatobiliary transport and metabolism. 
116
 Livers obtained from transporter knockout or transporter-
deficient (e.g. TR
-
 Wistar or EHBR Sprague-Dawley rats, which have a functionally relevant defect in the 
Abcc2 gene) also can be used in perfusion experiments. 
117,118
  
In Vivo Systems  
The gold standard for studying the role of hepatic transporters in the systemic disposition and 
elimination of xenobiotics is pharmacokinetic studies in humans. Evaluation of the whole integrative 
system provides the most robust information regarding the potential for DDIs, herb-drug or diet-drug 
interactions in the clinic by including compensatory elimination pathways. Although in vivo studies are 
the most relevant clinically, mechanistic evaluation of transporter-based interactions in humans is difficult 
because of the significant overlap of substrates and inhibitors for multiple transport proteins, and obvious 
limitations regarding the types of samples that can be collected.  
Single Nucleotide Polymorphisms and Knockout Models Humans with single nucleotide 
polymorphisms (SNPs) that alter the expression and/or function of hepatic transport, and genetic 
knockout models in rodents, offer a unique opportunity to study the role of transport proteins in the 
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hepatic and systemic disposition of drugs and xenobiotics; however, the compensatory up-regulation of 
other transporters or species differences must be considered prior to direct translation of the findings into 
the clinic. SNPs have been identified in almost all human genes, including both uptake and efflux 
transport proteins. Ho et al. demonstrated that polymorphisms in SLC10A1 (NTCP) resulted in decreased 
transport of prototypical bile acid substrates and paradoxically increased drug transport by NTCP in vitro. 
2,119
 Additionally, increased risk for statin induced myopathy and decreased efficacy have been well 
documented secondary to increased systemic and presumably lower hepatic concentrations in patients 
with polymorphisms in the genes encoding for OATP1B1. 
120
 Similarly, rodent models lacking Bcrp on 
the canalicular membrane exhibit decreased biliary clearance of rosuvastatin. Altered rosuvastatin 
pharmacokinetics has been confirmed in both Chinese and Finnish populations with polymorphisms in 
BCRP, which diminish its function, demonstrating the utility of knockout rodent models to predict altered 
pharmacokinetics in humans. 
121-123
 Studies to-date in knockout animals and humans with SNPs that alter 
transporter function have documented the importance of transport proteins in the systemic and hepatic 
disposition of some drugs and generated metabolites. Additional studies assessing the impact of altered 
hepatic transport function on the in vivo efficacy and toxicity of drugs, xenobiotics and endobiotics are 
needed to fully understand the pivotal role that transporters play. 
In Vivo Biliary Excretion Studies Biliary excretion is an important route of elimination for some drugs 
and represents a potential site of interactions that may alter hepatic and/or systemic drug exposure. 
Accurate measurement of biliary clearance and understanding the underlying mechanisms of biliary 
excretion are important in predicting clinical DDIs or proposing mechanisms of transporter-associated, 
drug-induced hepatobiliary toxicity. 
One method, primarily utilized in rodents, to completely collect bile involves cannulation of the 
bile duct and exteriorization of bile flow. Proper study design, including pharmacokinetic sampling and 
complete bile collection, generates datasets containing information about the extent of biliary excretion 
and involvement of enterohepatic recirculation in the overall systemic exposure. In general, in vivo biliary 
clearance correlates well with in vitro biliary clearance estimated in sandwich-cultured hepatocytes. 
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112,124,125
 A second method, used primarily in humans, is direct aspiration of duodenal fluids using an 
oroenteric tube or absorbent sponge that can be placed distal to the sphincter of Oddi to collect recently 
excreted bile. These methods allow relatively non-invasive collection of bile from humans, but complete 
collection of bile for designated time intervals requires specialized techniques, making these methods 
largely qualitative. Incomplete and highly variable recovery of total bile excreted can be minimized by 
administration of cholecystokinin 8 (CCK-8) intravenously to stimulate gall bladder contraction. To 
generate quantitative data, correction for gall bladder ejection fraction and the portion of the dose lost 
during collection can be achieved with concurrent direct hepatic imaging by quantification of hepatic 
gamma-ray or positron emissions from administered radioactive agents.  
Hepatobiliary Imaging Techniques Pharmacokinetic studies based on serum concentrations provide 
information on overall hepatic clearance, but do not allow determination of hepatic uptake, biliary 
clearance or liver concentrations/exposure. Quantification of the intrahepatic concentration of drugs may 
be especially relevant when the site of action or toxicity is in the liver. Therefore, several noninvasive 
imaging techniques such as gamma-ray quantification using 
99m
Tc-labeled compounds, positron emission 
tomography (PET) using short-lived 
11
C, 
13
N, 
15
O or 
18
F- isotopes and magnetic-resonance imaging (MRI) 
have been employed to allow direct quantification of hepatic concentrations. A combination of these 
methods with the aforementioned oroenteric tube and pharmacokinetic sampling, allows direct 
quantification of all relevant clearance processes involved in the hepatic disposition of the imaging agent 
used. 
Hendrikse et al. used the radiopharmaceuticals 
99m
Tc-HIDA and 
99m
Tc-MIBI to assess the 
function of the hepatic efflux proteins P-gp, Mrp1, and Mrp2 in vivo. 
126
 More recently, 
99m
Tc-mebrofenin 
has been used to study the inhibitory effects of ritonavir on hepatic uptake and biliary efflux transport 
proteins in healthy volunteers. 
90
 Similarly, non-radioactive MRI contrast agents have been investigated to 
study hepatic transport. The gadolinium (Gd) derivatives Gd-BOPTA and Gd-EOB-DPTA allow liver 
imaging and facilitate the distinction between normal and pathological tissue. Hepatic uptake of Gd 
compounds is thought to be mediated by OATPs, while MRP2 mediates biliary excretion. 
127,128
 Studies 
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conducted in patients with hepatocellular carcinoma correlated the degree of expression and localization 
of OATP1B1/1B3 and MRP2 with hepatocyte-specific enhancement. 
129,130
 A combination approach of 
pharmacokinetic sampling and hepatic imaging techniques may emerge as a powerful tool to elucidate 
drug disposition and predict drug-transport interactions. 
Drug Interactions in Hepatobiliary Transport 
In recent years, the importance of transporter-related DDIs has become well recognized in the 
drug discovery and development arena. As screening programs have successfully filtered out chemical 
entities that display high affinities for CYP450 enzymes, the likelihood of selecting compounds during 
drug discovery that are transport inhibitors and/or that depend on transporters for their 
elimination/distribution has increased as a consequence. A DDI in hepatobiliary transport may occur 
when one drug interferes with the functional activity (e.g. inhibition) and/or expression levels (e.g. 
induction, altered regulation) of a hepatic transport protein that is critically involved in hepatobiliary 
elimination of another drug. In addition, since endogenous compounds often rely on hepatic transport 
proteins to maintain normal hepatic physiology (e.g. bile flow), administration of drugs that inhibit the 
function of key transport proteins may cause disturbances in physiological homeostasis. One example of 
this phenomenon is drug-induced liver injury (DILI) due to inhibition of bile acid transport.  
A substantial number of DDIs in hepatobiliary transport reported in recent years occur at the level 
of hepatic uptake (see Table 1.5). Various clinical studies have revealed “perpetrator” drugs that inhibit 
the OATP family of transporters resulting in altered hepatic uptake of “victim” drugs such as HMG-CoA 
reductase inhibitors ("statins"). For example, concomitant treatment with the CYP3A4 inhibitor 
cyclosporin A (CsA) elevated cerivastatin plasma concentrations 3- to 5-fold, despite dual CYP2C8- and 
CYP3A4-mediated metabolism of cerivastatin; inhibition of OATP1B1-mediated uptake of cerivastatin 
was identified as a plausible mechanism. 
131,132
 Similarly, for atorvastatin, pravastatin, lovastatin, and 
rosuvastatin, 6-, 5-, 22-, and 7-fold increases in plasma concentrations, respectively, were observed upon 
coadministration with CsA compared to controls. 
133-135
 It should be noted, however, that for most 
clinically relevant drug interactions involving statins, the relative importance of CYP3A4 (or other CYPs) 
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136
 versus OATP1B1 
137
 inhibition remains to be elucidated. At least for rosuvastatin, where metabolism is 
a minor route of elimination, OATP1B1 inhibition appears to play the key role in this clinically observed 
DDI. 
136
 Transporter-mediated drug interactions elicited by CsA clearly are not limited to statins; CsA 
coadministration increased the plasma area under the curve (AUC) of the endothelin receptor antagonist 
bosentan (30-fold), the antidiabetic repaglinide (4-fold) as well as the antigout medication colchicine (3-
fold). 
138-140
 In vivo data generated in the rat with bosentan strongly suggest that inhibition of 
hepatocellular uptake plays an important role in this severe drug interaction. The important role of 
OATP1B1 in the hepatic uptake of repaglinide has been demonstrated in a separate study. 
141
 Inhibition of 
OATP1B1, in addition to CYP2C8 by the fibric acid derivative gemfibrozil may contribute to the DDI 
between gemfibrozil and repaglinide. Gemfibrozil also has been reported to alter the pharmacokinetics of 
statins, possibly due in part to inhibition of hepatic OATP1B1. The use of gemfibrozil as a comedication 
during cerivastatin therapy resulted in more than a 5-fold increase in cerivastatin exposure (plasma AUC). 
142
 Shitara et al. conducted in vitro studies to assess the relative importance of the inhibitory effects of 
gemfibrozil and gemfibrozil glucuronide on CYP2C8-mediated metabolism and on OATP1B1-mediated 
hepatic uptake of cerivastatin. 
143
 Both gemfibrozil and gemfibrozil glucuronide were more potent 
inhibitors of CYP2C8 than OATP1B1, suggesting a major role for CYP2C8 and possibly minor 
involvement of OATP1B1 in this DDI. A less pronounced interaction was reported between gemfibrozil 
and simvastatin, resulting in a ~1.9-fold increase in simvastatin acid AUC values. 
144
 Since no inhibition 
of CYP3A4, the major enzyme involved in simvastatin metabolism, by gemfibrozil was observed in vitro, 
the possible role for OATP inhibition in this DDI remains to be elucidated. The same conclusion can be 
drawn for DDIs following coadministration of gemfibrozil with pravastatin or lovastatin. 
145,146
 
Interestingly, recent in vitro data indicate that gemfibrozil stands out among other fibric acid derivatives 
tested for its potency to inhibit OATP1B1. 
147
  
Recently telaprevir, a first in class hepatitis C viral protease inhibitor, was approved as add-on 
therapy in the treatment of chronic hepatitis C. Early in vitro studies demonstrated that telaprevir is a 
potent inhibitor of CYP3A and P-gp. In two well-designed cross-over clinical studies, the AUC values of 
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CsA, tacrolimus and atorvastatin were increased by 4.6-, 70- and 7.9-fold when coadministered with 
telaprevir compared to control. 
148,149
 This interaction was attributed primarily to CYP inhibition, although 
telaprevir also inhibits P-gp. Subsequent data revealed that telaprevir potently inhibits OATP1B1, 
OATP1B3 and OCT2, with IC50 values between 2.15 and 6.77 µM. With steady-state plasma 
concentrations of telaprevir reported to reach 5.1 µM (2.1 µM unbound), inhibition of OATP-mediated 
hepatic uptake of CsA, tacrolimus and atorvastatin is likely, in addition to metabolism interactions with 
CYP3A. 
150
 This example highlights the importance of both hepatic metabolism and vectorial transport in 
understanding and predicting the mechanisms underlying DDIs.  
For some hepatic drug interactions, the use of animal models to elucidate the underlying 
mechanism(s) of interaction may be justified, despite considerable species differences in transporter 
affinity profiles and the fact that human transporters might not be orthologs of rat proteins (e.g. OATPs). 
For instance, for OATPs, the pharmacokinetic interaction between the antiarrhythmic drug amiodarone 
and digoxin has been observed in both humans and rats. 
151,152
 In vitro data suggest that inhibition of 
Oatp1a4-mediated hepatic uptake of digoxin by amiodarone probably plays a predominant role in this 
drug interaction. 
153
 Data generated in OAT2 expressing oocytes strongly support a role for OAT2 in the 
well-known drug interaction between theophylline and erythromycin in human liver. 
154
 Additional in 
vitro data have demonstrated substantial inhibition of OAT2-mediated tetracycline uptake in oocytes by 
acetaminophen, erythromycin, chloramphenicol, ibuprofen, bumetanide and furosemide; therefore, it is 
likely that DDIs may involve OAT2-mediated transport. 
154
 Numerous drugs (including H2 antagonists 
cimetidine and famotidine 
155
 and several HIV PIs 
156
) have been identified as potent inhibitors of OCT1 
and/or OCT3. Although numerous DDIs have been reported involving inhibition of OCT1/3-mediated 
tubular secretion in the kidney, clinically relevant drug interactions involving hepatic transport have not 
been reported.  
In addition to hepatic uptake proteins, inhibition of canalicular transport also has resulted in 
clinically relevant DDIs, including a reduction in digoxin biliary clearance (by about 40%) in patients 
who were coadministered the P-gp inhibitors quinidine or verapamil. 
157,158
 Inhibition of P-gp was 
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proposed as the mechanism behind the significant decrease in the non-renal clearance of digoxin in 
healthy volunteers who were coadministered the HIV PI ritonavir. 
89
 Although, P-gp inhibition would 
result in a decrease in non-renal clearance of digoxin, based on clinically relevant concentrations of 
ritonavir, this interaction may be attributed to inhibition of hepatic OATP–mediated uptake of digoxin. 
90,159
 Apart from the DDIs in hepatobiliary transport discussed above, various drugs interfere with the 
hepatic handling of endogenous compounds, including bilirubin, bile acids and thyroid hormones. For 
instance, Campbell et al. demonstrated that the in vitro potency of several OATP inhibitors (including 
CsA, rifamycin SV, and the PIs saquinavir and ritonavir) is directly correlated to the incidence of 
hyperbilirubinemia in humans. 
160
 These observations are consistent with the predominant role of 
OATP1B1 and OATP1B3 compared to other SLCO gene products in hepatic bilirubin uptake. 
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Numerous drugs also interact with BSEP-mediated bile acid transport, thus causing alterations in the 
hepatobiliary handling of bile acids, which may lead to hepatotoxicity (see Hepatic Transport Proteins as 
Determinants of Drug Toxicity section).  
In addition to direct inhibition of transporter activity, altered transporter expression following 
drug-mediated transporter induction is another important mechanism underlying DDIs in hepatobiliary 
transport. Indeed, as discussed in the Regulation of Hepatic Drug Transport Proteins section, transporters 
are under regulatory control of nuclear receptors such as PXR and CAR. Therefore, administration of 
drugs that are ligands for these orphan nuclear receptors may lead to altered transporter expression and 
activity (induction/up-regulation or down-regulation). This may cause substantial changes in the 
hepatobiliary elimination kinetics of drugs that are substrates for these transporters. Clinically relevant 
induction of P-gp has been observed at the intestinal level 
161
, and induction of hepatic P-gp in animals 
has been reported. For instance, rifampicin treatment resulted in a 4- to 13-fold increase in hepatic P-gp in 
monkeys. 
162
 Similarly, treatment of rats with the P-gp inducer tamoxifen resulted in about a 12-fold 
increase in hepatic Mdr1b mRNA accompanied by increased biliary excretion of tamoxifen and its 
metabolites. 
163
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In recent years, there has been an increasing number of reports concerning clinically relevant 
interactions in hepatobiliary drug transport. These findings illustrate the unmet need for sophisticated and 
representative model systems allowing the early prediction of hepatobiliary drug interaction potential in 
drug discovery programs. 
Interplay Between Drug Metabolism and Transport 
Drug elimination is mediated by the concerted action of multiple interacting processes including 
influx, metabolism, and efflux. An understanding of the interdependence of these processes is important 
to predict how alterations in one pathway affect alternative or compensatory pathways, and the overall 
impact of DDIs. Many in vivo studies in preclinical species have been conducted to provide mechanistic 
insight into the functional interplay between drug-metabolizing enzymes and transporters. 
164
  
Because of the intracellular localization of metabolizing enzymes, uptake across the plasma 
membrane is an important prerequisite for metabolism. Therefore, it is not surprising that altered function 
of uptake transport proteins can affect drug metabolism. For example, co-administration of digoxin with 
the Oatp2 inhibitor rifampicin reduced digoxin metabolism. 
165
 Interestingly, polymorphisms in 
OATP1B1 (e.g., OATP1B1*5) are associated with reduced erythromycin metabolism, independent of 
changes in CYP3A4 activity; these findings call into question the use of erythromycin as a probe to 
phenotype an individual’s CYP3A4 activity. 166  
Due to the substantial overlap in substrate and inhibitor specificity, along with the shared 
response to prototypical inducers, the interaction between CYP3A4 and P-gp has received considerable 
attention and numerous studies have demonstrated hepatic interplay between CYP3A4-mediated drug 
metabolism and P-gp-mediated biliary excretion. 
167
 For instance, the extent of hepatic metabolism of the 
dual CYP3a/P-gp substrate tacrolimus was increased due to P-gp inhibition during isolated rat liver 
perfusion. 
168,169
 Similarly, enhanced metabolism of the CYP3a/P-gp substrate digoxin upon 
coadministration with the P-gp inhibitor quinidine was observed. 
165
 The frequently observed reciprocal 
relationship between metabolism and drug transport (the “seesaw” phenomenon), with apparent increases 
in the amount excreted by one pathway when the other elimination pathway is inhibited, is typically the 
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result of increased drug concentrations due to inhibition of one elimination pathway rather than a 
mechanistic link between metabolism- and transporter-mediated processes. 
170
 Endres et al. cautioned that 
the erroneous conclusion of induction or activation of alternate metabolizing enzymes could be drawn, if 
basic pharmacokinetic principles are disregarded. 
170
  
In addition to CYP-mediated elimination, phase II metabolic pathways such as glucuronidation 
and sulfation are interlinked with hepatic transport processes. Highly polar, conjugated metabolites are 
dependent on the function of efflux transport proteins such as BCRP or MRPs for elimination. The 
excretion of conjugates correlates inversely with the intracellular conjugate concentrations because 
transporter-mediated excretion controls the elimination of conjugates from the cell. 
171
 Some conjugated 
metabolites may undergo deconjugation to reform the precursor molecule, a process called futile cycling 
or reversible metabolism. In addition, interconversion between parent drug and metabolite also exists for 
some phase I metabolites. Modeling and simulation studies have demonstrated that inhibition of biliary 
excretion of the conjugate can affect the disposition of the precursor in the presence of futile cycling. 
171,172
  
In addition to direct interactions through inhibition of uptake or efflux mechanisms, indirect 
mechanisms of interaction with transport proteins and metabolizing enzymes exist. The coordinate 
regulation of hepatic drug metabolizing enzymes and transport protein expression on the transcriptional 
level through NRs (see Regulation of Hepatic Drug Transport Proteins section) is thought to protect the 
hepatocyte from intracellular accumulation of toxic xenobiotics and formed metabolites. 
173
 It is 
interesting to note, that uptake transporters regulate access of drugs to NR proteins (e.g., PXR, CAR), 
thereby influencing the intracellular concentrations of drugs that act as NR inducers. For example, 
OATP1B1 expression is a major determinant of the extent of PXR activation by rifampin. 
174
 Following 
chronic administration of rifampin with at least a 12-hour washout period, the PXR-mediated induction of 
OATP1B1 and CYP3A4 resulted in decreased systemic concentrations of the OATP substrates 
atorvastatin and glyburide. 
175,176
 Alternatively, acute intravenous dosing of rifampin was associated with 
increased systemic concentrations of atorvastatin 
177
, likely due to acute inhibition of OATP transport. 
31 
 
Glyburide concentrations returned to baseline with chronic oral rifampin administration (6 day 
pretreatment) followed by an acute intravenous rifampin dose immediately prior to glyburide 
administration.  This study design highlighted that inhibition of OATP1B1 and CYP3A4 can counteract 
the inductive effects for this substrate. 
176
   
Hepatic Transport Proteins as Determinants of Drug Toxicity  
Altered function of hepatic transport proteins may have far reaching consequences for drug 
toxicity. One of the best documented cases exemplifying the contribution of hepatic uptake transporters to 
toxicity is the increased risk of myopathy after statin treatment in patients with genetic OATP1B1 
polymorphisms. Myopathy is a side effect that presents as muscle pain and fatigue, which can progress 
from mild myalgia to life-threatening rhabdomyolysis. Numerous studies have demonstrated that genetic 
variants linked to low activity of OATP1B1 (i.e., *5 and *15 haplotypes) are associated with an increased 
risk of statin-induced myopathy. (see comprehensive review in 
120
)  Physiologically-based modeling of 
statin disposition predicted increased systemic concentrations but only moderate effects on liver exposure 
with reduced OATP1B1 function. 
178
  
Transporter-mediated biliary excretion of irinotecan, mycophenolic acid, and nonsteroidal anti-
inflammatory drugs is associated with a high incidence of diarrhea due to drug-induced injury to the small 
intestine. 
179
 In many cases, hepatically-derived metabolites are responsible for intestinal injury and dose-
limiting toxicity. In addition to efflux transporters, hepatic uptake transporters might also contribute to 
gastrointestinal side effects. A genome-wide association study in children with acute lymphoblastic 
leukemia detected an association between certain OATP1B1 variants, which associated with enhanced 
clearance of methotrexate, and increased risk of gastrointestinal toxicity, which might be due to increased 
hepatic uptake and biliary clearance and subsequently higher intestinal concentrations. 
180
 
Another type of toxicity that may be associated with hepatic transport proteins is DILI. DILI may 
be mediated by the direct transport of hepatotoxic compounds, including metabolites, or the interaction of 
drugs/metabolites with the hepatic transport of endogenous substrates such as bile acids, which are 
cytotoxic at higher concentrations. 
181
 Drugs that are potent BSEP inhibitors are likely to be associated 
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with DILI including bosentan, cyclosporin A, glibenclamide, rifamycin, sulindac and troglitazone. 
182-185
 
Two recent systematic screening approaches that compared the potency of BSEP inhibition and 
cholestatic potential of drugs revealed a markedly higher incidence and potency of BSEP inhibition 
among drugs that caused cholestatic DILI compared to non-cholestatic drugs. 
13,182
 
The Future of Hepatic Drug Transport 
Although our knowledge of hepatic drug transport has increased tremendously during the past 
decade, considerable effort is still needed to understand the coordinated role of hepatic transport proteins 
in determining the systemic and hepatic exposure of drugs and metabolites. This is particularly important 
when the target site for drug efficacy and/or toxicity is the liver. Specifically, we have a rudimentary 
understanding of hepatic basolateral efflux proteins, how these proteins influence drug disposition, and 
the impact of disease, genetic variability, and DDIs on these proteins. In general, alterations in hepatic 
drug transport associated with disease remain to be elucidated. The structural features of a molecule that 
enhance the probability of interactions (e.g., transport, inhibition) with specific hepatic transport proteins 
remains to be defined. Molecular modeling approaches hold great promise in answering some of these 
fundamental questions. Additionally, a more sophisticated understanding of intracellular drug disposition 
is needed to fully understand indirect mechanisms of drug-transport interactions, such as altered 
trafficking and localization of transport proteins. The role of transport proteins other than those that reside 
on the basolateral and apical hepatocyte membranes (e.g., intracellular trafficking proteins, proteins on 
the endoplasmic reticulum), and the influence of these transport proteins on drug/metabolite disposition, 
efficacy, and toxicity, await exploration. More information about the hepatic disposition of endogenous 
substrates of hepatic transport proteins (e.g., bile acids) is urgently needed. This basic knowledge is 
prerequisite to accurate predictions of hepatic transporter-mediated DDIs and hepatotoxicity. The 
development of new techniques, tools, and/or model systems that address specific concerns with existing 
approaches (e.g., species-dependent differences, sample throughput, physiologic relevance, assessment of 
intracellular concentrations), and that can be used to answer both mechanistic and applied questions 
regarding hepatobiliary transport, is needed. Such tools will be useful in enhancing our understanding of 
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how drugs and metabolites move through the human liver to sites of action, biotransformation, and/or 
excretion. This knowledge is fundamental to the optimization of drug therapy to achieve desirable 
therapeutic outcomes, and to minimize the incidence of unwanted effects, including undesirable DDIs and 
DILI. 
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Table 1.1: Uptake transporter substrates 
Protein Gene Symbol Substrate 
NTCP SCL10A1 Bile acids, BSP, E1S, fluvastatin, pitavastatin, rosuvastatin 
OATP1B1 SLCO1B1 
Arsenic, atorvastatin, atrasentan, benzylpenicillin, bilirubin, bile acids, 
bosentan, BQ-123, BSP, caspofungin, cefazolin, cefditoren, 
cefoperazone, cerivastatin, darunavir, DHEAS, demethylphalloin, 
eltrombopag, enalapril, E217G, E1S, ezetimibe glucuronide, fluorescein, 
fluvastatin, gimatecan, hydroxyurea, LTC4, LTE4, lopinavir, mesalazine, 
MTX, microcystin, mycophenolic acid-7-O-glucuronide, nafcillin, 
olmesartan, phalloidin, pitavastatin, pravastatin, PGE2, rifampicin, 
rosuvastatin, saquinavir, simvastatin acid, SN-38, temocapril, 
thromboxane B2, thyroxine, torsemide, triiodothyronine, troglitazone 
sulfate, valsartan 
OATP1B3 SLCO1B3 
Amanitin, atrasentan, benzylpenicillin, bilirubin, bile acids, bosentan, 
BSP, cefadroxil, cefazolin, cefditoren, cefmetazole, cefoperazone, 
cephalexin, cholecystokinin 8, DHEAS, deltorphin II, demethylphalloin, 
diclofenac, digoxin, docetaxel, enalapril, epicatechin gallate, 
epigallocatechin gallate, erythromycin, E217G, E1S, fexofenadine, 
fluorescein, Fluo-3, fluvastatin, glutathione, hydroxyurea, imatinib, 
LTC4, mesalazine, MTX, microcystin, mycophenolic acid-7-O-
glucuronide, nafcillin, olmesartan, quabain, paclitaxel, phalloidin, 
pitavastatin, rifampicin, rosuvastatin, saquinavir, telmisartan, thyroxine, 
triiodthyronine, valsartan 
OATP2B1 SLCO2B1 Aliskiren, atorvastatin, benzylpenicillin, bile acids, bosentan, BSP, 
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DHEAS, eltrombopag, E1S, ezetimibe glucuronide, fexofenadine, 
fluvastatin, glibenclamide, latanoprost acid, mesalazine, montelukast, 
pravastatin, pitavastatin, pregnenolone sulfate, PGE2, rosuvastatin, 
talinolol, tebipenem pivoxil, thyroxine 
OAT2 SLC22A5 
5-fluorouracil, acyclovir, allopurinol, paclitaxel, p-aminohippurate, 
alpha-ketoglutarate, bumetanide, cAMP, cGMP, DHEAS, erythromycin, 
E1S, ganciclovir, glutamate, glutarate, L-ascorbic acid, MTX, orotic 
acid, penciclovir, PGE2, ranitidine, tetracycline, theophylline 
OAT7 SLC22A9 Butyrate, DHEAS, E1S 
OCT1 SLC22A1 
1-methyl-4-phenylpyridinium, acyclovir, choline, famotidine, 
ganciclovir, imatinib, metformin, n-methylnicotinamide, n-
methylquinidine, n-methylquinine, PGE2, PGF2α, ranitidine, 
tetraethylammonium, tributylmethylammonium 
OSTα/β SLC51a/b Bile acids, E1S, DHEAS 
BQ-123, cyclo(D-Trp-D-Asp-L-Pro-D-Val-L-Leu); BSP, bromosulfophthalein; cAMP, cyclic AMP; 
CCK-8, cholecystokinin; cGMP, cyclic GMP; DHEAS, dehydroepiandrosterone sulfate; E217G, 
estradiol-17β-D-glucuronide; E1S, estrone-3-sulfate; GSH, glutathione; PG, prostaglandin; LT, 
leukotriene; MTX, methotrexate 
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Table 1.2: Efflux transporter substrates 
Protein Gene Symbol Substrates 
Apical Membrane 
MDR1/P-gp ABCB1 
Aldosterone, amprenavir, berberine, colchicine, corticosterone, 
cyclosporin A, debrisoquine, dexamethasone, digoxin, 
doxorubicin, erythromycin, etoposide, fexofenadine, 
grepafloxacin, indinavir, irinotecan, levofloxacin, loperamide, 
lovastatin, losartan, nelfinavir, mitoxantrone, nicardipine, 
norverapamil, paclitaxel, quinidine, rhodamine 123, ritonavir, 
saquinavir, tacrolimus, talinolol, terfenadine, topotecan, 
valinomycin, verapamil, vinblastine 
MDR3 ABCB4 Phospholipids , digoxin, paclitaxel, verapamil, vinblastine 
BSEP ABCB11 Conjugated and unconjugated bile acids, pravastatin 
MRP2 ABCC2 
Carboxydichlorofluorescein, camptothecin, cerivastatin, cisplatin, 
cholecystokinin , DHEAS, doxorubicin, E217G, E1S, etoposide, 
glibenclamide, indomethacin, irinotecan, LTC4, MTX, ochratoxin 
A, olmesartan, para-aminohippurate, pravastatin, rifampin, SN-
38, valsartan, vinblastine, vincristine, numerous glucuronide, 
glutathione and sulfate conjugates 
BCRP ABCG2 
4-methylumbelliferone sulfate, 9-(2-phosphomethoxyethyl) 
adenine, acyclovir, aflatoxin B1, chlorothiazide, ciprofloxacin, 
dasatinib, daunorubicin, dipyridamole, doxorubicin, E217G, E1S, 
estradiol, etoposide, furosemide, ganciclovir, genistein, glyburide, 
harmol sulfate, hematoporphyrin, imatinib, irinotecan, lapatinib, 
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MTX, mitoxantrone, nitrofurantoin, ofloxacin, pitavastatin, 
prazosin, rhodamine 123, rosuvastatin, SN-38, sulfasalazine, 
tamoxifen, taurocholate, teniposide, testosterone, topotecan, urate 
MATE1 SLC47A1 
1-methyl-4-phenylpyridinium, acyclovir, cimetidine, creatinine, 
E1S, fexofenadine, guanidine, metformin, oxaliplatin, 
procainamide, tetraethylammonium, thiamine, topotecan 
Basolateral Membrane 
MRP1 ABCC1 
Aflatoxin B1, bilirubin, daunorubicin, difloxacin, doxorubicin, 
etoposide, flutamide, folic acid, glutathione, grepafloxacin, 
irinotecan, leucovorin, MTX, paclitaxel, saquinavir, ritonavir, 
vinblastine, vincristine, and numerous glutathione, glucuronide, 
and sulfate conjugates 
MRP3 ABCC3 
Acetaminophen glucuronide, DHEAS, E217G, ethinylestradiol 
glucuronide, etoposide, fexofenadine, folic acid, leucovorin, 
LTC4, MTX, monovalent and sulfated bile salts 
MRP4 ABCC4 
9-(2-phosphomethoxyethyl) adenine, adefovir, ADP, 
azidothymidine, chenodeoxycholylglycine, cholate, taurocholate, 
cAMP, cGMP, DHEAS, E217G, folic acid, MTX, nelfinavir, 
olmesartan, para-aminohippurate, PGE1, PGE2, rosuvastatin, 
tenofovir, topotecan, urate, ADP,  
MRP5 ABCC5 Adefovir, cAMP, cGMP 
MRP6 ABCC6 BQ-123, LTC4-glutathione, dinitrophenol glucuronide 
ADP, adenosine diphosphate; cAMP, cyclic AMP; cGMP, cyclic GMP; CSA, cyclosporin; DHEAS, 
dehydroepiandrosterone sulfate; E217G, estradiol-17β-D-glucuronide; E1S, estrone-3-sulfate; MTX, 
methotrexate; PG, prostaglandin; LT, leukotriene; TC, taurocholate 
  
 
 
5
4
  
Table 1.3: Nuclear receptors (NRs) and transporter regulation 
Nuclear 
Receptor 
Transport 
Protein 
Change RNA/Protein Ligand Test System
a
 
AhR 
 
NTCP ↓ mRNA TCDD HH 
Oatp1a1 (m) ↓ mRNA TCDD, BNF In vivo 
Oatp1a4 (r) ↓ mRNA, protein TCDD, BNF, PCB126 In vivo 
OATP1B3 ↓ mRNA TCDD HH 
OATP2B1 ↓ mRNA TCDD HH 
OAT2 ↓ mRNA TCDD HH 
OCT1 ↓ mRNA TCDD HH 
MDR1 ↑ mRNA TCDD HH 
BSEP ↓ mRNA TCDD HH 
Mrp2 (m) ↑ mRNA 3-MC, TCDD, PCB126, BNF In vivo 
BCRP ↑ mRNA TCDD HepG2, HH 
Bcrp (m) ↔ mRNA TCDD, 3-MC In vivo 
Mrp3 (m) ↑ mRNA TCDD, PCB126, BNF In vivo 
MRP4 ↑ mRNA, protein TCDD, 3-MC HepG2, HH 
  
 
 
5
5
  
Mrp5 (m) ↑ mRNA TCDD, PCB126, BNF In vivo 
CAR 
 
NTCP ↓,↑ mRNA PB HH, HLS 
OATP1B3 ↓ mRNA PB HH 
OATP2B1 ↓ mRNA PB HH 
Oatp1a1 (m) ↓ mRNA PB,TCPOBOP, DAS In vivo 
Oatp1a4 (m) ↑ mRNA PB,TCPOBOP In vivo 
Oatp1a4 (r) ↑ mRNA, protein PB, DAS, PCB99 In vivo 
Oatp1a5 (m) ↓ mRNA PB,TCPOBOP, DAS In vivo 
OCT1 ↓ mRNA PB HH 
MDR1 ↑ mRNA PB HH 
MDR1 ↑ mRNA PB HLS 
BSEP ↓ mRNA PB HH 
BSEP ↑ mRNA PB HLS 
BCRP ↑ mRNA PB HH 
MRP2 ↑ mRNA PB HH, HLS 
Mrp2 (m) ↑ mRNA TCPOBOP In vivo 
Mrp2 (r)  ↑ mRNA PB RH 
Mrp3 (r) ↑ mRNA PB, PCB99, DAS, PB In vivo, HepG2 
  
 
 
5
6
  
Mrp3 (m) ↑ mRNA TCPOBOP, DAS, PB In vivo 
Mrp4 (m) ↑ mRNA, protein TCPOBOP, PB In vivo 
Mrp5 (m) ↑ mRNA TCPOBOP, DAS In vivo 
FXR 
Ntcp (m) ↓ mRNA Bile duct ligation, CA In vivo 
OATP1B3 ↓ mRNA CDCA HLS 
BSEP ↑ mRNA CDCA HLS 
MRP2 ↑ mRNA CDCA, GW4064 HepG2 
Mrp2 (r) ↑ mRNA CDCA, GW4064 HH, FAO 
Nrf2 
NTCP ↓ mRNA OPZ HH 
OATP1B3 ↓ mRNA OPZ HH 
Oatp1a1 (m) ↓ mRNA BHA, EXQ In vivo 
Oatp2b1 (m) ↑ mRNA BHA, EXQ In vivo 
OAT2 ↓ mRNA OPZ HH 
MDR1 ↑ mRNA OPZ HH 
BSEP ↓ mRNA OPZ HH 
BCRP ↑ mRNA OPZ HH 
MRP2 ↑ mRNA OPZ HH 
Mrp2 (m) ↑ mRNA OPZ, BHA, EXQ In vivo 
  
 
 
5
7
  
Mrp2 (r) ↑ protein OPZ, EXQ In vivo 
MRP3 ↑ mRNA OPZ HH 
Mrp3 (m) ↑ mRNA OPZ, BHA In vivo 
Mrp3 (r) ↑ mRNA OPZ, BHA, EXQ In vivo 
MRP4 ↑ mRNA, protein OPZ HepG2, HH 
Mrp4 (m) ↑ mRNA OPZ, BHA, EXQ In vivo 
Mrp5 (m) ↑ mRNA BHA, OPZ, EXQ In vivo 
PPARα 
Ntcp (m) ↓ protein CPFB In vivo 
Oatp1a1 (m) ↓ mRNA, protein CLFB, DEHP, CPFB In vivo 
Oatp1a6 (m) ↓ mRNA CLFB In vivo 
Oatp2b1 (m) ↓ mRNA CLFB, DEHP In vivo 
Mdr1 (m) ↑ protein CPFB In vivo 
Bsep (m) ↓ protein CPFB In vivo 
Mrp2 (r) ↔ (protein), 
↓(mRNA) 
mRNA, protein CLFB, DEHP, PFDA In vivo 
Bcrp (m) ↑ mRNA, protein CLFB In vivo 
Mrp3 (m) ↑ mRNA, protein CLFB, CPFB, DEHP In vivo 
Mrp4 (m) ↑ mRNA, protein CLFB In vivo 
  
 
 
5
8
  
PXR 
NTCP ↓ mRNA RIF HH 
OATP1B1 ↑ mRNA RIF HH 
Oatp1a1 (m) ↓ mRNA PCN, SPR, DEX In vivo 
Oatp1a4 (m) ↑ mRNA PCN, SPR In vivo 
Oatp1a4 (r) ↑ mRNA, protein PCN, SPR, DEX In vivo 
Oatp1a5 (m) ↓ mRNA SPR, DEX In vivo 
OCT1 ↓ mRNA RIF HH 
BSEP ↓ mRNA RIF HH 
BSEP ↑ mRNA RIF HLS 
Mrp2 (m) ↑ mRNA PCN, SPR In vivo 
Mrp2 (r) ↑ mRNA, protein DEX, PCN, SPR RH, in vivo 
MRP2 ↑ mRNA RIF HH, HLS 
BCRP ↑ mRNA RIF HH 
Bcrp (m)  mRNA PCN In vivo 
a 
FAO, rat hepatoma cell line; HLS, human liver slices; HH, human hepatocytes; HepG2, human-derived liver cell line, m, mouse; r, rat; RH, rat 
hepatocytes 
3-MC, 3-methylcholanthrene; BHA, butylated hydroxyanisole; BNF, β-naphthoflavone; CA, cholic acid; CDCA, chenodeoxycholic acid; CLFB, 
clofibric acid; CPFB, ciprofibrate; DAS, diallyl sulfide; DEX, dexamethasone; DEHP, di-(2-ethylhexyl)phthalate; EXQ, ethoxyquin; GW4064, 3-
  
 
 
5
9
  
(2,6-Dichlorophenyl)-4-(3’-carboxy-2-chlorostilben-4-yl)oxymethyl-5-isopropylisoxazole; OPZ, oltipraz; PB, phenobarbital; PCN, pregenolone-
16α-carbonitrile; PCB99, 2,2'4,4',6-pentachlorobiphenyl ;PCB126, 3,3’,4,4’,5-pentachlorobiphenyl; PFDA, perfluorodecanoic acid; RIF, 
rifampicin; SPR, spironolactone; TCDD, 2,3,7,8-tetrachlorodibenzo-p-dioxin; TCPOBOP, 1,4-Bis-[2-(3,5-dichloropyridyloxy)]benzene, 3,3’,5,5’-
Tetrachloro-1,4-bis(pyridyloxy)benzene
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Table 1.4: Model systems for studying hepatic drug transport: Summary of major applications and 
advantages/disadvantages  
Model System Major Applications  Advantages/Disadvantages 
In Vitro    
Membrane vesicles 
prepared from 
transfected systems 
Screening for substrates 
and inhibitors of efflux 
transporters 
+ 
+ 
+ 
 
- 
 
- 
 
- 
High throughput 
High transporter expression can be achieved 
Preparation of large batches and 
cryopreservation possible 
Interplay of multiple transport proteins 
cannot be assessed 
Endogenous transport proteins may affect 
data interpretation 
Parental cell differences might alter transport 
function (e.g. due to differences in 
cholesterol content or glycosylation) 
Purified membrane 
vesicles from liver 
tissue 
Mechanistic studies of 
substrate transport at a 
particular membrane 
domain 
+ 
 
- 
 
- 
All relevant transporters expressed, no 
interference from metabolism 
Preparation of high-purity vesicles is 
technically challenging and labor-intensive 
Contribution of a single transporter is 
difficult to assess 
Non-polarized 
transfected cells 
High-throughput screening 
for substrates and 
+ 
+ 
High-throughput cell-based model 
Stable transfection allows for multiple 
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inhibitors; evaluation of 
drug interactions 
 
- 
 
- 
 
- 
passages 
Endogenous transport proteins may affect 
data interpretation 
Transporter expression levels difficult to 
standardize 
Not optimal to study efflux transport proteins 
Polarized transfected 
cells 
Investigation of vectorial 
transport and qualitative 
interplay between uptake 
and efflux transporters 
+ 
 
+ 
 
+ 
 
- 
 
- 
Polarized phenotype mimics hepatocyte 
polarity 
Active transport vs. diffusion can be assessed 
Multiple transfections with transport proteins 
and/or metabolizing enzymes can be 
conducted 
Transporter expression levels difficult to 
standardize 
Complicated assay design 
Suspended hepatocytes 
Investigation of hepatic 
uptake; identification of 
uptake inhibitors; 
characterization of substrate 
uptake kinetics  
+ 
 
+ 
- 
- 
Expression of uptake transporters may be 
closer to in vivo  
Easily transferable to species of interest 
Rapid loss of viability 
Not suitable to study canalicular efflux 
transporters 
Sandwich-cultured 
hepatocytes 
Evaluation of hepatobiliary 
disposition, hepatic drug 
interactions, transporter 
interplay and regulation; 
+ 
 
 
+ 
Expression of hepatic transporters, drug-
metabolizing enzymes and regulatory 
proteins resembles in vivo  
Can be established from cryopreserved or 
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assessment of intracellular 
concentrations and 
subcellular distribution 
 
 
+ 
 
- 
 
- 
freshly isolated hepatocytes from the species 
of interest 
Identification of inhibitors and inducers of 
transport proteins possible 
Formation of polarized phenotype requires 
time 
Expression of transporters and metabolizing 
enzymes may be altered by culture 
conditions 
Liver slices 
Mechanistic studies on 
interplay of hepatic 
metabolism and transport 
+ 
 
- 
In vivo architecture maintained at cellular 
level 
Viability limited to a few hours 
Isolated perfused liver 
Mechanistic studies of 
hepatic uptake, metabolism 
and biliary excretion 
+ 
 
+ 
 
+ 
 
 
- 
- 
 
- 
Intact organ physiology and bile flow 
maintained 
No interference with non-hepatic transport 
and/or non-hepatic metabolism 
Animals can be pre-treated to assess the 
effects of inhibitors and inducers on transport 
protein expression 
Low throughput, labor- and animal-intensive  
Viability limited to ~3 hours after liver 
isolation 
Limited to rodents due to technical/practical 
issues 
In Vivo    
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Human genetic 
polymorphism or 
rodent knockout   
Investigation of the impact 
of transporter loss-of-
function on whole body 
disposition  
+ 
 
 
+ 
 
 
- 
 
 
- 
 
- 
Non-invasive assessment of impact of a 
single transporter on systemic disposition of 
drugs/metabolites 
Ability to evaluate impact of basolateral 
(uptake and efflux) and canalicular 
transporters 
Depending on frequency, identification of 
human subjects with nonfunctional 
polymorphism may be rate-limiting 
Alteration in compensatory pathways may 
confound data interpretation 
Very low throughput 
Magnetic resonance 
imaging 
Investigation of liver and 
biliary tree anatomy and 
function of hepatic uptake 
and efflux transporters 
+ 
 
 
+ 
- 
 
- 
 
- 
Non-invasive 3D image of liver and biliary 
tree with inherent ability to quantify total 
intracellular drug concentrations 
Safer compared to radiation-based imaging 
Probes are limited to existing MRI imaging 
agents  
Parent agent and metabolites cannot be 
differentiated 
Low throughput/expensive 
Single-photon 
emission computed 
tomography (SPECT) 
and positron emission 
Investigate the function of 
hepatic uptake and efflux 
transporters 
+ 
 
 
- 
Non-invasive 3D image of liver and biliary 
tree with inherent ability to quantify total 
intracellular drug concentration 
Use of short half-life radionuclides limits the 
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tomography (PET)  
 
- 
 
 
- 
 
- 
potential number of substrates that can be 
synthesized (PET) 
Use of technetium-chelated ligands limits 
useful probes to those currently used in 
clinical practice (SPECT)  
Parent drug and metabolites cannot be 
differentiated 
Low throughput/expensive 
Bile duct cannulation/ 
CHOL-ect
®
  
multi-lumen catheter 
Direct measurement of 
biliary excretion 
+ 
 
- 
- 
- 
Studies may be conducted in humans/freely 
moving animals 
Very low throughput/expensive 
Technically challenging 
Long-term cannulation might affect normal 
physiology (e.g. changes in bile acid pool) 
 
  65  
 
Table 1.5: Examples of clinically relevant transporter-mediated DDIs 
Inhibiting Drug 
Transporter 
Substrate 
Affected 
Effect, Protein(s) Involved, Proposed Mechanism(s) 
Amiodarone 
Digoxin Digoxin concentrations 2-fold ↑ in humans and rats; in 
vitro data support inhibition of Oatp2-mediated digoxin 
uptake in rats 
Atorvastatin 
Repaglinide Repaglinide AUC and Cmax ↑ 43% and 18%, respectively; 
likely OATP1B1 inhibition 
Cyclosporin A 
Bosentan 30-fold ↑ bosentan plasma concentrations in humans; 
inhibition of OATP-mediated hepatic uptake of bosentan in 
rat 
Cerivastatin Cerivastatin AUC 4-fold ↑; OATP1B1 inhibition (Ki = 0.2 
µM) 
Colchicine Colchicine AUC and Cmax ~3-fold ↑; inhibition of P-gp and 
CYP3A4 
Pravastatin Pravastatin AUC and Cmax ~10-fold higher than historic 
controls; OATP inhibition by CsA 
Repaglinide Repaglinide AUC 4-fold ↑; inhibition of CYP3A4 and 
OATP1B1 
Rosuvastatin Rosuvastatin AUC 7.1-fold ↑; OATP1B1 inhibition (IC50 = 
2.2 µM at 5 µM rosuvastatin) 
Erythromycin 
Theophylline 25% erythromycin dose reduction advised; inhibition of 
OAT2-mediated theophylline transport, enzyme inhibition 
also may be involved 
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Gemfibrozil 
Atorvastatin Atorvastatin and metabolites AUC and Cmax ↑ 
Cerivastatin Cerivastatin AUC 5.6-fold ↑; inhibition of CYP2C8 
(major) and possibly OATP1B1 (minor) 
Lovastatin Lovastatin acid AUC 2.8-fold ↑; mechanism(s) not 
elucidated 
Pravastatin Pravastatin AUC 2-fold ↑ and CLrenal ↓; possibly in part 
hepatic OATP1B1 inhibition 
Repaglinide Repaglinide AUC 8.1-fold ↑; CYP2C8 inhibition by 
gemfibrozil glucuronide, possibly OATP1B1 inhibition 
Rosuvastatin Rosuvastatin AUC 1.9-fold ↑; OATP1B1 inhibition 
Simvastatin Simvastatin acid AUC 1.9-fold ↑; mechanism(s) not 
confirmed, contribution of OATP1B1 to hepatic uptake 
may be limited 
Quinine/Quinidine Digoxin Digoxin CLbiliary ↓ by 35-42%; Pgp inhibition 
Rifampicin 
Atorvastatin Atorvastatin acid AUC ~7-fold ↑; 2-hydroxy- and 4-
hydroxy-atorvastatin acid AUC  ~7- and 4-fold ↑; 
inhibition of OATP1B1B1/1B3 
Fimasartan Fimasartan Cmax ~10-fold ↑; OATP1B1 inhibition 
Pravastatin Pravastatin AUC and Cmax ~2.5-fold ↑ 
Rifampin 
Atorvastatin AUC and Cmax of atorvastatin and metabolites ↓ by 43-93% 
Digoxin Digoxin AUC and Cmax ↓;  CLnonrenal ↑ 
Talinolol Talinolol AUC, Cmax and t1/2 ↓, CLnonrenal and Vd ↑; likely 
hepatic and intestinal P-gp induction 
St John’s Wort 
Talinolol Talinolol CLnonrenal ↑ by ~40%; likely combination of 
hepatic and intestinal P-gp induction 
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Telaprevir 
Atorvastatin Atorvastatin AUC ~8-fold ↑; inhibition of OATP1B1/1B3 
and CYP 3A4 
Cyclosporin A Cyclosporin A AUC ~5-fold ↑ 
Tacrolimus Tacrolimus AUC ~70-fold ↑; inhibition of hepatic uptake 
and CYP3A4 
Tipranavir/Ritonavir 
Atorvastatin Steady-state tipranavir/RTV ↑ atorvastatin AUC and Cmax 
~9-fold 
Rosuvastatin Steady-state tipranavir/RTV ↑ rosuvastatin AUC and Cmax 
~2-fold 
Verapamil Digoxin Digoxin CLbiliary ↓ by 43%; Pgp inhibition 
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Figure 1.1: In vivo architecture of the liver (A), reproduced with permission from Chu et al.
20
, and 
localization of transport proteins in hepatocytes (B), reproduced with permission from Köck and 
Brouwer.
164
 Hepatocytes are polarized cells with two separate membrane domains facing blood and bile. 
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Project Rationale and Specific Aims 
The objective of this dissertation research was to develop preclinical and clinical tools to assess 
the impact of liver pathology on transporter-mediated systemic and hepatic exposure to medications.    
The research strategy utilized preclinical models (including membrane vesicles from transporter-
expressing cells and sandwich-cultured hepatocytes), mathematical modeling, and a novel clinical study 
to evaluate transporter function.  This work provides a mechanistic understanding of the impact that 
hepatic transporter function has on the disposition of drugs and endogenous compounds under normal 
conditions and in response to altered liver function due to drug-induced phospholipidosis or liver disease, 
specifically non-alcoholic steatohepatitis.   
 Phospholipidosis (PLD) is a lysosomal storage disorder where phospholipids accumulate 
resulting in concentric lamellar bodies within the lysosome.  Drug-induced PLD can occur in any tissue.  
Certain adverse or undesired effects (i.e. hepatic fibrosis, hERG channel inhibition and renal tubular 
toxicity) positively associate with known PLD inducers
1-3
, but little is known about the impact of PLD on 
hepatic transport.  Significant attention by industrial and regulatory scientists has been devoted to 
developing sensitive and specific models to detect PLD during pre-clinical drug development. Although 
in silico and in vitro models exist, unfortunately these models may not accurately predict PLD induced by 
metabolites, or which tissue(s) will be affected.  Therefore, the first aim of this research was to develop a 
novel method using rat SCH to investigate whether SCH can serve as a sensitive and selective model to 
evaluate hepatic drug-induced PLD and determine whether PLD alters hepatic transporter-mediated 
uptake and biliary excretion processes. 
The second aim of this project was to determine the involvement of two hepatic basolateral efflux 
transporters known to be up-regulated in inflammatory liver disease (i.e., MRP3 and MRP4) on 
enalaprilat transport from the hepatocyte to blood.  The transport proteins responsible for the hepatic 
uptake and biliary excretion of enalapril and enalaprilat have been well described
4-7
, but the processes 
involved in basolateral efflux of enalaprilat have not been well-characterized.  Following oral 
administration, enalapril enters the hepatocyte and is hydrolyzed to the active form, enalaprilat, by hepatic 
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carboxylesterases.  Enalaprilat must undergo excretion from the hepatocyte across the basolateral 
membrane into the systemic circulation to exert its systemic pharmacologic effect.
8
  Additionally, 
enalapril is being investigated as an anti-fibrotic agent in patients with NASH.
9
  Therefore, given the 
postulated intra-hepatocyte mechanism of action
10
, understanding the mechanisms responsible for the 
hepatic disposition of enalaprilat following transformation from enalapril may have important therapeutic 
implications in liver disease where alterations in efflux function may impact both systemic as well as 
hepatic efficacy.     
NASH is an intermediate pathologic state on the pathway from simple steatosis to cirrhosis that is 
characterized by hepatocyte steatosis, ballooning, inflammation and fibrosis.  Multiple therapeutics have 
been used to improve insulin resistance in an effort to revert the inflammation associated with non-
alcoholic fatty liver disease (NAFLD) and prevent fibrosis, including metformin, pioglitazone, 
rosiglitazone and rosuvastatin.
11-14
  Unfortunately, the progression of fibrosis was not prevented reliably, 
or did not regress, for any tested pharmacologic intervention.  Recently, expression of many uptake and 
efflux transporters and drug metabolizing enzymes was evaluated in liver samples from patients with 
NASH compared to healthy controls.  In general, transport proteins responsible for hepatic drug uptake 
were down-regulated (e.g., OATPs, NTCP), while excretory proteins were up-regulated (e.g., MRP3, 
MRP4, BCRP) in NASH.
15-18
  Since the major site of action for biguanides, glitazones and statins is 
within hepatocytes, diminished pharmacologic activity may be due, in part, to decreased intracellular 
hepatocyte concentrations as a consequence of altered hepatic transport.  Therefore, the objective of the 
third aim of this dissertation research was to determine the functional impact of increased MRP3 protein 
expression on basolateral efflux of a probe substrate in patients with biopsy-confirmed NASH compared 
to healthy subjects.  Following intravenous administration of morphine, the pharmacokinetics of 
morphine glucuronides, MRP3 substrates, were compared between healthy subjects and patients with 
NASH to determine the impact of altered basolateral efflux transporter expression.   
In summary, this work follows a translational continuum ranging from identification of altered 
hepatic transport in response to drug-induced liver pathology (Aim #1, phospholipidosis) to identification 
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of hepatic transport proteins involved in the disposition of hepatically-derived active metabolites in vitro 
(Aim #2, enalaprilat), to developing in vivo methods to assess the impact of altered expression of 
basolateral efflux transporters secondary to liver disease (Aim #3, NASH).  
 
 
Aim #1. Develop a novel screening tool to assess drug-induced hepatic phospholipidosis (PLD) and 
evaluate the impact of PLD on the hepatobiliary disposition of two probe substrates of hepatic 
basolateral and canalicular transport proteins. 
Hypothesis: Rat SCH can be used as a sensitive and selective model for hepatic PLD. Pathologic 
enlargement of lysosomes impairs hepatic transport of organic anions, as assessed using taurocholate 
and rosuvastatin. 
1.a. Develop a protocol to induce PLD in rat SCH using prototypic PLD-inducing compounds; confirm 
PLD by lysosomal visualization and transmission electron microscopy. 
1.b. Evaluate the impact of PLD on hepatic basolateral and canalicular transport of organic anions using 
two probe substrates, taurocholate and rosuvastatin. 
Aim #2. Elucidate the hepatic basolateral efflux proteins involved in the active transport of 
enalaprilat. 
Hypothesis: Enalaprilat undergoes efflux by MRP3 and/or MRP4 across the hepatic basolateral 
membrane; enalaprilat transport is inhibited by rosuvastatin.  
2.a. Identify basolateral efflux protein(s) involved in the hepatic basolateral excretion of enalaprilat using 
isolated expression systems in the presence and absence of rosuvastatin and the prototypic pan-MRP 
inhibitor MK-571. 
2.b. Quantify the impact of basolateral transport protein inhibition with rosuvastatin and MK-571 on the 
excretion of enalaprilat in vitro using human SCH. 
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Aim #3. Quantify the functional consequences of altered hepatic transport protein expression in 
patients with non-alcoholic steatohepatitis (NASH) on the systemic disposition of morphine and its 
hepatically-derived glucuronide metabolites. 
Hypothesis: Altered hepatic excretory transport function in NASH patients will increase maximal plasma 
concentrations of morphine glucuronides following intravenous morphine administration compared to 
healthy subjects 
3.a. Develop a physiologically-based mathematical model to predict morphine and morphine 
glucuronides disposition in healthy subjects and patients with NASH to inform design of a clinical 
study. 
3.b. Quantify the effect of altered hepatic excretory transport function in patients with NASH compared 
to healthy subjects on the pharmacokinetics of morphine glucuronide conjugates. 
3.c. Evaluate the impact of NASH severity on morphine glucuronides pharmacokinetic metrics. 
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CHAPTER 2.  Identification of Hepatic Phospholipidosis Inducers in Sandwich-Cultured Rat 
Hepatocytes, a Physiologically Relevant Model, Reveals Altered Basolateral Uptake and Biliary 
Excretion of Anionic Probe Substrates 
 
Introduction 
Drug-induced phospholipidosis (PLD) manifests as lysosomal accumulation of phospholipids, 
resulting in development of concentric lamellar bodies visible via the gold standard method, electron 
microscopy
1
. Predictive computer models of PLD potential have suggested that most precipitant drugs are 
weakly basic and have amphiphilic features. These cationic amphiphilic drugs (CADs), including 
antiarrhythmics, antidepressants, and anti-infectives, are able to cross the lysosomal membrane where 
they become protonated at low physiologic pH (pH 3-5) and trapped due to an inability to exit the 
lysosomal compartment following protonation. Lysosomal trapping and PLD have been observed in many 
different tissue/cell types including lung, nerve, kidney, and liver cells
2-8
. Several mechanisms have been 
proposed for CAD-induced PLD, including inhibition of lysosomal phospholipases, inhibition of H
+
-
ATPases and direct binding to the phospholipids, resulting in inert phospholipid-drug complexes
9,10
. 
PLD has been associated with hepatic/alveolar fibrosis (amiodarone), renal tubular toxicity (gentamicin), 
and QT-wave prolongation secondary to inhibition of hERG channels in the heart (tamoxifen)
5,6,11-13
. 
Accordingly, significant industrial and regulatory attention, including the formation of the FDA 
sponsored PLD Working group in 2004, has been devoted to developing sensitive and specific 
 
This work has been presented, in part, at the SOT Annual Meeting, San Antonio, TX, March 10-14, 2013 
and has been published as Ferslew BC and Brouwer KL, Identification of Hepatic Phospholipidosis 
Inducers in Sandwich-Cultured Rat Hepatocytes, a Physiologically Relevant Model, Reveals Altered 
Basolateral Uptake and Biliary Excretion of Anionic Probe Substrates, Toxicological Sciences, 2014, 139 
(1): 99-107, reprinted by permission of Oxford University Press and is presented in the style of that 
journal. 
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models to detect PLD during pre-clinical drug development. In response, multiple computer, non-cell, and 
cell-based models have been evaluated. Computer models utilizing molecular structure, as well as non-
cell-based and cell-based models focusing on altered gene expression or lysosomal uptake and retention 
of fluorescent probes (e.g., Nile red, LysoTracker Red
®
), have shown modest sensitivity and 
specificity
8,14-17
. Unfortunately, computer or non-cell based models may not be predictive of PLD induced 
by metabolites, and often fail to predict which tissue(s) will be affected due to the absence of 
metabolizing enzymes and transport processes. Methods to visualize lysosomal compartments within the 
cell to screen for PLD potential are of particular interest to reduce the burden of confirmatory studies with 
electron microscopy.  
Although most PLD-inducing drugs contain a cationic amphiphilic moiety, metabolically-
deficient models may not accurately predict PLD liability of metabolites. Sandwich-cultured hepatocytes 
(SCH) are fully differentiated, express relevant metabolizing enzymes and hepatic transporters, and can 
be used to assess hepatic transport processes involved in the clearance of endogenous and exogenous 
substrates
 18-22
. Therefore, this established system was selected for subsequent investigations to test the 
hypothesis that SCH represent a sensitive and selective model to screen for drug-induced hepatic PLD. 
Lysosomal dysfunction secondary to PLD may alter the cycling of transporters to and from the relevant 
membranes (basolateral or canalicular), resulting in altered hepatic transporter-mediated clearance of 
susceptible compounds. 
The goal of the present study was to determine whether primary rat SCH can serve as a sensitive 
and selective model to evaluate hepatic drug-induced PLD and determine if PLD alters hepatic transport 
processes. Structurally diverse drugs that cause PLD to varying degrees by distinct mechanisms were 
selected for investigation. First, lysosomal localization was determined using LysoTracker Red
®
. Second, 
the presence or absence of PLD was confirmed using transmission electron microscopy. Third, hepatic 
uptake by sodium-taurocholate cotransporting polypeptide (Ntcp) and organic anion-transporting 
polypeptides (Oatps), and biliary excretion by the bile salt export pump (Bsep), multidrug resistance-
associated protein 2 (Mrp2), and breast cancer resistance protein (Bcrp) were evaluated using taurocholate 
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(TC) and rosuvastatin (RSV) as probes for Ntcp/Bsep and Oatps/Mrp2/Bcrp, respectively. Results 
demonstrated that rat SCH are a promising screening tool for drug-induced PLD.  
Methods 
Chemicals and Reagents.  
Dexamethasone, TC, amiodarone (AMD), chloroquine (CHQ), desipramine (DES), azithromycin 
(AZI), gentamicin (GTM), Hanks’ balanced salt solution (HBSS; standard buffer), Ca2+/Mg2+-free HBSS 
(Ca
2+
-free buffer), and thiazolyl blue tetrazolium bromide were purchased from Sigma-Aldrich (St. Louis, 
MO). Rosuvastatin (RSV) was purchased from Toronto Research Chemicals (Toronto, Ontario, Canada). 
[
3
H]TC (1 mCi/mL; >97% purity) and [
3
H]RSV (1 mCi/mL; >97% purity) were purchased from 
PerkinElmer (Waltham, MA) and American Radiolabeled Chemicals (St. Louis, MO), respectively. 
Dulbecco’s Modified Eagle’s Medium (DMEM), fetal bovine serum, penicillin/streptomycin and insulin 
were purchased from Gibco (Grand Island, NY). Minimum essential medium, nonessential amino acids, 
and LysoTracker Red
®
 were purchased from Invitrogen (Carlsbad, CA). BioCoat™ culture plates, 
BioCoat™ glass inserts, Matrigel™ extracellular matrix, and insulin/transferrin/selenium culture 
supplement were purchased from BD Biosciences (Bedford, MA). All other chemicals and reagents were 
of analytical grade and readily available from commercial sources. 
Animals 
Male Wistar wild-type (WT) rats (250-350 g) from Charles River Labs (Wilmington, MA) were 
used as hepatocyte donors. Rats were allowed free access to water and food and were acclimated for a 
minimum of one week prior to experimentation. All animal procedures complied with the guidelines of 
the Institutional Animal Care and Use Committee at the University of North Carolina at Chapel Hill 
(Chapel Hill, NC). All procedures were performed while rats were under full anesthesia with 
ketamine/xylazine (140/8 mg/kg i.p.). 
Culture of Primary Rat Hepatocytes in Sandwich Configuration.  
Primary rat hepatocytes were isolated and cultured as described previously
22
. Briefly, hepatocytes 
were seeded at a density of 1.75 x 10
6
 cells/well onto six-well BioCoat™ plates. Approximately 24 h 
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later, hepatocytes were overlaid with 2 ml of 0.25 mg/ml BD Matrigel™ basement membrane matrix in 
DMEM. Hepatocytes were cultured for 4 days to allow formation of canalicular networks before 
experimentation; medium was changed daily. For single (‘acute’) administration experiments, the 2-4 day 
feeding medium was not supplemented with DMSO or PLD-inducing drugs. For multiple (‘chronic’) 
administration experiments, the feeding medium used on days 2-4 (48 h) of culture was supplemented 
with 0.1% DMSO (vehicle control, used to solubilize PLD-inducing drugs), AMD (1, 10, or 50 µM), 
CHQ (1 or 10 µM), DES (1, 10, or 50 µM), AZI (1, 10, or 50 µM), or GTM (1 mM). The concentrations 
of the PLD-inducing drugs selected for investigation were based on in vivo plasma concentrations and 
estimated hepatic concentrations
23
.  
MTT Assay 
Following incubation of rat SCH with the PLD inducers or vehicle control at 37°C for 48 h, the 
medium was aspirated, and 2 mL of 0.5 mg/mL thiazolyl blue tetrazolium bromide solution in plain 
DMEM was added. After 30 min, the medium was aspirated, and 1 mL of 0.04 M HCL in isopropanol 
was added to solubilize the cells. Lysates were analyzed by absorbance at 570 nm and 650 nm. SCH 
treated for 48 h with 100 µM CHQ and 0.1% DMSO served as positive and negative/vehicle controls, 
respectively. 
LysoTracker Red
®
 Localization in Rat Sandwich-Cultured Hepatocytes 
On day 4, the medium from SCH treated with PLD-inducing drugs or vehicle control was 
aspirated and replaced with fresh medium containing 100 nM LysoTracker Red
®
. After 30 min at 37°C, 
wells were washed rapidly twice with warm Dulbecco’s phosphate buffered saline, and both light and 
fluorescent (excitation/emission wavelengths of 577/590 nm) digital images were captured using a Zeiss 
Axiovert 200TV (Thornwood, NY) inverted phase contrast microscope. Images were analyzed using 
ImageJ software (free online at rsbweb.nih.gov).  
Electron Microscopy of Rat Sandwich-Cultured Hepatocytes 
BioCoat™ glass inserts were placed in the BioCoat™ plates, and hepatocytes were cultured as 
described above. The medium was aspirated on day 4, when SCH were fixed for 1 h with 2 mL of 2.5% 
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gluteraldehyde/1% tannic acid in 0.1 M sodium cacodylate (pH 7.3). The fixation solution was aspirated, 
and SCH were washed with 0.1 M cacodylate solution 3 times for 5 min each. SCH were post-fixed with 
1% osmium tetroxide in 0.1 M cacodylate for 20 min, then rinsed 3 times with distilled water and 2 times 
with 50% ethanol for 5 min each. SCH were stained further with 2% uranyl acetate in 50% ethanol for 30 
min. Finally, the SCH were dehydrated with increasing concentrations of ethanol (2 times with 70, 80, 90 
and 95%, and then 3 times with 100%, for 5 min each), infiltrated with propylene oxide [1:1, 2:1, and 3:1 
ratios of Epon 812 (Hatfield, PA) to propylene oxide for 1 h each], and finished with pure Epon for 1 h. 
The glass inserts were removed from the BioCoat™ plates, embedded in Epon 812, and allowed to cure at 
60°C for at least 18 h. The glass inserts were dissolved with concentrated hydrofluoric acid and thinly 
sectioned on a Leica Ultracut ultramicrotome (Leica Microsystems, Buffalo Grove, IL). Sections were 
placed on copper grids and restained with uranyl acetate and lead citrate, after which digital images were 
captured using a Tecnai 12 electron microscope (Hillsboro, OR). Multiple SCH sections from each 
treatment were imaged using a Gatan Multiscan digital camera (Pleasanton, CA). 
Probe Substrate Transport in Rat Sandwich-Cultured Hepatocytes  
Determination of the uptake and biliary excretion of the probe substrates TC (Ntcp/Bsep) and 
RSV (Oatp/Mrp2/Bcrp) in rat SCH was described previously
24
. Prior studies have established that these 
probes are metabolically stable in rat SCH
25,26
. Briefly, day 4 SCH were washed twice with 2 ml of warm 
Ca
2+
-containing
 
HBSS (standard; cells + bile) or Ca
2+
-free HBSS (cells) and then incubated with the same 
buffer for 10 min at 37°C. Subsequently, SCH were incubated with 1.5 ml of standard HBSS containing 
[
3
H]TC (1 µM; 100 nCi/ml) or [
3
H]RSV (1 µM; 100 nCi/ml) for 10 min.  For acute dosing studies, PLD-
inducing drugs (AMD 50 µM, CHQ 10 µM, DES 50 µM, AZI 50 µM, or GTM 1 mM) or vehicle control 
(0.1% DMSO) also were added to the incubation medium along with the probe substrates. After 10 min, 
SCH were washed 3 times with ice-cold standard HBSS and lysed with 0.5% Triton X-100 in phosphate-
buffered saline. Radioactivity in cell lysates was quantified by liquid scintillation spectroscopy (Packard 
Tricarb; PerkinElmer, Waltham, MA). Accumulation of TC and RSV was normalized to hepatocyte total 
protein using a BCA protein assay (Pierce Chemical, Rockford, IL). The biliary excretion index (BEI) and 
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in vitro biliary clearance (CLbiliary; ml/min/kg) were calculated using B-CLEAR
®
 technology (Qualyst 
Transporter Solutions, LCC, Durham, NC) based on the following equations: 
Equation 1:  BEI  
Accumulationcells bile- Accumulationcells
Accumulationcells bile
 
Equation 2:   CLbiliary 
Accumulationcells bile- Accumulationcells
AUC
medium 0-T
 
where AUCmedium 0-T represents the product of the incubation time (T) and the initial TC or RSV 
concentration in the medium
22,24,26
. CLbiliary units were converted to ml/min/kg body weight based on 
previously reported values for protein content in liver tissue (200 mg/g liver weight) and liver weight (40 
g/kg body weight)
27
. 
Data Analysis 
The impact of chronic or acute incubation with PLD-inducing drugs on total (cells + bile) and 
cellular accumulation, BEI and CLbiliary was determined using one-way ANOVA with Dunnett’s post-hoc 
test. A p-value of <0.05 was considered significant for all tests. All data are presented as mean ± standard 
error of the mean (SEM) unless otherwise indicated. 
 
Results 
Rat Sandwich-Cultured Hepatocyte Toxicity 
Initial pilot experiments showed that SCH incubated for 48 h with medium supplemented with 
50-100 µM CHQ exhibited complete toxicity based on the MTT assay. Thus, SCH incubated for 48 h 
with DMEM containing 100 µM CHQ or 0.1% DMSO were selected as positive and negative (vehicle) 
controls, respectively. SCH treated with PLD-inducing drugs exhibited minimal to moderate toxicity (Fig 
2.1):  8-43% for AMD, 17-29% for CHQ, 2-55% for DES, 19-43% for AZI, and 26% for GTM. Toxicity 
increased as the dosing concentration increased for AMD, CHQ, DES, and AZI.  
 
LysoTracker
®
 Red Localization 
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LysoTracker Red
®
 localization was used to assess qualitatively the size and number of lysosomes 
in SCH treated with PLD-inducing drugs. Under standard conditions, LysoTracker Red
®
 (depicted as 
green fluorescence for contrast, Figure 2.2) localized in vesicles close to the canalicular membrane. 
Exposure for 48 h to AMD, CHQ, DES, and AZI resulted in notably increased lysosomal size and/or 
number relative to control (Figure 2.2), suggestive of PLD. Increased background fluorescence was 
observed only with CHQ treatment. Interestingly, GTM-treated SCH did not exhibit increased lysosomal 
number or size.  
 
Transmission Electron Microscopy 
All major cellular organelles including the nucleus, rough/smooth endoplasmic reticulum, Golgi 
apparatus, and tight junctions between hepatocytes were visualized in each SCH preparation. Inspection 
of SCH treated with 0.1% DMSO and 1 mM GTM by electron microscopy showed a large number of 
mitochondria, glycogen granules, and small lysosomes; no pathologic lysosomes and only a few lipid 
droplets were observed. Inspection of SCH treated with AMD (50 µM), CHQ (10 µM), DES (50 µM), 
and AZI (50 µM) showed increased lipid droplet formation and enlarged lysosomal compartments with 
electron-dense deposits and membranous structures resembling laminar body inclusions, indicative of 
PLD (Figure 2.3).  
Accumulation and Excretion of Taurocholate and Rosuvastatin in Rat SCH Following Acute (10-min) 
Exposure to PLD-Inducing Drugs  
Total and cellular accumulation, BEI, and in vitro CLbiliary of TC and RSV were compared in SCH 
after acute exposure to PLD-inducing drugs.  Following a 10-min incubation of 1 µM [
3
H]TC or [
3
H]RSV 
with vehicle control (0.1% DMSO), AMD (50 µM), CHQ (10 µM), DES (50 µM), AZI (50 µM), or GTM 
(1 mM), no significant differences in total accumulation (cells + bile) or cellular accumulation of TC or 
RSV were observed. Likewise, no statistically significant differences were observed for BEI or in vitro 
CLbiliary of either TC or RSV (Figure 2.4).  
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Accumulation and Excretion of Taurocholate and Rosuvastatin in Rat SCH Following Chronic (48-h) 
Exposure to PLD-Inducing Drugs  
Accumulation of [
3
H]TC and [
3
H]RSV in cells + bile and cells, as well as the in vitro CLbiliary, 
were compared between SCH treated for 48 h with vehicle control or PLD-inducing drugs following a 10-
min incubation with 1 µM [
3
H]TC or [
3
H]RSV. Total accumulation of TC (cells + bile) significantly 
decreased with increasing concentrations of AMD, CHQ, DES, and AZI (Figure 2.5, left panel). At the 
highest concentrations tested, TC total (cells + bile) accumulation decreased by 87.2% ± 1.8%, 71.8% ± 
3.2%, 73.4% ± 0.9, and 75.3% ± 3.6% compared to control for AMD, CHQ, DES, and AZI, respectively. 
TC BEI significantly decreased at the highest tested concentrations of AMD, DES, and AZI (Table 2.1). 
At the highest concentrations tested, the TC CLbiliary decreased by 92.3% ± 1.4%, 76.7% ± 3.4%, 81.0% ± 
1.2%, and 89.3% ± 5.1% compared to control for AMD, CHQ, DES, and AZI, respectively. In contrast, 
TC cellular accumulation was not affected by any treatment (Figure 2.5, left panel). 
Similarly, total (cells + bile) accumulation of RSV significantly decreased with increasing 
concentrations of AMD, CHQ, DES, and AZI (Figure 2.5, right panel). At the highest concentrations 
tested, RSV total (cells + bile) accumulation decreased by 89.2% ± 0.4%, 58.8% ± 2.2%, 85.2% ± 2.5%, 
and 77.1% ± 0.7% compared with control for AMD, CHQ, DES, and AZI, respectively. In contrast to TC, 
cellular RSV accumulation decreased with increasing concentrations of AMD, CHQ, DES, and AZI 
(Figure 2.5, right panel). At the highest concentrations tested, RSV cellular accumulation significantly 
decreased by 89.5 ± 1.8%, 68.9 ± 4.3%, 76.8 ± 1.3%, and 69.4 ± 2.5% compared with control for AMD, 
CHQ, DES and AZI, respectively. CLbiliary of RSV decreased whereas BEI was unaffected by increasing 
concentrations of AMD, CHQ, DES, and AZI (Table 2.1). At the highest concentrations tested, RSV 
CLbiliary decreased by 88.6% ± 2.8%, 50.5% ± 6.1%, 89.7% ± 2.5% and 81.4% ± 2.2%, compared with 
control for AMD, CHQ, DES and AZI, respectively. The kidney-specific PLD-inducer, GTM, had no 
effect on total accumulation, cellular accumulation, BEI or in vitro CLbiliary of TC or RSV (Figure 2.5, 
Table 2.1). 
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Discussion 
The primary goal of this study was to determine whether rat SCH could be used to detect hepatic 
drug-induced PLD.  In addition, studies were designed to assess whether lysosomal dysfunction altered 
vectorial transport of two metabolically stable probe compounds
25,28
, TC and RSV. Five structurally 
different prototypic PLD-inducing drugs with distinct mechanisms were selected: AMD, CHQ, DES, 
AZI, and GTM. All of these drugs are known to cause hepatic PLD, with the exception of GTM, which 
induces PLD in kidney at human-relevant physiologic concentrations. Maximal plasma concentrations 
(Cmax) following a standard does of AMD (~4.3 µM), CHQ (~3.7 µM), DES (~1.9 µM),  AZI (~1.1 µM) 
and GTM (~12 µM) were considered in selection of the lowest concentration of PLD-inducing drugs (1 
µM) for investigation in the SCH system
23
. Concentrations that approximated 10- and 50-fold above the 
Cmax values also were examined because these drugs accumulate in hepatocytes. The high concentration 
of GTM was selected as a negative control to demonstrate that hepatic PLD would not be detected, and no 
changes in transport of anionic substrates would be observed. Experiments with the well-established 
lysosomal imaging probe, LysoTracker Red
®
, demonstrated that a 48-h exposure of rat SCH to each of 
the four hepatic PLD inducers resulted in a qualitative increase in the number and/or size of lysosomal 
compartments, indicative of PLD (Figure 2.2). The increased background noted in SCH treated with CHQ 
likely was due to an increase in lysosomal pH associated with CHQ’s distinct mechanism of action 
(inhibition of H
+
-ATPase)
29,30
. Nonetheless, distinct and enlarged lysosomal compartments could be 
visualized in SCH treated with CHQ. As anticipated, GTM had no effect on either lysosomal number or 
size (Figure 2.2).  
  Transmission electron microscopy of rat SCH exposed for 48 h to PLD-inducing drugs enabled 
visualization of all major organelles; enlarged lysosomal compartments with laminar figures diagnostic of 
PLD were observed in SCH treated with all PLD-inducing drugs except for GTM, which had no effect 
(Figure 2.3). In agreement with previous publications, these results suggest that LysoTracker Red
®
 may 
be a useful tool for screening novel drug candidates in SCH with hepatic PLD potential
16
 (Figures 2.2 and 
2.3). Transmission electron microscopy also showed that both the cellular and organelle membranes were 
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grossly intact. Membrane disruption has been reported in rats treated with high doses of AMD (150 
mg/kg body weight per day) for three weeks
11
. However, at the concentrations investigated for all PLD-
inducing drugs, there was no evidence of membrane disruption. Therefore, the mitochondrial toxicity 
observed in the current work, as measured by MTT formazan formation, does not appear to be due to 
membrane disruption.  
An additional benefit of the rat SCH model is the ability to assess transporter-mediated vectorial 
flux of compounds through the hepatocyte into bile. Two probe substrates were selected to evaluate 
distinct transporters on the sinusoidal (blood side) and canalicular (bile side) membranes of hepatocytes. 
TC is a metabolically stable bile acid that is transported efficiently into the hepatocyte via Ntcp, and 
excreted into bile via Bsep; RSV is taken up by Oatps and possibly by Ntcp, and excreted into bile by 
Mrp2 and Bcrp
24,31-35
. Changes in cellular accumulation and biliary excretion of probe compounds were 
examined to determine potential transporter-mediated alterations due to ‘acute’ (10-min exposure with no 
pre-treatment) and ‘chronic’ (48-h pre-treatment) administration of PLD inducers (Figures 2.4 and 2.5) 22. 
Alterations due to PLD-inducing drugs might be attributed to acute effects, or due to indirect effects, 
which would be present only after chronic administration. Following acute administration of each PLD-
inducing drug, no significant changes were observed in TC or RSV total accumulation, cellular 
accumulation, BEI or CLbiliary (Figure 2.4, Table 2.1). However, following chronic administration, all 
drugs that induced PLD decreased CLbiliary of TC and RSV, while cellular accumulation was reduced only 
for RSV. Reduced total accumulation, BEI and CLbiliary of TC with no change in cellular accumulation (in 
other words, reduced excretion of TC into the bile compartment) secondary to PLD is consistent with 
canalicular transporter dysfunction, specifically reduced Bsep-mediated biliary excretion in the case of 
TC
36
. Decreased RSV total (cells + bile) and cellular accumulation as well as CLbiliary, but no change in 
BEI, is consistent with decreased Oatp-mediated uptake
36
. Importantly, following chronic GTM 
administration, PLD was not observed in rat SCH, and no differences in TC or RSV disposition were 
noted (Figure 2.5 and Table 2.1). Taken together, results from the acute- and chronic- exposure 
experiments indicated that PLD leads to functional changes in hepatic Oatp- and Bsep-mediated uptake 
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and excretion, respectively. Results also suggest that Ntcp function is maintained and that RSV biliary 
excretion, mediated by both Mrp2 and Bcrp, does not appear to be altered by PLD.  Lysosomal-associated 
alterations in the disposition and toxicity of drugs have been reported previously. For example, the impact 
of lysosomal pH-dependent entrapment on the cytotoxicity of chemotherapeutics with and without 
susceptibility to lysosomal sequestration was examined
29
. When pH-dependent lysosomal sequestration 
was inhibited by CHQ, cellular toxicity of the lysosomotropic chemotherapeutic agent was enhanced, 
whereas no effect on toxicity was observed for the non-lysosomotropic chemotherapeutic agent. 
Additionally, exacerbation of the PLD phenotype with sucrose increased the uptake and lysosomal 
sequestration of CHQ, which was not observed when PLD induction was inhibited by bafilomycin A1
37
. 
Therefore, lysosomal enlargement and sequestration appear to alter active anionic transport processes 
based on the present results, as well as the intracellular disposition of lysosomotropic drugs
8,37
. 
Some limitations are associated with this work. First, compared to many published studies using 
immortalized cell lines to screen PLD potential, fewer drugs have been studied in rat SCH. Although this 
model is lower throughput than typical immortalized cell line screens, development of hepatic-specific 
PLD with drugs that exhibited a range of hepatic induction potency was demonstrated (AMD and CHQ 
are strong inducers while DES and AZI are weaker hepatic PLD inducers). Additionally, the PLD-
inducing drugs investigated in this study affect different organ systems in vivo and have diverse 
postulated induction mechanisms in vivo  (i.e. inhibition of phospholipid metabolism with AMD, 
inhibition of H
+
-ATPase with CHQ). The present data indicate that rat SCH are both a sensitive and 
specific model for identification of drugs that cause hepatic PLD. All drugs tested, including GTM, 
caused mild to moderate toxicity based on the MTT assay (Figure 2.1). Although drug-induced PLD has 
not been associated directly with cellular toxicity, the altered anionic transport observed may be related to 
toxicity. Interestingly, moderate toxicity was observed with GTM although no PLD or change in TC or 
RSV transport was apparent. This supports the hypothesis that altered TC and RSV transport secondary to 
PLD are not likely caused solely by the mild to moderate toxicity observed.  Additionally, preliminary 
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data indicate that streptomycin, an aminoglycoside included in the feeding medium that is structurally 
similar to GTM, did not induce PLD at the low concentrations utilized (172nM). 
Drug-induced PLD leads to impaired phospholipid storage, metabolism, and excretion
1
. Several 
model systems have been evaluated to identify PLD-inducing drugs as early as possible during drug 
development. As such, PLD potential often is identified during early preclinical development and is 
handled on a case-by-case basis depending on the severity and target organ(s) affected
38
. This case-based 
assessment poses challenges due to a limited understanding of the (presumed) association between PLD 
and organ toxicity. Consequently, increasing attention has been placed on developing sensitive and 
specific models to predict drug-induced PLD, thereby avoiding late-stage failures due to unanticipated 
toxicities. A report by leading investigators encourages selection of lead drug candidates based on in 
silico and/or in vitro screening for PLD potential
38
. Multiple in silico quantitative structure-activity 
relationship (QSAR) and in vitro non-cell-based and cell-based models have been developed
2,14-16,39-41
. 
These screening methods have identified primarily cationic amphiphilic drugs as causal agents, with a 
few notable exceptions (i.e., GTM). Although invaluable for initial risk-benefit analyses, these models 
have limitations. In vitro (and by inference in silico) models that lack metabolic and transport processes 
may underestimate PLD potential, as evidenced by the observation that isolated, metabolically active 
murine macrophages exhibited greater sensitivity and specificity to predict PLD in vivo than immortalized 
cell lines
41
. Additionally, organ-specific transporters and metabolizing enzymes are germane to assess 
PLD potential in vitro as well as facilitate accurate in vivo extrapolation to target organs. SCH are a well-
established system expressing hepatic-relevant metabolizing enzymes and transport proteins, which may 
aid in increasing assay sensitivity to identify drugs that require metabolism or transport to induce hepatic 
PLD
22
.  
In conclusion, rat SCH are a viable system to evaluate drug-induced hepatic PLD. Initial 
screening with LysoTracker Red
®
 localization would increase throughput. PLD screening should be 
evaluated in a metabolically-capable cell-based model such as SCH, which provide the additional benefit 
that transport processes can be evaluated concurrently. The present data reveal for the first time that drug-
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induced hepatic lysosomal dysfunction may be associated with altered Oatp- and Bsep-mediated anionic 
transport.  Clearly, PLD-inducing drugs may exhibit many toxicologic endpoints that require further 
preclinical evaluation.  
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Table 2.1: BEI and In Vitro CLbiliary of Taurocholate (TC) and Rosuvastatin (RSV) Based on Data Presented in Figure 3.5 in Day 4 Rat SCH 
Following a 10-min Incubation With 1µM [
3
H]TC or [
3
H]RSV 
 
 
Notes: SCH were treated for 48 h (“chronic exposure”) with vehicle control (0.1% DMSO) or PLD-inducing drugs. Data represent the mean 
(SEM) of triplicate measurements (n = 3–7 hepatocyte preparations). 
*p < 0.05, control versus treated 
  Control AMD CHQ DES AZI GTM 
   10 µM 50 µM 1 µM 10 µM 1 µM 10 µM 50 µM 1 µM 10 µM 50 µM 1 mM 
TC 
BEI (%) 
88.3  
(1.2) 
87.2 
(0.8) 
52.9 * 
(3.7) 
86.5 
(1.9) 
73.4 
(4.0) 
84.5 
(1.5) 
87.0 
(1.7) 
62.0 * 
(3.2) 
75.3 
(10.5) 
72.8 
(4.7) 
34.8 * 
(13.0) 
87.8 
(1.5) 
CLbiliary 
(mL/min/ kg) 
31.7 
(5.0) 
20.8 
(6.3) 
3.3 * 
(1.2) 
26.3 
(8.4) 
9.0 * 
(2.9) 
25.7 
(7.9) 
16.9 
(2.1) 
4.7 * 
(0.7) 
16.1 
(7.4) 
8.0 * 
(2.6) 
2.5 * 
(1.0) 
40.4 
(3.2) 
RSV 
BEI (%) 
56.7 
(3.6) 
62.8 
(4.2) 
50.1 
(9.3) 
53.2 
(4.4) 
62.7 
(7.8) 
46.0 
(5.7) 
55.6 
(3.7) 
41.3 
(0.9) 
59.4 
(2.9) 
64.9 
(3.7) 
50.6 
(6.7) 
50.3 
(5.4) 
CLbiliary 
(mL/min/ kg) 
78.5 
(13.5) 
41.4 
(8.6) 
7.7 * 
(3.7) 
51.5 
(10.5) 
27.6 * 
(6.2) 
66.8 
(13.8) 
69.2 
(12.5) 
10.3 * 
(1.6) 
73.4 
(9.8) 
38.8 
(5.4) 
19.6 * 
(2.3) 
61.9 
(6.0) 
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Figure 2.1: Toxicity of AMD, CHQ, DES, AZI, and GTM (incubation for 48 hr) evaluated in day 4 rat 
SCH measured as percent inhibition of MTT formazan formation. SCH treated with chloroquine at 100 
µM and 0.1% DMSO (vehicle) were used as the positive and negative controls, respectively. Data are 
presented as mean ± SEM, n=3-7 replicates measured in triplicate. 
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Figure 2.2: Representative images of day 4 rat SCH incubated for 30 min with 100 nM LysoTracker Red
®
 following culture with PLD-inducing 
drugs or vehicle control (0.1% DMSO) for 48 h; only the highest incubation concentration is shown for clarity. Upper panel: light microscopy 
image; middle panel: LysoTracker Red
®
 fluorescence; lower panel: overlaid light and fluorescent images filtered to appear blue and green, 
respectively, for contrast (inset in upper right is enlarged image). Scale bar in upper left corner of each image represents 20 µm. 
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Figure 2.3: Representative electron micrographs of day 4 rat SCH after 48 h culture with PLD-inducing 
drugs or vehicle control (0.1% DMSO). Arrows indicate normal or enlarged laminar body-containing 
lysosomes. Scale bar represents 0.5 µm for all phospholipidosis-inducing drugs except control and 
gentamicin, for which the scale bar represents 2 and 1 µm, respectively. 
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Figure 2.4: Accumulation of TC (left panel) and RSV(right panel) in cells + bile (black bars) and cells 
(white bars) of day 4 rat SCH following a 10-min co-incubation (“acute exposure”) with 1 µM [3H]TC or 
[
3
H]RSV in the presence of vehicle control (0.1% DMSO) or PLD-inducing drugs: AMD, CHQ, DES, 
AZI, and GTM. Data represent the mean ± SEM of triplicate measurements in n=3 hepatocyte 
preparations. No statistically significant differences were observed between control vs. treated for total 
(cell + bile) accumulation or cellular accumulation. 
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Figure 2.5: Accumulation of TC (left panel) and RSV (right panel) in cells + bile (black bars) and cells 
(white bars) of day 4 rat SCH following a 10-min incubation with 1 µM [
3
H]TC or [
3
H]RSV. SCH were 
treated for 48 h (“chronic exposure”) with vehicle control (0.1% DMSO) or PLD-inducing drugs: AMD, 
CHQ, DES, AZI, and GTM. Data represent the mean ± SEM of triplicate measurements (n=3-7 
hepatocyte preparations); *p<0.05, control vs. treated. 
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Chapter 3. Role of Multidrug Resistance-Associated Protein 4 in the Basolateral Efflux of 
Hepatically-Derived Enalaprilat 
 
Introduction 
The liver plays a central role in the metabolism, detoxification and elimination of endogenous and 
exogenous compounds.  Following uptake across the basolateral membrane from the blood to the 
hepatocyte, metabolism typically results in formation of a more hydrophilic, charged molecule that can be 
eliminated either via the bile, or across the basolateral membrane into the systemic circulation for renal 
excretion.  Importantly, following hydrophilic transformation, active efflux processes typically are 
required for the metabolite to exit the liver.  In contrast to biliary excretion, changes in active basolateral 
efflux processes (either due to drug-drug interactions [DDIs] or disease-mediated changes in efflux 
transporter function) are under appreciated
1-3
.  Changes in basolateral efflux of active metabolites may 
alter systemic concentrations and thus, systemic efficacy/toxicity, and potentially warrant detailed 
evaluation during drug development
3,4
.   
Enalapril is a prodrug transformed in the liver by carboxylesterases to the active moiety, 
enalaprilat.  Transformation removes the ethylester from enalapril, adding a negative charge, and 
increasing the potency to inhibit angiotensin converting enzyme, thereby lowering blood pressure and 
preventing cardiac remodeling and renal dysfunction
5
.  Due to the inherent negative charge on the parent 
drug and added polarity after metabolism, enalapril and enalaprilat require active transport processes to 
cross membranes. Interestingly, the presence of a diffusional barrier for enalapril and enalaprilat  
 
This work has been presented, in part, at the ISSX Annual Meeting, Dallas, TX, October 14-18, 2012 and 
has been published in Drug Metabolism and Disposition and is presented in the style of that journal. 
Copyright 2014 by the American Society for Pharmacology and Experimental Therapeutics. Reprinted 
with permission of the American Society for Pharmacology and Experimental Therapeutics. All rights 
reserved. 
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disposition helped lay the foundation for the identification of transporter-mediated disposition and 
clearance mechanisms of charged molecules
6-9
.  Rat organic anion transporting polypeptide (OATP)1a1 
and human OATP1B1 are responsible for the uptake of enalapril into the hepatocyte.   
Enalaprilat derived in the liver can be excreted into the bile or translocated across the basolateral 
membrane into the systemic circulation
8,10,11
. Although multidrug resistance-associated protein (MRP)2 is 
capable of excreting enalaprilat from the hepatocyte into bile, the majority of the absorbed dose of 
enalapril is excreted in the urine as enalaprilat, which suggests that basolateral efflux of enalaprilat into 
the systemic circulation predominates since enalaprilat appears to be formed only in the hepatocyte
11-13
.  
As the site of action for enalaprilat is in the systemic circulation (inhibition of angiotensin converting 
enzyme), hepatic basolateral efflux is germane in regulating enalaprilat’s beneficial effects on blood 
pressure, cardiac remodeling and kidney protection.  Two proteins that may be able to transport 
enalaprilat from the hepatocyte into sinusoidal blood are MRP3 and MRP4.  The localization of MRP3 
and MRP4 on the basolateral membrane, and substrate specificity profiles, make them prime candidates to 
mediate enalaprilat transport
14-16
.   
Although, enalapril is prescribed extensively in many chronic diseases, including diabetes, non-
alcoholic fatty liver disease, and renal failure, little is known about how co-administered medications or 
disease-associated changes in MRP expression affect enalaprilat disposition.  In addition to specific 
disease states, disease severity also can alter basolateral efflux transporter expression
17-21
. For example, 
inflammation associated with non-alcoholic fatty liver disease increases protein expression of MRPs (e.g., 
MRP3, MRP4, MRP6) on the basolateral membrane
17
.  Without knowledge of the basolateral transport 
process(es) involved in enalaprilat disposition, it is difficult to accurately predict how disease state 
alterations and DDIs may impact systemic concentrations and pharmacological effects.   
This study was designed to determine whether MRP3 and/or MRP4 are involved in the hepatic 
basolateral efflux of enalaprilat, and to demonstrate the impact of MRP inhibition on the hepatic 
basolateral efflux clearance of enalaprilat.  Enalapril and enalaprilat transport were evaluated in 
membrane vesicles prepared from cells expressing either MRP3 or MRP4.  Additionally, a novel 
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experimental protocol was developed in human sandwich-cultured hepatocytes (SCH) to assess the 
potential impact of coadministered medications on enalaprilat basolateral efflux.  
Materials and Methods 
Materials 
Enalapril maleate, d5-enalapril, enalaprilat, d5-enalaprilat, taurocholate, Hanks’ balanced salt 
solution (HBSS), and Ca
2+/
Mg
2+-
free HBSS (Ca
2+
-free HBSS) were purchased from Sigma-Aldrich (St. 
Louis, MO).  MK-571 was purchased from Cayman Chemical Company (Ann Arbor, MI).  Rosuvastatin 
was purchased from Toronto Research Chemicals (Toronto, Ontario, Canada).  [
3
H]Taurocholate (1 
mCi/mL; >97% purity) and [
3
H]rosuvastatin (1 mCi/mL; >97% purity) were purchased from PerkinElmer 
(Waltham, MA) and American Radiolabeled Chemicals (St. Louis, MO), respectively. All other 
chemicals were commercially available and of the highest grade available.  
Human Embryonic Kidney Cell Culture and Overexpression of MRP3 and MRP4 
Human MRP3 plasmid [pcDNA3.1(-)-MRP3] and MRP4 plasmid [pcDNA3.1(+)-MRP4] were 
kindly provided by Dr. Susan Cole (Queen’s University, Kingston, Canada) and Dr. Dietrich Keppler 
(German Cancer Research Center, Heidelberg, Germany), respectively. Human embryonic kidney 
(HEK293T) cells were cultured in Dulbecco’s Modified Eagle Medium (DMEM) supplemented with 10% 
fetal bovine serum in a humidified incubator. 
For MRP4, a stable transfected cell line was developed as previously described
18
.  For MRP3, 
transient transfection of HEK293T cells with X-tremeGENE 9 DNA Transfection Reagent (Roche 
Diagnostics, Mannheim, Germany) was performed according to the manufacturer’s instructions. Seventy-
two hours after transfection, the cells were harvested. Non-transfected and mock-transfected cells were 
used to generate control membrane vesicles for the MRP3 and MRP4 assays, respectively. Cells were 
harvested by trypsinizing and centrifuging the transporter overexpressing cells and the respective control 
cell lines. The cell pellets were washed in Tris-Sucrose-buffer (TSB; 250 mM sucrose/50 mM Tris, pH 
7.4) containing 0.25 mM CaCl2. The final cell pellet was overlaid with 10 ml TSB containing 0.25 mM 
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CaCl2 and protease inhibitors (complete Mini EDTA-free, Roche Diagnostics, Mannheim, Germany), 
snap-frozen in liquid nitrogen, and stored at -80°C. 
Membrane Vesicle Preparation 
Membrane vesicles were prepared for MRP4, MRP3 and respective controls as described 
previously
22
. Briefly, frozen cell pellets were thawed, resuspended in TSB, and exploded by N2 cavitation 
(300 psi, 5 min). After addition of EDTA (1mM), the suspension was centrifuged (800 x g, 10 min, 4°C) 
and the supernatant was collected. The pellet was resuspended in TSB with 0.5 mM EDTA, and 
centrifuged (800 x g, 10 min, 4°C). The resulting supernatants were overlaid over 35% (w/w) sucrose/50 
mM Tris buffer in a high speed centrifuge tube. After centrifugation (100,000 x g, 90 min, 4°C), the 
interphase was collected and added to a new high-speed centrifuge tube with 25 mM sucrose/50 mM Tris 
buffer. After additional centrifugation (100,000 x g, 45 min, 4°C), the pellet was resuspended in 1 ml 
TSB. The suspension was added to a high-speed centrifuge tube and centrifuged (100,000 x g, 20 min, 
4°C). The supernatant was discarded and the pellet was resuspended in TSB. Subsequently, the 
suspension was homogenized using a 27-gauge needle (15 strokes). The membrane vesicle suspension 
was divided into aliquots, snap-frozen in liquid nitrogen, and stored at -80°C until use.  Successful 
transfection was confirmed via Western blotting and transport of radiolabeled prototypic probes as 
described previously
18
. 
Membrane Vesicle Assay 
Membrane vesicles (10 μg) were incubated at 37°C with enalapril or enalaprilat (100 μM) with 
and without  MK-571 (50 µM) in TSB containing MgCl2 (10 mM), creatine phosphate (10 mM), creatine 
kinase (100 µg/mL), and ATP (4 mM) in a final volume of 50 μL. Enalapril, enalaprilat, and MK-571 
stock solutions were prepared in TSB or 100% dimethylsulfoxide (DMSO) with a resulting DMSO final 
concentration of less than 1% in the total incubation volume. ATP was replaced by AMP (4 mM) for 
control reactions. At least three separate experiments in triplicate were performed for all incubations, 
unless otherwise noted. After incubation for 5 min, the reactions were stopped by addition of 800 μL of 
ice-cold TSB and immediately filtered through glass fiber filters (Pall Life Sciences, Port Washington, 
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NY) presoaked in 3 mM reduced glutathione/10mM dithiothreitol in TSB overnight. Filters were washed 
three times with ice-cold TSB.  Filters were air dried and dissolved in 1 mL of pure HPLC methanol 
containing d5-enalapril and d5-enalaprilat for LC-MS/MS analysis. ATP-dependent uptake was calculated 
as the difference in uptake in the presence of AMP and ATP. MRP-dependent substrate transport was 
calculated by subtracting ATP-dependent uptake in control membrane vesicles from uptake in membrane 
vesicles prepared from MRP3- or MRP4-expressing cells.  
Sandwich-Cultured Hepatocyte (SCH) Isolation and Culture  
Human hepatocytes from three donors were kindly provided by Life Technologies (Research 
Triangle Park, NC) and Triangle Research Labs (Research Triangle Park, NC), and cultured as previously 
described
23
.  Hepatocyte donors included three Caucasian men ranging in age from 20 to 48 years with a 
body mass index of 19 to 31 kg/m
2
.  Briefly, freshly isolated human hepatocytes were seeded in 6-well 
BioCoat
®
 plates (BD Biosciences, San Jose, CA) at a density of 1.5×10
6
 cells/well. Hepatocytes were 
overlaid with Matrigel
®
 basement membrane matrix (BD Biosciences) and maintained as described 
previously
23
.   
Sandwich-Cultured Hepatocyte Uptake and Biliary Excretion Studies  
Determination of the uptake and biliary excretion of probe substrates in human SCH has been 
described previously
24
.  Slight modifications were made to allow determination of enalapril and 
enalaprilat uptake, formation and excretion.  Briefly, human SCH were washed twice with 2 ml of warm 
Ca
2+
-containing standard
 
HBSS (cells + bile) or Ca
2+
-free HBSS (cells) and incubated with 1.5 mL of the 
same buffer for 10 min at 37°C containing either [
3
H]taurocholate (1 µM; 100 nCi/ml), [
3
H]rosuvastatin 
(1 µM; 100 nCi/ml), or enalapril (5 µM). After 10 min, cells were washed 3 times with ice-cold standard 
HBSS and lysed with either 0.5% Triton X-100 in phosphate-buffered saline (for [
3
H]taurocholate and 
[
3
H]rosuvastatin analysis) or pure HPLC grade methanol containing internal standards (for enalapril and 
enalaprilat analysis). Radioactivity in cell lysates was quantified by liquid scintillation spectroscopy 
(Packard Tricarb; PerkinElmer, Waltham, MA).  Enalapril and enalaprilat were quantified in cell lysates 
using LC-MS/MS.  Accumulation of taurocholate, rosuvastatin, enalapril and enalaprilat in cells and cells 
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+ bile was normalized to protein determined using a BCA protein assay (Pierce Chemical, Rockford, IL). 
The biliary excretion index (BEI, %) and in vitro biliary clearance (CLbiliary; ml/min/kg) were calculated 
using B-CLEAR
®
 technology (Qualyst Transporter Solutions, LCC, Durham, NC) based on the following 
equations: 
BEI  
Accumulationcells bile  Accumulationcells
Accumulationcells bile
 
 
C biliary 
Accumulationcells bile  Accumulationcells
AUCmedium   T
 
 
where the area under the curve in the medium from time 0 to T (AUCmedium 0-T) represents the product of 
the incubation time (T) and the initial, taurocholate, rosuvastatin or enalapril concentration in the 
medium. CLbiliary units were converted to ml/min/kg body weight based on previously reported values for 
human protein content in liver tissue (90 mg/g liver weight) and liver weight (25.7  g/kg body weight)
25
.   
Sandwich-Cultured Hepatocyte Basolateral Efflux Studies 
On day 6 of culture, human SCH were loaded with enalapril for 60 min at 37°C with 2 mL/well 
of standard HBSS containing 5 µM enalapril with and without 25 µM MK-571. The buffer was removed 
and the cells were washed two times with warm, standard HBSS. At this point, 1 mL of methanol 
containing internal standards was added to one set of each SCH preparation (designated as “Pre-Efflux 
SCH”) to assess intracellular accumulation of enalapril and derived enalaprilat.  Enalaprilat efflux was 
initiated in the other set of SCH by adding 2 mL of fresh warm standard HBSS without enalapril followed 
by incubation for 30 min at 37°C. Aliquots (100 µL) of efflux buffer were taken at 5, 10 and 30 min to 
determine the amount of enalaprilat translocated into the efflux buffer.  At 30 min, the buffer was 
aspirated and the cells were washed three times with ice-cold buffer. “Post-Efflux SCH” were lysed in 1 
mL of ice-cold methanol containing internal standards.  Enalapril and enalaprilat were quantified in efflux 
buffer, and pre- and post-efflux SCH lysates, by LC-MS/MS (Figure 3.1; Table 3.1).  Intracellular 
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enalaprilat concentrations pre- and post-efflux were calculated by dividing the total mass present in the 
cell lysate by the estimated hepatocyte volume reported previously as 7.69 µL/mg protein, assuming 1 mg 
cellular protein per well
26
.  Intrinsic basolateral efflux clearance of enalaprilat, CLint, basolateral, was 
calculated according to the following equation,  
 
CL      asolateral 
X              t1 t2
AUCCell t1 t2
 
 
where XEfflux Buffer was the cumulative amount of enalaprilat excreted from the cell over the efflux period 
(t1 t2), assuming that biliary excretion and flux from the bile compartment into the efflux buffer were 
negligible; AUCCell represented the log-trapezoidal exposure of intracellular enalaprilat over the efflux 
period. 
LC-MS/MS Analysis 
Enalapril and enalaprilat were quantified by LC-MS/MS using an Applied Biosystems (Foster 
City, CA) API 4000 triple quadrupole mass spectrometer equipped with a TurboV
®
 ion source (Applied 
Biosystems, Foster City, CA), a Shimadzu solvent delivery system (Columbia, MD), and a thermostatted 
CTC PAL autosampler (Leap Technologies, Carborro, NC).   Tuning, operation, integration, and data 
analysis were carried out in positive mode using multiple reaction monitoring (Analyst
®
 software v.1.4.1, 
Applied Biosystems). Following an 8 µL injection onto a Varian Pursuit 3 PFP column (50 x 2mm, 3 μm 
particle size; Santa Clara, CA), analytes were eluted via reverse phase gradient at 0.30 mL/min. Mobile 
phase A consisted of water and 0.1% formic acid; mobile phase B consisted of methanol with 0.1% 
formic acid.  The initial condition was 80% aqueous, reaching 50% methanol at 1 min, and 97% methanol 
at 4 min.  After a 0.4 min hold at 97% methanol, the mobile phase returned to initial conditions at 4.5 
min.  The total run time, including re-equilibration, was 5 min.  The specific analytes were monitored as 
follows; enalapril (377.0  234.0), d5-enalapril (internal standard, 382.0  239.0), enalaprilat (349.0  
206.0), and d5-enalaprilat (internal standard, 354.0  211.0)).  Duplicate eight-point calibration curves 
for both enalapril and enalaprilat (0.075-375 nM) were constructed using the peak area ratio of analyte to 
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deuterated internal standard.  In an attempt to mimic the various matrix components (lipids, salts, 
proteins), separate calibration curves were constructed with blank matrix from each of the different 
samples types (i.e., vesicles, cell lysate and buffer). 
Data Analysis  
Data are presented as mean ± SD unless otherwise noted.  A two-sided Student’s t-test was used 
to determine significant differences; in all cases, p<0.05 was considered significant.     
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Results 
ATP-Dependent Transport of Enalapril and Enalaprilat by Membrane Vesicles Prepared from MRP3- 
and MRP4-Expressing Cells 
Prior to enalapril and enalaprilat uptake studies, each batch of membrane vesicles was 
characterized for protein expression and transport activity of probe substrates as described previously
18
.  
ATP-dependent uptake of enalapril and enalaprilat by membrane vesicles prepared from MRP3- and 
MRP4-expressing cells was determined in vesicles incubated with enalapril or enalaprilat (Figure 3.2).  
ATP-dependent uptake of enalapril was not significantly different in membrane vesicles prepared from 
MRP3- or MRP4-expressing cells compared to the respective control (Figure 3.2A).  Although, ATP-
dependent enalaprilat uptake was not significantly different between control and MRP3-expressing 
vesicles, statistically significant MRP4-dependent uptake was observed (277 ± 194 pmol/mg 
protein/min); the uptake rate of enalaprilat was 382 ± 133% greater in vesicles from MRP4-expressing 
cells compared to mock-transfected control cells.  MRP4-mediated enalaprilat transport was investigated 
in the presence of the prototypical MRP inhibitor MK-571, at a concentration of 50 µM.  MK-571 
significantly inhibited enalaprilat transport by 83 ± 30% (Figure 3.3).  MRP4-mediated enalaprilat 
transport was modestly inhibited by rosuvastatin, but differences were not statistically significant (data 
not shown). 
Human Sandwich-Cultured Hepatocyte (SCH) Uptake and Biliary Excretion Studies 
Studies were conducted in human SCH to determine the total and cellular accumulation, biliary 
excretion index, and CLbiliary of the positive controls, taurocholate and rosuvastatin.  Following a 10-min 
incubation of human SCH with 1 µM [
3
H]taurocholate or 1 µM [
3
H]rosuvastatin, total accumulation (cells 
+ bile), cellular accumulation (cells) and BEI of taurocholate and rosuvastatin were determined (Figure 
3.4A)
24
.  BEI and CLbiliary values for taurocholate and rosuvastatin were 81 ± 9% and 22.4 ± 4.6 
mL/min/kg body weight, and 39 ± 7% and 6.4 ± 1.3 mL/min/kg body weight, respectively, indicating 
robust biliary clearance of these compounds
24
.  Additionally, total accumulation, cellular accumulation, 
and the BEI of enalapril were measured.  Following a 10-min incubation of human SCH with enalapril, a 
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higher total accumulation and cellular accumulation of derived enalaprilat compared to enalapril was 
observed (Figure 3.4B) suggesting rapid and extensive conversion of enalapril to enalaprilat.  CLbiliary of 
parent enalapril was negligible in human SCH (0.02 ± 0.01 mL/min/kg body weight; mean ± SD, n=2 in 
triplicate).   Biliary excretion of derived enalaprilat was not quantifiable in human SCH after a 10-min 
incubation period.   
Human Sandwich-Cultured Hepatocyte Basolateral Efflux Studies 
Basolateral efflux clearance of enalaprilat was assessed in human SCH.  Following the 60-min 
loading phase with and without MK-571, accumulation of enalapril within the hepatocytes was negligible 
due to rapid conversion to enalaprilat.  Pre-efflux cellular accumulation of derived enalaprilat was 
decreased when MK-571 was co-incubated with enalapril during the loading phase, suggesting inhibition 
of enalapril uptake processes (Table 3.1).  Correspondingly, with decreased intracellular concentrations 
over the entire efflux period, the total mass available for efflux across the basolateral membrane in human 
SCH co-incubated with MK-571 also decreased compared to control.  Therefore, intrinsic basolateral 
efflux clearance was calculated by dividing the total mass effluxed across the basolateral membrane by 
the calculated enalaprilat area under the cellular concentration-time curve (Table 3.1).   MK-571 
significantly decreased intrinsic basolateral efflux clearance (Table 3.1, Figure 3.5).  Enalaprilat intrinsic 
basolateral efflux clearance was modestly inhibited by rosuvastatin, but differences were not statistically 
significant (data not shown).  
 
  
  
 
108 
 
Discussion 
The present study was designed to determine the involvement of MRP3 and/or MRP4 in the 
basolateral efflux of enalapril and enalaprilat.  Using membrane vesicles, MRP3 did not appear to 
transport either enalapril or enalaprilat.  Enalaprilat, but not enalapril, was actively transported by MRP4.  
To confirm MRP4-mediated transport of enalaprilat, inhibition of uptake by the pan-MRP prototypical 
inhibitor, MK-571, was evaluated
18,27
.  Indeed, potent inhibition by MK-571 (83%) was observed. 
Studies were conducted in human SCH to assess the basolateral efflux of derived enalaprilat in 
intact hepatocytes.  First, the accumulation and biliary excretion of taurocholate and rosuvastatin, two 
prototypical positive controls that are excreted into bile, was measured to confirm the functionality of the 
basolateral uptake and canalicular transport processes in the SCH used in this study.  Indeed, human SCH 
exhibited extensive hepatic uptake and biliary clearance of both taurocholate and rosuvastatin.  Biliary 
excretion of enalaprilat was negligible following a 10-min incubation with enalapril in human SCH 
(Figure 3.4A).  Cellular accumulation of preformed enalaprilat in rat SCH was negligible (data not 
shown), consistent with previously published data demonstrating a diffusional barrier for hepatic uptake 
of enalaprilat
11
.  Taken together, these data suggest that the basolateral translocation of enalaprilat into the 
efflux buffer appears to be the only route of excretion of derived enalaprilat in SCH, and that reuptake of 
enalaprilat does not occur to any measureable extent.  Therefore, basolateral excretion of derived 
enalaprilat was determined in human SCH in the presence and absence of MK-571 to assess the impact of 
MRP-mediated inhibition of basolateral efflux.   Interestingly, the relative extent of inhibition of 
basolateral efflux clearance of enalaprilat in human SCH was similar to that observed in membrane 
vesicles prepared from HEK293T cells expressing MRP4 (Figures 3.3 and 3.5); MK-571 inhibition of 
uptake into membrane vesicles and intrinsic basolateral efflux clearance in human SCH was 83% and 
67%, respectively.  This finding should be interpreted cautiously because MK-571 is a non-selective 
MRP inhibitor and other MRP transporters in addition to MRP4 could contribute to the basolateral efflux 
of enalaprilat in human hepatocytes. 
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Following intestinal absorption of enalapril, the predominant route of excretion is presumed to be 
hepatic metabolism to enalaprilat followed by basolateral efflux of enalaprilat into the systemic 
circulation and subsequent renal excretion
28
.  In isolated perfused rat livers, the magnitude of the 
basolateral efflux clearance of derived enalaprilat was at least 2-fold greater than biliary clearance
11
. This 
preclinical data is consistent with human data indicating that >90% of orally absorbed enalapril is 
recovered in the urine as enalaprilat
28,29
.  Given this disposition profile, where enalaprilat is excreted 
preferentially from the liver into the systemic circulation followed by renal excretion, inhibition of MRP4 
transport would be expected to decrease systemic enalaprilat concentrations in vivo and the resulting 
pharmacodynamic effect.  The converse also may be true, where increased MRP4 protein expression due 
to disease (e.g. nonalcoholic steatohepatitis
17
) would be expected to increase systemic concentrations. 
In the present study, a novel basolateral efflux protocol was developed in human SCH to 
elucidate the impact of basolateral efflux transporter inhibition (e.g. MRP4) on enalaprilat disposition.  
Following confirmation of MRP4’s role in enalaprilat transport, basolateral efflux clearance was 
calculated by dividing the amount of enalaprilat translocated from the hepatocyte into the efflux buffer by 
the estimated exposure of intracellular enalaprilat. Accurate determination of basolateral efflux using this 
method assumes that: 1) biliary excretion of the compound is negligible, 2) the compound, once effluxed 
from the hepatocyte, does not reenter the hepatocyte (i.e. the metabolite must be hepatically-derived), and 
3) any further conversion from parent to metabolite after the loading phase is insignificant. Data presented 
in this manuscript suggest that these assumptions are true in the SCH model under the described study 
conditions.  Enalapril and enalaprilat biliary excretion was minimal in human SCH (Figure 3.4); thus, 
potential flux during the efflux phase from the bile canaliculi of SCH into the medium would be 
negligible.  Pilot studies in rat SCH indicated that preformed enalaprilat does not re-enter the hepatocyte 
(data not shown), consistent with previous reports that enalaprilat is not transported by rat Oatp1a1
8
.  
Although rat Oatp1a1 and human OATP1B1 are not completely homologous, pharmacophore modeling 
indicated that substrates for these transporters have similar structural moieties
30
.  Finally, the 
concentration of enalapril in the hepatocyte was very low compared to enalaprilat following both the 
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loading phase and the efflux phase in the human SCH protocol, indicating rapid conversion of enalapril to 
enalaprilat in the hepatocyte.  Alternatively, to assess the impact of delayed conversion of parent to 
metabolite, the relative concentration of parent to metabolite after the loading phase should be assessed.  
If the amount of parent left in the cell following the loading phase is greater than 10% of the amount of 
generated metabolite, conversion during the efflux phase may require further investigation or 
optimization of the loading protocol.  If these assumptions are violated, the interplay between uptake, 
metabolism, basolateral efflux and biliary excretion would need to be deconvoluted using mathematical 
modeling.  
 Although inhibition of enalapril uptake would not impact the results of the current study design, 
it should be noted that enalaprilat cellular concentrations were greatly decreased in human SCH treated 
concomitantly with MK-571, likely due to inhibition of OATP1B1-mediated uptake of enalapril into 
hepatocytes.  MK-571 is a potent inhibitor (IC50 = 0.3 µM) of OATP1B1
31
.  Importantly, failing to 
account for decreased uptake by direct measurement of cellular concentrations prior to initiation of the 
efflux phase may result in overestimation of basolateral efflux inhibition.  
Results suggest that altered MRP4 function may modulate systemic enalaprilat concentrations 
and thus enalapril efficacy in vivo.  Our group recently identified many drugs as potent MRP4 inhibitors 
that are commonly co-administered in patients with metabolic disease or hypertension
18
.  In addition to 
co-medications, concomitant genetic variation or disease states may further influence enalapril and 
enalaprilat pharmacokinetics and pharmacodynamics. Interestingly, genetic variation resulting in reduced 
OATP1B1 function increased enalapril and decreased enalaprilat systemic concentrations, which may 
lead to decreased systemic pharmacologic activity
32
.  Similarly, patients with inflammatory liver disease 
(e.g. nonalcoholic steatohepatitis) have decreased OATP and increased MRP4 expression
33,34
.  These 
changes in transporter expression together with frequent coadministration of potent MRP4 inhibitors (i.e. 
glyburide, fluoxetine, furosemide, simvastatin
18,35
) may unpredictably alter hepatic and systemic 
concentrations of drugs/metabolites that are transported in a manner similar to enalapril/enalaprilat, 
potentially leading to therapeutic failure or unexpected toxicity.  Depending on the culture conditions, 
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MRP4 has been shown to be up-regulated in SCH from various species over the culture period
36,37
.  
Although this does not affect the inhibition profile of MK-571, careful evaluation of factors that alter 
protein expression in vitro should be considered before data are extrapolated from SCH to in vivo. 
Human SCH have been utilized to mechanistically evaluate hepatocyte vectorial transport and 
reveal the relative contribution of basolateral versus biliary efflux to overall clearance.  Recently, Pfeifer 
et al. and Matsunaga et al. demonstrated the importance of the interplay between basolateral and 
canalicular efflux in the systemic and hepatic disposition of rosuvastatin and mycophenolic acid 
glucuronide, respectively
27,38,39
.  Extensive biliary excretion of rosuvastatin and mycophenolic acid 
glucuronide required mathematical modeling to deconvolute the contribution of basolateral versus 
canalicular transport.  In contrast, enalapril/enalaprilat exhibited minimal biliary excretion, allowing 
direct measurement of basolateral efflux in the present studies.  These reports demonstrate that altered 
hepatic transport may result in modulation of both hepatic and systemic concentrations of drugs and 
derived metabolites.  In fact, inhibition of hepatic uptake and biliary excretion of mycophenolic acid 
glucuronide, which disrupts enterohepatic recirculation of the parent mycophenolic acid, is postulated as 
the mechanism behind decreased systemic exposure to mycophenolic acid during coadministration with 
cyclosporine in transplant patients
38,40
.  Additionally, investigation of rosuvastatin disposition in human 
SCH and isolated perfused rat livers revealed that basolateral and canalicular efflux clearances were 
approximately equal
27,39
.  This finding demonstrates that although rosuvastatin is excreted primarily as 
unchanged drug in the feces, basolateral efflux in concert with canalicular efflux are key determinants of 
rosuvastatin overall disposition, and may impact pharmacologic efficacy and/or toxicity.  These 
examples, together with the present study, illustrate the importance of hepatic basolateral and canalicular 
efflux processes in determining both the pharmacokinetic and pharmaco-/toxico-dynamic profile of drugs 
and their metabolites.  
In summary, enalaprilat, the active metabolite of enalapril, is effluxed across the basolateral 
membrane of hepatocytes by MRP4.  MRP4 transport may be inhibited by concomitantly administered 
drugs
41-43
. This work highlights the significance of active basolateral efflux in the therapeutic efficacy of 
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active metabolites derived in the liver and excreted into the systemic circulation.  SCH represent a robust 
model to study the interplay between basolateral and canalicular efflux.  Further studies are required to 
understand the mechanistic basis for preferential basolateral or biliary efflux of compounds, and fully 
appreciate the consequences on the systemic and hepatic action of active/toxic metabolites.  
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Table 3.1: Parameters describing hepatically-derived enalaprilat disposition in human sandwich-cultured 
hepatocytes (SCH). Human SCH were incubated with 5 µM enalapril with and without MK-571 (25 µM) 
for 60 min.  Enalapril and enalaprilat concentrations in the post-efflux medium, and in hepatocytes pre- 
and post-efflux, were quantified as described in the “Materials and Methods”. 
 
Kinetic Parameters 
Enalapril (5 µM) 
Control 
Enalapril (5 µM) 
+ MK-571  
(25 µM) 
Pre-Efflux 
Pre-Efflux Enalaprilat  
Cellular Concentration 
(pmol/µL)  
Liver 1 25.5 ± 2.5 6.9 ± 0.6 
Liver 2 5.5 ± 0.3 3.0 ± 0.1 
Liver 3 6.5 ± 0.7 2.0 ± 0.2 
Mean 12.5 ± 11.3 4.0 ± 2.6 
Post-Efflux 
Post-Efflux Enalaprilat 
Cellular Concentration 
(pmol/µL)  
Liver 1 20.4 ± 1.7 5.2 ± 0.2 
Liver 2 5.2 ± 0.6 3.1 ± 0.2 
Liver 3 6.7 ± 0.8 2.4 ± 0.1 
Mean 10.8 ± 8.4 3.6 ± 1.5 
Mass Enalaprilat Excreted  
into Efflux Buffer 
(X
Efflux Buffer 030
, pmol) 
Liver 1 16.9 ± 1.5 0.8 ± 1.3 
Liver 2 2.3 † 0.4 ± 0.7 
Liver 3 7.5 ± 0.6 1.3 ± 0.5 
Mean 8.9 ± 7.4 0.8 ± 0.4 
 
Cellular Enalaprilat 
Exposure 
(AUC
Cell 030
, pmol*min/µL) 
Liver 1 684 ± 16.9 180 ± 3.2 
Liver 2 160 ± 13.6 91.3 ± 3.4 
Liver 3 199 ± 16.2 65.4 ± 4.3 
Mean 348 ± 293 112 ± 60.4 
Basolateral Enalaprilat 
Clearance 
(CL
int, basolateral
, µL/min) 
Liver 1 0.024 ± 0.001 0.004 ± 0.004 
Liver 2 0.014 † 0.004 ± 0.007 
Liver 3 0.037 ± 0.002 0.019 ± 0.008 
Mean 0.026 ± 0.012 0.009 ± 0.009 * 
Data are presented as mean ± SD; n= 3 independent hepatocyte preparations performed in triplicate. 
† Value imputed due to analytical error as the difference in enalaprilat intracellular concentration pre- vs. 
post-efflux, assuming a cellular volume of 7.69 µL/mg protein. 
*p<0.05 vehicle control vs. MK-571. 
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Figure 3.1: A. Scheme depicting efflux studies in human sandwich-cultured hepatocytes (SCH) 
describing the loading and efflux phases (see “Materials and Methods” section for a detailed description; 
HBSS, Hanks’ balanced salt solution with calcium).  B.  Average enalaprilat cellular accumulation (red 
squares) and mass excreted into the efflux buffer (blue diamonds) observed during the efflux phase in a 
representative human SCH preparation under control conditions according to the scheme depicted in A 
(mean ± SD of triplicate measurements).  The green dotted line indicates the presumed cellular 
accumulation of enalaprilat during the loading phase.  Enalaprilat cellular exposure during the efflux 
phase (AUCcell 030; red trapezoid) was calculated as the log-trapezoidal product of intracellular 
enalaprilat mass divided by the estimated intracellular volume and time. The mass of enalaprilat excreted 
into the efflux buffer (XEfflux Buffer) was determined by multiplying the concentration measured in the 
buffer by the buffer volume. 
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Figure 3.2: Transport of enalapril and enalaprilat by MRP3 and MRP4. Uptake of enalapril (100 µM; A) 
and enalaprilat (100 µM; B) into membrane vesicles prepared from HEK293T cells expressing MRP3 or 
MRP4 (10 µg; solid bars), or mock-transfected controls (10 µg; open bars), was determined after a 5-min 
incubation in the presence of ATP or AMP.  Data are presented as mean ± SD. ATP-dependent uptake 
into vesicles was determined from three (MRP3) or four (MRP4) independent experiments performed in 
triplicate; *p<0.05 vs. respective control. 
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Figure 3.3: Effect of MK-571 on MRP4-mediated enalaprilat transport.  Membrane vesicles prepared 
from MRP4-expressing HEK293T cells were incubated with enalaprilat (100 µM) for 5 min with and 
without MK-571 (50 µM).  MRP4-dependent ATP-dependent uptake was calculated and normalized to 
transport in MRP4 vesicles in the absence of MK-571.  Data are presented as mean ± SD of three 
independent experiments performed in triplicate; *p<0.05 vehicle control vs. MK-571. 
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Figure 3.4: Disposition of taurocholate and rosuvastatin (left panel) as well as enalapril and derived 
enalaprilat (right panel) in human sandwich-cultured hepatocytes (SCH). Accumulation of taurocholate, 
rosuvastatin, enalapril and enalaprilat in cells + bile (black bars) and cells (white bars) in human SCH was 
measured following a 10-min incubation with [
3
H]taurocholate (1 µM), [
3
H]rosuvastatin (1 µM) or 
enalapril (5 µM) .  The biliary excretion index (BEI) was calculated as detailed in the “Materials and 
Methods” section; BEI values for enalapril and enalaprilat were negligible.  Data represent the mean ± SD 
of triplicate measurements in three independent hepatocyte preparations for taurocholate and rosuvastatin, 
or triplicate measurements in two independent hepatocyte preparations for enalapril and enalaprilat.  
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Figure 3.5: Effect of MK-571 on the intrinsic basolateral efflux clearance of enalaprilat in human 
sandwich-cultured hepatocytes.  Intrinsic basolateral efflux clearance (CLint, basolateral) of enalaprilat was 
calculated as described in the “Materials and Methods”.  Clearance values are expressed as a percent of 
vehicle-treated control.  Data are presented as mean ± SD of three independent experiments performed in 
triplicate; *p<0.05 vehicle control vs. MK-571. 
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CHAPTER 4.  Altered Morphine-Glucuronide and Bile Acid Disposition in Patients with 
Non-Alcoholic Steatohepatitis 
 
Introduction  
 Non-alcoholic fatty liver disease (NAFLD) is a progressive liver disease ranging from simple 
steatosis to cirrhosis of the liver. Non-alcoholic steatohepatitis (NASH) is an intermediate pathologic state 
on the pathway from simple steatosis to cirrhosis that is characterized by hepatocyte steatosis, ballooning, 
inflammation and fibrosis.
1
  NASH is strongly associated with insulin resistance and metabolic syndrome.  
NAFLD is believed to be the most common cause of chronic liver disease in the Western world and is 
recognized as a major public health concern.
2
  Equally concerning is the fact that many patients are 
unaware of their disease until progression to advanced stages has occurred.
3
  Left untreated, NAFLD and 
NASH can progress to advanced fibrosis, cirrhosis and hepatocellular carcinoma, ultimately requiring 
liver transplantation in some patients.
1
  Medications such as metformin, pioglitazone, rosiglitazone and 
rosuvastatin have been used to improve insulin resistance to reverse the inflammation associated with 
NAFLD and prevent fibrosis.
4-7
  Although modest reductions in serum liver function markers were 
observed with these medications, histologically, the progression of fibrosis was not reliably prevented or 
did not regress for any tested pharmacologic intervention.  The major site of action of these medications is 
within hepatocytes; thus, diminished activity may be partially due to decreased hepatocellular 
concentrations.
8
   
The dynamic interplay between hepatic sinusoidal uptake transporters, drug metabolizing 
enzymes, and basolateral and/or canalicular efflux transporters regulates hepatocellular concentrations 
 
This work has been presented, in part, at the ASCPT Annual Meeting, Atlanta, GA, March 18-22, 2014 
and has been submitted to Clinical Pharmacology and Therapeutics and is presented in the style of that 
journal.    
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and exposure to medications and their metabolites.
9,10
  Modest changes in one or more of these processes 
can impact systemic and/or hepatocellular concentrations.
11,12
 Bile acid concentrations are regulated by 
these factors as well as de novo synthesis within hepatocytes; intestinal hydrolysis and transporters, which 
facilitate reabsorption, also contribute to bile acid exposure.
13
  Recently, expression of many uptake and 
efflux transporters and drug metabolizing enzymes was evaluated in liver samples from patients with 
NASH compared to healthy subjects.  In general, NASH down-regulated transport proteins responsible 
for hepatic uptake of drugs and bile acids (e.g., organic anion transporting polypeptides [OATPs], 
sodium-taurocholate cotransporting polypeptide [NTCP]), and up-regulated hepatic excretory proteins 
(e.g., multidrug resistance-associated protein [MRP]3, MRP4, breast cancer resistance protein [BCRP], 
MRP2).
14-17
  However, the impact of the observed up-regulation in MRP2 protein is difficult to predict 
due to altered localization of this canalicular protein. In contrast to the predictable nature of the changes 
observed with transporters (i.e., decreased uptake and increased efflux), cytochrome P450s (CYPs), 
uridine 5’-diphospho-glucuronosyltransferases (UGTs) and sulfotransferases (SULTs) generally were 
unchanged with few exceptions.
16
  Altered transporter expression in NASH patients is expected to impair 
hepatic uptake and shift excretion of anionic drugs/hepatically-derived metabolites from bile to sinusoidal 
blood, resulting in decreased liver exposure and increased systemic concentrations/exposure. These 
changes may decrease activity or efficacy of highly transported bioactive endogenous substrates, 
medications and/or hepatically-derived metabolites with an intrahepatic site of action.
4-7
 
Despite a general understanding of the impact of decreased transporter-mediated hepatic uptake 
of medications on systemic and hepatic concentrations
11,18
, the importance of altered basolateral efflux is 
underappreciated.  The functional impact of altered uptake and/or efflux transporter expression has not 
been evaluated in NASH patients.
9,10,19
  Therefore, the primary objective of this study was to assess the 
functional impact of altered hepatic transporter expression in patients with biopsy-confirmed NASH 
compared to healthy subjects.  Hepatically-derived glucuronide conjugates of morphine were selected as a 
phenotypic probe to evaluate MRP3 function for several reasons: 1) morphine enters the hepatocyte via a 
combination of passive diffusion and active transport
20
 and is unaffected by changes in uptake 
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transporters known to be altered in NASH
17
; 2) hepatic expression of UGT2B7, which metabolizes 
morphine to morphine-3- and -6-glucuronide, is not altered in NASH
9,10,16,21
; 3) morphine is eliminated 
almost exclusively as morphine glucuronide in the urine, suggesting that basolateral efflux is important in 
the systemic and hepatic disposition; and 4) MRP3 appears to be the only protein that transports 
hepatically-derived morphine glucuronide into sinusoidal blood.
22,23
  Additionally, Mrp3 protein 
expression positively correlated with basolateral efflux clearance of the Mrp3 substrate acetaminophen 
glucuronide in rat, and human UGT2B7 polymorphisms that exhibit decreased function appear to have 
minimal impact on the systemic concentrations of morphine glucuronide.
24,25
  Therefore, systemic 
morphine glucuronide concentrations should increase in patients with NASH due to MRP3 up-regulation 
compared to healthy subjects; the pharmacokinetics of parent morphine should be unaffected.  Altered 
transporter expression in patients with NASH could have implications for other MRP3-transported 
substrates such as endogenous glycocholate and taurocholate.
26
  Although bile acids are formed in the 
liver and generally undergo efficient enterohepatic recirculation
27
, increased serum concentrations under 
fasting conditions would be consistent with decreased  hepatic uptake and increased basolateral efflux. 
Therefore, the secondary objective of this study was to evaluate fasting serum concentrations of total bile 
acids, glycocholate and taurocholate in patients with NASH compared to healthy subjects.   
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Results 
Study Subjects 
 Twenty-one volunteers (14 healthy subjects and 7 patients with biopsy-confirmed NASH) were 
studied (Table 4.1; see Supplementary Figure 4.1 for a summary of volunteer recruitment, enrollment and 
completion).  In selecting healthy subjects, effort was made to recruit a control cohort comparable to the 
NASH cohort with respect to age, sex, race, and ethnicity.  As expected, patients with NASH weighed 
more and had a higher body mass index (BMI) than the healthy subjects.  Serum creatinine was within 
normal limits for both groups (Table 4.2), resulting in glomerular filtration rates within normal limits for 
all subjects. Compared to healthy subjects, patients with NASH had higher serum alanine 
aminotransferase (ALT), alkaline phosphatase (ALP), triglycerides, and insulin resistance as 
demonstrated by increased fasting glucose and insulin levels, as well as homeostasis model for assessing 
insulin resistance (HOMA-IR) scores, and decreased HDL (Table 4.2).  Biopsy results indicated that all 
NASH patients had a NAFLD activity score (NAS) of at least 4 with a maximum score of 6 and minimal 
to moderate (F0 to F3) fibrosis (Table 4.2).   
 
Morphine Pharmacokinetics 
 The presence of NASH had minimal impact on the pharmacokinetics of intravenously 
administered morphine (Figure 4.1A and Table 4.3).  No statistically significant mean differences were 
observed between subject groups for maximum serum concentration (Cmax), area under the serum 
concentration-time curve to the last measured timepoint (AUC0-last), AUC extrapolated to infinity (AUC0-
∞), total mass of morphine excreted in urine over the 8-hr collection interval (Xurine), terminal volume of 
distribution (Vz), total body clearance (CL), or half-life (t1/2).  Cmax for each subject was always at the 
timepoint immediately following the end of the infusion.  The geometric mean Cmax and AUC0-last for 
NASH patients were within 12% and 17%, respectively, of the corresponding values for healthy subjects 
(Table 4.3).      
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Morphine Glucuronide Pharmacokinetics 
 The geometric mean morphine-3-glucuonide AUC0-∞ was approximately 10-fold higher than 
morphine-6-glucuronide AUC0-∞ in healthy subjects (Figure 4.1), consistent with literature reports.
28,29
 
The percent difference in Cmax, time to reach Cmax (Tmax), AUC0-last, AUC0-∞, and t1/2 for morphine-3-
glucuronide in both subject groups (Figure 4.1) exhibited similar trends as morphine-6-glucuronide when 
evaluated separately.  Therefore, for brevity, morphine-3-glucuronide and morphine-6-glucuronide molar 
concentrations were combined for statistical analysis and reported as “morphine glucuronide”. 
Morphine glucuronide geometric mean Cmax and AUC0-last were 52% and 58% higher, 
respectively, in patients with NASH compared to healthy subjects following intravenous morphine 
administration (P = 0.001 and P = 0.005, respectively; Figure 4.1B and Table 4.3). From controls to 
NASH patients, the median Tmax shifted by 61% from 38 min to 15 min (P = 0.427).   The two cohorts 
were similar with respect to morphine glucuronide Xurine (P = 0.475) and t1/2 (P = 0.163) (Table 4.3).     
 
Fasting Serum Bile Acids 
 Fasting total bile acids, glycocholate and taurocholate serum concentrations in healthy subjects 
were 1.5±0.6, 0.08±0.06 and 0.02±0.02 µM, similar to previous reports.
30
 Total bile acid, glycocholate 
and taurocholate serum concentrations in patients with NASH were increased 2.5-, 3.1-, and 5.7-fold, 
respectively, compared to healthy subjects (P = 0.022, P = 0.017, P = 0.047, respectively; Figure 4.2). 
 
Linear Regression 
 Linear regression models detected an association between the NASH severity score 
(NAS+Fibrosis scores) and fasting total bile acid, glycocholate and taurocholate serum concentrations 
(Figure 4.3).  Linear regression models also were used to identify clinical predictors of morphine 
glucuronide disposition.  Considered individually, the clinical predictors identified included NASH 
severity score, waist circumference, waist-to-hip circumference ratio, ALP, fasting glucose, triglycerides, 
HDL, insulin and HOMA-IR (Table 4.4).  When these candidate clinical predictors of morphine 
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glucuronide were included together in multivariable linear regression models for Cmax and AUC0-last, only 
NASH severity remained statistically significantly (Figure 4.3 and Table 4.4).  
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Discussion 
 This study is the first designed to assess the impact of a disease-associated increase in hepatic 
basolateral efflux transporter expression on drug disposition in humans.  This study demonstrated that 
patients with NASH, a liver disease associated with increased protein expression of the hepatic 
basolateral efflux transporter MRP3, exhibited increased systemic concentrations of morphine 
glucuronide.
15
  The primary endpoint, Cmax of hepatically-derived morphine glucuronide, which was 
selected based on the mathematical model developed a priori, was higher in patients with NASH 
compared to healthy subjects (Figure 4.1 and Table 4.3).  The increase in morphine glucuronide Cmax in 
patients with NASH likely reflected increased hepatic MRP3, which transports glucuronide conjugates 
from hepatocytes to blood.
15,22
   Multivariable linear regression analysis of clinical liver function markers, 
insulin resistance metrics and biopsy results indicated that only biopsy-determined NASH severity 
(NAS+Fibrosis) independently predicted the increase in both morphine glucuronide Cmax and AUC0-last 
(Figure 4.3 and Table 4.4).  The secondary endpoint, fasting serum bile acid concentrations, was 
statistically significantly higher in patients with NASH compared to healthy volunteers and positively 
correlated with NASH severity based on biopsy scores (Figure 4.2).  Specifically, serum concentrations of 
glycocholate and taurocholate, endogenous bile acids that are MRP3 substrates
26
, also were increased in 
NASH patients with varying degrees of disease progression/inflammation.  These findings suggest that in 
the progressive inflammatory states investigated in this study, increasing NASH severity may further 
increase MRP3 function.  
   Recently, altered drug metabolizing enzyme and transporter expression was evaluated in liver 
biopsies from healthy subjects and from patients exhibiting varying degrees of NAFLD, from simple 
steatosis to steatohepatitis.
14-17
  Through what appears to be an adaptive mechanism to prevent further 
hepatic damage, uptake transporters are generally down-regulated, whereas efflux transporters are up-
regulated.  Although these changes in expression patterns may protect the hepatocyte from toxins (e.g., 
increased bile acid concentrations), such alterations may have unanticipated effects on the efficacy of 
medications that rely on these transporters for hepatic entry and retention.  Results from this study and 
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prior pharmacokinetic modeling of morphine/morphine glucuronide hepatic exposure are consistent with 
this notion.
31
   
Although systematic, comprehensive investigations of altered drug metabolism and/or transport 
have not been conducted for most hepatic disease states, altered clearance of choline following oral 
administration to patients with NASH was decreased compared to healthy volunteers.
32
  The authors 
proposed that the increased systemic choline concentrations were due to decreased metabolism secondary 
to reduced microsomal triglyceride transfer protein function in patients with NASH.  Alternatively, 
increased choline elimination from the blood can be attributed, at least in part, to reduced hepatic uptake 
and/or increased basolateral efflux.
33
  Altered hepatic drug transport was observed in rodent models of 
NASH.
34
  For example, increased systemic and decreased hepatic exposure to simvastatin acid were 
reported in rats with diet-induced NASH compared to control.
34
  Additionally, bile acid concentrations 
were increased in rodent models of steatosis.
35
  Clearly, a growing body of literature demonstrates the 
importance of altered hepatic uptake and efflux on the systemic and hepatic disposition of many drugs, 
metabolites, and endogenous substrates.
32,34,35
 
Altered hepatic transport due to disease or drug-drug interactions that shifts the predominant 
excretion pathway of drugs/metabolites can have unexpected consequences on systemic and hepatic 
disposition and ultimately, therapeutic efficacy and/or toxicity.  For example, coadministration of 
cyclosporine, a potent inhibitor of hepatic transport proteins, with mycophenolate mofetil in transplant 
patients unexpectedly decreased mycophenolic acid systemic exposure.
36
  Further investigation revealed 
that inhibition of canalicular transport likely shifted the excretion profile of mycophenolic acid 
glucuronide from predominantly biliary, with subsequent enterohepatic recycling of mycophenolic acid, 
to hepatic basolateral efflux and ultimately urinary excretion.
37
  The recent failure of rosuvastatin to 
decrease histologic severity or prevent worsening fibrosis in patients with NASH
7
 may be an example of 
altered transporter-mediated pharmacokinetics; decreased hepatic uptake
17,34
, with a shift toward 
basolateral excretion and ultimately terminal urinary elimination
38,39
, potentially decreased the hepatic 
exposure and therapeutic efficacy of rosuvastatin.   
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Altered hepatic transporter expression may influence the disposition of endogenous compounds 
(e.g., bile acids) in addition to drugs/metabolites.  Bile acids are formed in the liver and undergo efficient 
enterohepatic recirculation, resulting in low systemic serum concentrations.
30
  Fasting serum 
concentrations of total bile acids, glycocholate, and taurocholate were increased 2.5- to 5.7-fold in 
patients with NASH compared to healthy controls.  These changes correlate with previous reports of 
intrahepatic bile acid concentrations in liver tissue from patients with NASH compared to healthy 
subjects.
40
  In addition to MRP3 up-regulation, and down-regulation of NTCP and OATPs, taurine 
conjugation is increased.
40
  Further studies are ongoing to investigate the influence of alterations in the 
bile acid profile in patients with NASH on drug disposition, efficacy and toxicity. 
Some limitations are associated with this work.  First, this study enrolled a relatively small 
number of patients with NASH.  However, low enrollment was balanced by increased statistical precision 
obtained by recruiting 2:1 healthy subjects to patients with NASH.  Second, to define a homogenous 
population of healthy subjects, only subjects without insulin resistance and with normal liver enzymes 
were enrolled in an effort to exclude subjects with prevalent steatosis.  Exclusion of patients with 
probable steatosis was performed for two reasons: 1) since biopsies were not obtained as part of this study 
and the prevalence of undiagnosed NAFLD/NASH is very high in the overall population, differentiation 
of non-NAFLD healthy subjects with insulin resistance vs. prevalent simple steatosis or NASH was not 
possible, and 2) changes in transporter-mediated drug/metabolite disposition are only expected following 
onset of inflammation (i.e., NAS>3) when efflux transporter expression is up-regulated.
15,17
 
In conclusion, patients with NASH exhibited increased morphine glucuronide Cmax and AUC0-last, 
as well as fasting serum concentrations of total bile acids, glycocholate, and taurocholate compared to 
healthy volunteers.  These changes are consistent with NASH-associated alterations in expression of 
hepatic transport proteins reported previously (e.g., increased MRP3).  Increased Cmax and exposure to 
morphine glucuronide conjugates, as well as bile acids, positively correlated with biopsy-determined 
NASH severity.  Given the increasing incidence of NASH, changes in hepatic transport proteins 
contributing to altered disposition of drugs/metabolites and bile acids may have a major impact on drug 
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efficacy and/or toxicity.  Understanding the consequences of alterations in transporter-mediated 
disposition is paramount for new medications that will be administered to patients who may have 
underlying, undiagnosed liver disease.   
  
   
 
133 
 
Patients and Methods 
Patients 
Healthy subjects and patients with biopsy-confirmed NASH, between 18 and 65 years of age and 
of any race and ethnicity who reported drinking less than 20 g/day of alcohol, were enrolled in the study.  
General inclusion criteria for both groups were normal serum creatinine and total bilirubin levels; 
nonreactive HIV, hepatitis B antigen and hepatitis C antibody; no history of gastrointestinal surgery, 
autoimmune disease or other GI/liver disease.  Subjects were excluded if they were unable to pass a urine 
drug screen for opiates, marijuana and barbiturates; female subjects were excluded if they were, or were 
trying to become, pregnant.  Healthy volunteers were eligible if all of the following applied: ALP and 
ALT levels within normal limits; HOMA-IR score < 2.5; BMI ≤ 30 kg/m2; not taking any concomitant 
medications other than birth control or a standard multivitamin.  In selecting healthy subjects, effort was 
made to recruit a control cohort comparable to the NASH cohort with respect to age, sex, race, and 
ethnicity.  Patients with NASH were recruited from the University of North Carolina at Chapel Hill 
(UNC-CH) hepatology clinic and were eligible for enrollment if all of the following applied: biopsy 
confirmed non-cirrhotic NASH with non-alcoholic fatty liver disease activity score (NAS) >3 
41; BMI ≤ 
45 kg/m
2
; no treatment for type 2 diabetes other than metformin; no milk thistle products or high dose 
antioxidant treatment during the prior 30 days; absence of prior treatment with NASH-inducing drugs 
(i.e., tamoxifen, amiodarone, valproate, methotrexate).  Written informed consent was obtained from all 
subjects.  This study was approved by the UNC Biomedical Institutional Review Board and published in 
ClinicalTrials.gov (NCT01766960).  
 
Study Design 
 This single center, comparative cohort, proof-of-concept study evaluated morphine and morphine 
glucuronide pharmacokinetics in healthy subjects and patients with NASH.  Subjects and patients who 
met all inclusion/exclusion criteria fasted overnight prior to presenting to the Clinical and Translational 
Research Center at UNC-CH Hospitals.  Following admission, hip and waist circumferences were 
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measured, vital signs were assessed, and an i.v. catheter was placed in each arm delivering 50 mL/hr of 
either normal saline or lactated Ringer’s solution.  Patients ate a standardized breakfast sandwich 
containing 23.9 g of fat and finished within 30 min.  Two hours after completion of the meal, a 5 mg i.v. 
dose of morphine sulfate was administered as an infusion over 5 min.  Blood (5 mL) was collected in 
glass tubes pre-dose, end of infusion (0), and 5, 10, 15, 30, 45, 60, 90, 120, 180, 240, 300, 360, 420, and 
480 min after the end of the infusion; urine was collected at 4-hr intervals after the end of the infusion. 
Blood samples were allowed to clot for 30 to 60 min, and serum was separated, divided into aliquots and 
frozen. Serum and urine samples were stored at -80°C until analysis.  Following discontinuation of both 
i.v. lines, patients were administered a safety questionnaire and discharged to a waiting third party to be 
driven home.     
 
Sample Processing and Analysis 
Morphine serum and urine samples were analyzed in batches every three months according to a 
validated bioanalytical method (see supplementary materials).
42
  Briefly, aliquots (100 µL) of serum and 
urine samples were transferred to a 96-well plate insert; proteins were precipitated with 600 µL 
acetonitrile containing morphine-d3, morphine-3-glucuronide-d3 and morphine-6-glucuronide-d3 (100 
ng/mL) as internal standards (Lipomed, Cambridge, MA).  Samples were mixed by vortex for 2.5 min 
and centrifuged (3,000g for 20 min at 4° C).  Supernatant (500 μL) was transferred to a separate 96-well 
plate insert, dried under nitrogen, and 100 µL of 50:50 water:methanol were added to each insert.  
Calibration solutions and quality controls containing all three analytes (Lipomed) were prepared similarly 
using pooled naïve plasma or urine.   
Morphine and morphine glucuronide concentrations were measured by high resolution liquid 
chromatography coupled with an ABSciex 5600 TripleTOF mass spectrometer (LC-MS/MS) as described 
previously.
42
  For morphine analysis, the product of 286.14 with an exact m/z of 286.1200 was monitored.  
Morphine-3-glucuronide and morphine-6-glucuronide were monitored using an exact m/z of 462.1700.  
The deuterated internal standards for the glucuronides were monitored using an exact m/z of 465.1900.  
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Deuterated morphine was monitored at an exact m/z of 289.1600.  The two morphine glucuronides were 
separated chromatographically; insource fragmentation from morphine glucuronide to morphine was 
negligible. 
All 30 bile acid standards were obtained from Steraloids Inc. (Newport, RI), and stable isotope- 
labeled standards were obtained from C/D/N Isotopes Inc. (Quebec, Canada).  The sample preparation 
followed a published method with modifications.
30
  Briefly, 50 µL of serum or standard solution was 
spiked with 150 µL of internal standard (IS).  After centrifugation, the supernatant was transferred to a 
clean plate and evaporated to dryness.  The residue was reconstituted with 20 µL of acetonitrile and 20 
µL of water and filtered through a 0.45 µm membrane before injecting 5 µL into the UPLC-MS/MS 
(ACQUITY UPLC-Xevo TQ-S, Waters Corp., Milford, MA) to quantitate 30 bile acids in serum.  The 
optimized instrument settings are described in the supplementary materials.  The sum of all measured bile 
acids is reported as total bile acids.  
 
Mathematical Modeling and Simulation for Sample Size Calculation 
A previously published whole body physiologically-based pharmacokinetic (PBPK) model was 
used as a base model to describe the disposition of morphine and morphine glucuronide.
43
 The model was 
developed using Phoenix
®
 WinNonlin
®
 (v6.3; Certara, St. Louis, MO) and was parameterized with adult 
reference values.
43,44
 The kinetics of morphine in all the tissues was assumed to be described by a flow-
limited, well-mixed model; the distribution of morphine glucuronide was governed by hepatic MRP3-
mediated basolateral, and MRP2-mediated canalicular, efflux clearances (CLMRP3 and CLMRP2, 
respectively). Serum morphine-3- and -6-glucuronide were modeled as a single metabolite, morphine 
glucuronide. Morphine glucuronide metabolites were assumed to be eliminated by the kidney via 
glomerular filtration. Model optimization was guided by assessing the model output compared to data 
extracted from published clinical studies.
28,29,45-48
 The model was used to simulate altered disposition of 
morphine and metabolites in virtual patients. Patients with NASH were assumed to have a 3-fold higher 
morphine glucuronide CLMRP3 based on published MRP3 protein expression compared to healthy 
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patients.
15
 Simulations demonstrated a 36% increase in glucuronide Cmax (data not shown).
31
  The 
difference in mean Cmax (∆ Cmax) was selected as the primary endpoint.  Based on the modeling output and 
estimates of variability from two studies using similar analytical techniques
28,47
, the number of subjects 
recruited (14 healthy subjects, 7 NASH patients) was projected to provide sufficient power to reject the 
null hypothesis of no difference in Cmax between subject groups.   
 
Pharmacokinetic Data Analysis 
Morphine, morphine-3-glucuronide and morphine-6-glucuronide pharmacokinetics were 
evaluated using non-compartmental analysis (Phoenix
®
 WinNonlin
®
 v6.3).  Cmax, time to reach Cmax 
(Tmax), last measureable concentration (Clast), terminal volume of distribution (Vz, for morphine only) and 
terminal elimination rate constant (λz) were estimated from the serum concentration-time profile.  The 
area under the concentration-time curve (AUC) from time zero to the last measurable concentration 
(AUC0-last) was determined using a linear-up log-trapezoidal-down algorithm.  Total AUC (AUC0-∞) was 
calculated as the sum of AUC0-last and Clast/λz.  The terminal half-life (t1/2) was calculated as 0.693/λz.  
Total body clearance (CL) of morphine was calculated as the ratio of dose to AUC0-∞.  The total mass of 
morphine and morphine glucuronide excreted in urine over the 8-hr collection interval (Xurine) was 
calculated as the product of urine concentration and volume of urine collected.  Concentrations below the 
limit of quantification were excluded from the analysis. 
Statistical Analysis Strategy 
Morphine and morphine glucuronide pharmacokinetic metrics are presented as geometric means 
and 95% CIs with the exception of Tmax, which is presented as median and range.  Log transformed 
metrics were compared between groups using a two-tailed t-test of size  = 0.05; the Wilcoxon Mann-
Whitney test was used to detect cohort differences in median Tmax.  
Linear regression models were used to identify clinical predictors of morphine glucuronide 
AUC0-last and Cmax.  Candidate clinical predictors included age, BMI, body weight, waist and hip 
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circumference, waist-to-hip ratio, SCr, ALT, ALP, albumin, total bilirubin, NASH severity score,  fasting 
glucose, triglycerides, HDL and LDL cholesterol, insulin, and HOMA-IR.  Separate models for AUC0-last 
and Cmax were fit for each of these predictors.   Clinical variables with statistically significant predictive 
value were included in a multivariable regression model subject to backward elimination. The criterion 
for retention in the multivariable model was P ≤ 0.10.  NASH severity scores for healthy subjects were 
assumed to be zero.  All statistical computations for the primary analyses were performed using SAS 
software (v9.3; SAS Institute, Inc., Cary, NC).  Unless otherwise stated, data are presented as mean and 
standard deviation, and a two-tailed t-test was used to determine significant differences; P<0.05 was 
considered significant for all tests. 
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Study Highlights 
What is the current knowledge on the topic? 
Hepatic transport protein expression is altered in patients with NASH (e.g., MRP3 up-regulation), a 
prevalent form of liver disease associated with increased mortality.  However, functional changes in 
transporter-mediated drug disposition have not been evaluated in NASH. 
 
What question did the study address? 
Hepatically-derived morphine glucuronide and fasting bile acid serum concentrations were evaluated as a 
phenotypic probe of MRP3 in biopsy-confirmed NASH patients vs. healthy subjects. 
 
What this study adds to our knowledge? 
Morphine glucuronide systemic exposure and serum bile acid concentrations were significantly higher in 
NASH patients vs. healthy subjects.  NASH severity was significantly associated with morphine 
glucuronide and bile acid serum concentrations. 
 
How this might change clinical pharmacology and therapeutics? 
NASH patients may exhibit increased systemic exposure to MRP3 substrates (e.g., anionic 
drugs/metabolites, bile acids).  These changes may lead to increased systemic toxicities and decreased 
hepatic drug efficacy.  Understanding the consequences of altered transporter-mediated disposition and 
hepatic clearance is paramount for medications used in NASH patients.  This new knowledge may help 
guide drug/dose selection in NASH.   
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Table 4.1: Demographic Characteristics of Study Participants 
Parameter Healthy (n=14) NASH (n=7) 
Sex    
 Men 7 3 
 Women 7 4 
Ethnicity    
 Hispanic 1 1 
 Non-Hispanic 13 6 
Race    
 White 12 7 
 Black 2 0 
Age 
(years) 
 42 
(13) 
48 
(10) 
Body weight 
(kg) 
 76 
(14) 
93 * 
(17) 
Body mass index 
(kg/m
2
) 
 26 
(2.7) 
32 * 
(5.2) 
Waist circumference 
(cm) 
 90 
(7.8) 
118 * 
(23.5) 
Hip circumference 
(cm) 
 103 
(6.4) 
117 * 
(16.4) 
Waist-to-hip ratio All subjects 0.87 
(0.05) 
1.03 * 
(0.26) 
 Men 0.90 
(0.03) 
0.96 * 
(0.01) 
 Women 0.84 
(0.06) 
1.08 
(0.36) 
Data presented as mean (SD) 
* P<0.05 Student’s two-tailed t-test comparing healthy subjects to patients with NASH 
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Table 4.2: Serum chemistries, insulin resistance and liver biopsy grade. 
Clinical Parameter Healthy NASH 
Creatinine  
(mg/dL) 
0.82 
(0.14) 
0.80 
 (0.22) 
ALT  
(U/L) 
33 
 (11) 
75 * 
 (36) 
ALP  
(U/L) 
63 
 (13) 
80 * 
 (14) 
Albumin  
(g/dL) 
4.3 
 (0.3) 
4.5 
 (0.4) 
Total Bilirubin  
(mg/dL) 
0.64 
 (0.22) 
0.81 
 (0.29) 
Cholesterol 
(mg/dL) 
189 
 (40) 
190 
 (48) 
Triglycerides  
(mg/dL) 
91 
 (46) 
253 * 
 (98) 
HDL Cholesterol  
(mg/dL) 
68 
 (26) 
37 * 
 (5) 
LDL, calculated 
(mg/dL) 
102 
 (34) 
101 
 (47) 
Fasting glucose  
(mg/dL) 
86 
 (8) 
124 * 
 (16) 
Serum Insulin  
(μIU/mL) 
8 
 (3) 
40 * 
 (27) 
HOMA-IR 2 
 (1) 
12 * 
 (9) 
Total NAS Score 
N/A 
5 
 (4-6) 
Steatosis 
N/A 
2 
 (1-3) 
Hepatocyte Ballooning 
N/A 
2 
 (1-3) 
Inflammation 
N/A 
1 
 (0-2) 
Fibrosis 
N/A 
1 
 (0-3) 
NAS + Fibrosis 
N/A 
7 
 (4-8) 
Data presented as mean (SD); biopsy scoring presented as median (range) 
ALT; alanine aminotransferase 
ALP; alkaline phosphatase 
HDL; high-density lipoprotein cholesterol 
LDL; low-density lipoprotein cholesterol 
NAS: non-alcoholic fatty liver disease activity score 
HOMA-IR; homeostasis model for assessing insulin resistance 
N/A; not applicable 
* P<0.05 Student’s two-tailed t-test comparing healthy subjects to patients with NASH 
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Table 4.3: Pharmacokinetic parameters for morphine and morphine glucuronide determined by non-
compartmental analysis in healthy subjects and patients with NASH    
 
 Morphine Morphine Glucuronide 
Parameter Healthy NASH Healthy NASH 
Cmax  
(nM) 
296 
(237-369) 
332 
(200-551) 
225 
(194-261) 
343 * 
(284-413) 
Tmax
 a
  
(min) 
0  
(0-0) 
0  
(0-0) 
38  
(5-240) 
15  
(5-90) 
AUC0-last 
(µM*min) 
4.1 
(3.1-5.3) 
3.5 
(2.4-5.0) 
37.2 
(31.6-43.7) 
58.8 * 
(41.6-83.0) 
AUC0-∞ 
(µM*min) 
5.5 
(4.3-6.9) 
5.2 
(3.7-7.4) 
45.2 
(37.5-54.5) 
67.8 * 
(46.7-98.5) 
Vz  
(L) 
153 
(125-188) 
173 
(113-264) 
N/D N/D 
CL 
(L/min) 
1.2 
(1.0-1.5) 
1.3 
(0.9-1.8) 
N/D N/D 
Half-life  
(min) 
88 
(66-117) 
95 
(49-182) 
187 
(153-229) 
146 
(104-205) 
Xurine
b 
(µmole) 
0.89 
(0.73-1.16) 
0.64 
(0.52-0.78) 
5.38 
(4.52-7.01) 
6.23 
(3.89-9.59) 
 
Geometric mean (95% CI) 
 a 
Sum of molar concentrations of morphine-3- and morphine-6-glucuronide  
b 
Median (range)  
c
 Total mass excreted over 8-hr collection interval  
* P<0.05 Student’s two-tailed t-test of natural log transformed data comparing healthy subjects to patients 
with NASH 
N/D: not determined 
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Table 4.4: Clinical predictors of morphine glucuronide Cmax and AUC0-last. 
 
 Morphine Glucuronide
a
 
 Cmax AUC0-last 
Parameter β P-value β P-value 
NASH Severity Score
b
 18.51 
(4.72) 
0.001 
4.11 
(1.02) 
0.001 
Waist 1.96 
(0.87) 
0.036 
0.40 
(0.19) 
0.051 
Waist-to-Hip Ratio 157 
(110) 
0.170 
48.86 
(22.62) 
0.044 
ALP 3.14 
(1.07) 
0.008 
0.59 
(0.25) 
0.027 
Fasting Glucose 2.27 
(0.75) 
0.007 
0.45 
(0.17) 
0.017 
Triglycerides 0.42 
(0.17) 
0.019 
0.09 
(0.04) 
0.024 
HDL -1.75 
(0.62) 
0.011 
-0.20 
(0.16) 
0.216 
Insulin 2.05 
(0.78) 
0.017 
0.38 
(0.18) 
0.049 
HOMA-IR 6.20 
(2.35) 
0.016 
1.15 
(0.54) 
0.046 
 
Data are presented as the regression parameter estimate (β) (standard error [SE] of the parameter 
estimate). 
a
 Sum of molar concentrations of morphine-3- and morphine-6-glucuronide  
b
 Only NASH severity score remained statistically significant when all nine clinical predictors were 
included in a multivariable regression model subject to backward elimination 
ALP; alkaline phosphatase 
NAS+Fibrosis; sum of non-alcoholic fatty liver disease activity and fibrosis scores 
HOMA-IR; homeostasis model for assessing insulin resistance 
N/S; not statistically significant 
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Figure Legends: 
Figure 4.1: Serum morphine (circles, A), morphine-3-glucuronide (triangles, B), and morphine-6-
glucuronide (squares, B) concentration vs. time profiles in healthy subjects (blue) and patients with 
NASH (red).  Data are presented as geometric mean and 95% confidence intervals. 
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Figure 4.2: Fasting total bile acids, glycocholate and taurocholate serum concentrations in healthy 
subjects (black bars) and patients with NASH (grey bars). Data are presented as mean ± SE; * P<0.05. 
Results of univariate linear regression analysis of NASH severity (NAS+Fibrosis; sum of non-alcoholic 
fatty liver disease activity and fibrosis scores) with serum bile acid concentrations are included.  Data are 
presented as the regression parameter estimate (β) and SE of the parameter estimate. 
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Figure 4.3: Association of the NASH severity score (NAS+Fibrosis severity scores) with morphine 
glucuronide Cmax (A) and AUC0-last (B).  Values for patients with NASH (red triangles) and values for 
healthy subjects (blue circles) are shown with the linear regression and its 95% confidence limits (shaded 
area). The NASH severity score is the sum of the NAS and fibrosis biopsy scores; for healthy subjects, an 
imputed value of zero was assumed.   
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Supplement 
Supplementary Methods: Morphine Serum and Urine Sample Processing and Analysis  
Morphine and morphine glucuronide metabolites were analyzed using liquid chromatography coupled 
with tandem mass spectrometry (LC-MS/MS) as described previously.
1
  A solvent delivery system 
(Shimadzu, Columbia, MD) and a Leap HTC Pal thermostated autosampler (LEAP Technologies, 
Carrboro, NC) connected to an AB Sciex 5600 TripleTOF (Framingham, MA) were used for analysis.  
Analyte separation was accomplished using an Aquasil C18, 150- 2.1-mm column, with a 5-µm particle 
size (Keystone Scientific, now Thermo Fisher Scientific, Waltham, MA). Analysis required 5 µl of 
sample and a solvent flow of 0.4 ml/min.  The mass spectrometer was operated in positive ion time-of-
flight- (TOF)-high resolution mode.  Morphine 3-glucuronide and morphine 6-glucuronide were 
monitored using an exact m/z of 462.1700.  The internal standards for the glucuronides were monitored 
using an exact m/z of 465.1900.  Deuterated morphine was monitored at an exact m/z of 289.1600.  
However, interference precluded simple TOF monitoring of morphine.  Thus, the product of 286.14 with 
an exact mass of 286.1200 was monitored.  Calibration solutions (2.5-500 ng/mL and 25-5000 ng/mL for 
serum and urine, respectively) and quality controls (2.5, 8, 200 ng/mL and 25, 75, 250, 375, 1000, 4000 
ng/mL for serum and urine, respectively) containing all three analytes (Lipomed) were prepared similarly 
using pooled naïve plasma or urine.  Calibration curves were generated using peak area ratios of analyte 
to internal standard, samples were analyzed with matrix-matched standards and controls, care was taken 
to chromatographically separate the two morphine glucuronide metabolites, and there was negligible 
insource fragmentation from morphine glucuronide to morphine. 
 
Quantitative Bile Acid Sample Preparation and Analysis 
All 30 bile acid standards were obtained from Steraloids Inc. (Newport, RI), and stable isotope-labeled 
standards were obtained from C/D/N Isotopes Inc. (Quebec, Canada).  The sample preparation followed a 
published method with modifications.
2
 Briefly, 50 µL of serum or standard solution was spiked with 150 
µL of internal standards (50 nM d4-cholic acid, d4-ursodeoxycholic acid, and d4-lithocholic acids)  The 
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extraction of bile acids was conducted over 15 min at 1,500 rpm.  After centrifugation, the supernatant 
was transferred to a centrifuge tube for evaporation to dryness.  The residue was reconstituted in 20 µL of 
acetonitrile and 20 µL of water, and filtered through a 0.45 µm membrane before injection. The injection 
volume was 5 µL.  A UPLC-MS/MS system (ACQUITY UPLC-Xevo TQ-S, Waters Corp., Milford, 
MA) with VanGuard pre-column (2.1×5 mm ) and ACQUITY BEH C18 1.7 µM (2.1×100 mm) heated to 
45°C was used to quantitate 30 bile acids in the human serum. The aqueous phase, A, was 0.1% formic 
acid in LC-MS grade water.  The mobile phase, B, was 0.1% formic acid in LC-MS grade acetonitrile.  
The flow rate was 0.45 mL/min with the following mobile phase gradient: 0-1 min (5% B), 1-5 min (5-
25% B), 5-15.5 min (25-40% B), 15.5-17.5 min (40-95% B), 17.5-19 min (95% B), 19-19.5 min (95-5% 
B), 19.6-21 min (5% B). The mass spectrometer was operated in negative ion mode with a 1.2 kV 
capillary voltage. The source and desolvation gas temperature was 150 and 550 °C, respectively. The 
cone and collision energy for each bile acid used the optimized settings from QuanOptimize application 
manager (Waters Corp., Milford, MA).  The data were collected with multiple reaction monitoring 
(MRM).  Calibration solutions containing all 30 analytes were prepared at a series of concentrations of 1, 
2, 5, 10, 50, 100, 500, 1000, and 5000 nM in pooled naïve plasma depleted of bile acids using activated 
charcoal.  Bile acid concentrations in unknown samples were back-calculated from the generated 
calibrations curves of standards using the TargetLynx application manager (Waters Corp., Milford, MA). 
 
Supplementary Data: Adverse Effects 
 Four subjects experienced nausea and vomiting following morphine administration.  These 
subjects received one or two doses of ondansetron.  Ondansetron was chosen as the antiemetic because it 
does not affect the disposition of morphine or morphine glucuronide metabolites in humans.
3
  One healthy 
subject experienced prolonged nausea and intractable vomiting with ondansetron.  This subject was not 
included in the analysis due to non-protocol administration of metoclopramide and possibility of viral 
infection the day of the pharmacokinetic study.  No other adverse effects associated with morphine 
administration were noted. 
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Supplementary Figure 1: Study Subject Disposition 
 
 
 
 
 
 
 
 
 
    
 
 
 
  
41 Subjects 
Assessed for eligibility 
10 Patients with NASH Excluded: 
    4 chronic opiate use 
    3 GI surgery 
    1 excluded medication use 
    1 unexplained anemia 
    1 failure to follow-up 
10 Healthy Subjects Excluded: 
    3 abnormal serum chemistry 
    2 elevated HOMA-IR 
    1 GI surgery 
    1 recent participation in      
research trial 
    1 vasovagal reaction to blood 
draw 
    1 positive drug screen 
    1 failure to follow-up 
14 Healthy Subjects Enrolled and 
Completed 
7 Patients with NASH Enrolled and 
Completed 
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Chapter 5. Summary and Future Directions 
 
This dissertation research has focused on developing preclinical and clinical tools to assess the 
impact of liver pathology on transporter-mediated systemic and hepatic exposure to medications.  Despite 
a general understanding of the impact of alterations in transporter-mediated hepatic uptake of medications 
on systemic and hepatic exposure
1-3
, the importance of basolateral efflux transporters is underappreciated.  
For example, altered expression of hepatic transporters (e.g., OATPs, BSEP, MRP2, MRP3, or MRP4) 
may change both hepatic and systemic concentrations of a drug/metabolite substrate if the affected 
transport represents a primary clearance route into or from the liver.  Furthermore, the functional impact 
of altered hepatic transporter expression has not been investigated in many hepatic diseases such as 
NASH.  To address this knowledge gap, a translational approach was designed and conducted ranging 
from identification of altered hepatic transport in response to drug-induced liver pathology (i.e., PLD), to 
identification of hepatic transport proteins involved in the disposition of hepatically-derived active 
metabolites in vitro (i.e., enalaprilat), to developing in vivo methods to assess the impact of altered 
expression of basolateral efflux transporters secondary to liver disease (i.e., NASH).  This research 
focused primarily on four compounds and their metabolites: taurocholate, rosuvastatin, enalapril, and 
morphine. 
Taurocholate and rosuvastatin are model probe substrates for both hepatic uptake and canalicular 
efflux transporters.  Taurocholate is a metabolically stable bile acid that is transported efficiently into the 
hepatocyte via NTCP/Ntcp, and excreted into bile via BSEP/Bsep; rosuvastatin is taken up by 
OATPs/Oatps and reportedly Ntcp, and excreted into bile by MRP2/Mrp2 and BCRP/Bcrp
4-9
.  
Examination of these probe substrates in tandem allows simultaneous functional evaluation of the major 
basolateral uptake and canalicular efflux proteins.  Enalapril is a prodrug transformed in the liver by 
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carboxylesterases to the active moiety, enalaprilat.  Transformation removes the ethylester from enalapril, 
adding a negative charge, increasing the potency to inhibit angiotensin converting enzyme, and thereby 
lowering blood pressure and preventing cardiac remodeling and renal dysfunction
10
.  The presence of a 
diffusional barrier for enalapril and enalaprilat disposition helped lay the foundation for the identification 
of transporter-mediated hepatic disposition and clearance mechanisms of charged molecules
11-14
.  Rat 
Oatp1a1 and human OATP1B1 are responsible for the hepatic uptake of enalapril following oral 
absorption.  Once inside the hepatocyte, enalapril and hepatically-derived enalaprilat can be excreted into 
the bile via Mrp2
15
 or fluxed across the basolateral membrane.  Enalapril currently is being evaluated for 
its anti-fibrotic effect in patients with NASH
16
.  Thus, knowledge of the efflux transporters involved in 
enalaprilat hepatobiliary disposition may help to inform study design in patients with NASH, where 
transporter-mediated efflux may be altered.  The pharmacokinetics of hepatically-derived morphine 
glucuronides, MRP3 substrates
17,18
, were evaluated in patients with NASH compared to healthy controls 
to investigate the impact of the reported NASH-associated change in MRP3 expression.  Morphine has 
been reported to enter the hepatocyte via a combination of passive diffusion and active transport
19
 where 
it is metabolized almost exclusively to morphine-3- and -6-glucuronide by UGT2B7
20,21
. The glucuronide 
metabolites are transported predominantly across the hepatic basolateral membrane into the systemic 
circulation by MRP3
17,18
.  Given that Mrp3 protein expression positively correlated with the efflux of 
acetaminophen glucuronide
22
, and assuming that MRP3 represents the predominant excretion pathway of 
morphine glucuronides from the hepatocyte, systemic concentrations may be expected to increase in 
patients with NASH due to up-regulation of MRP3. 
Although this translational research project has answered many questions, additional studies are 
required to fully understand the impact of altered hepatic transport across a greater spectrum of liver 
pathologies.  An overview of the experimental findings and future directions for this work are discussed 
in the following section. 
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Identification of Hepatic Phospholipidosis Inducers in Sandwich-Cultured Rat Hepatocytes, a 
Physiologically Relevant Model, Reveals Altered Basolateral Uptake and Biliary Excretion of 
Anionic Probe Substrates (Chapter 2) 
Phospholipidosis (PLD) is a lysosomal storage disorder where phospholipids accumulate, 
resulting in concentric lamellar bodies within the lysosome.  Drug-induced PLD can occur in any tissue 
typically following administration of drugs with weakly basic and lipophilic structural moieties.  
Although PLD has not been linked directly to toxicity
23
, certain adverse or undesired effects (i.e. hepatic 
fibrosis, hERG channel inhibition and renal tubular toxicity) positively associate with known PLD 
inducers
24-28
.  These effects could be direct effects of the drugs within the affected organ or secondary to 
altered lysosomal function and cellular signaling cascades
27
.  The FDA sponsored a working group to 
further investigate the impact of PLD on organ function and draft a guidance for evaluating these issues in 
drug development.  As part of this ongoing work, model systems that are sensitive and selective for PLD, 
and capable of determining organ-specific involvement, are needed.  Therefore, the current work 
describes the development of a protocol in rat SCH to screen compounds for hepatic PLD liability.  The 
SCH model also enables the evaluation of transporter-mediated vectorial transport of probe substrates.  
The disposition of the probe substrates, taurocholate and rosuvastatin, was investigated in SCH cultured 
under normal conditions compared to hepatocytes pre-incubated with PLD-inducing drugs.  Importantly, 
the current work indicates that PLD results in altered OATP-mediated uptake and BSEP-mediated biliary 
excretion processes.   
Five prototypical PLD-inducing drugs were chosen for initial investigation: amiodarone, 
chloroquine, desipramine, azithromycin and gentamicin.  These drugs were selected because they exhibit 
varying potencies to induce hepatic PLD as well as distinct postulated induction mechanisms
29,30
.  
Gentamicin was included because it is only known to induce renal PLD at physiologically-relevant 
concentrations, thus acting as a negative control for hepatic PLD.  Although the number of drugs 
evaluated was relatively small, the sensitivity and specificity of the rat SCH model to detect drug-induced 
PLD was evaluated.  Lysosomal size was evaluated with LysoTracker Red and PLD was confirmed using 
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the gold-standard, transmission electron microscopy.  The presence of enlarged lysosomes visualized with 
LysoTracker Red positively correlated with induction of PLD, similar to previous reports
31,32
.  This 
finding suggested that LysoTracker Red localization may be used as an initial screening tool to quickly 
assess the PLD liability of a compound.  Although electron microscopy confirmation should be performed 
once a lead compound is identified, initially screening compounds with LysoTracker Red in SCH would 
increase throughput
31,32
. 
 The current work suggests that following PLD induction, the function of both basolateral and 
canalicular transport proteins is disturbed in rat hepatocytes.  Specifically, following PLD induction in rat 
SCH, altered vectorial transport of rosuvastatin and taurocholate suggested decreased function of Oatps 
and Bsep.  These findings should be confirmed initially in human SCH.  If translation to human SCH 
reveals similar results, evaluation of the disposition of OATP and/or BSEP probes in patients with 
biopsy-confirmed PLD should be compared to age-, sex-, and comorbid disease-matched patients without 
PLD.  Initially, the mechanism for altered transporter function could be investigated using 
immunohistochemistry.  The localization of transport proteins should be compared in hepatocytes treated 
with both negative control and PLD-inducing drugs.  The observed decrease in Oatp and Bsep function 
may be due to altered protein trafficking or decreased protein and/or mRNA expression.  In addition to 
these in vitro studies, confirmation of these changes in vivo would be informative.  Care should be taken 
prior to in vivo assessment of transporter probe substrate disposition to adequately characterize the hepatic 
induction of PLD and transporter localization in the liver.  Additionally, PLD itself can alter the 
lysosomal sequestration and systemic pharmacokinetics of drugs
30,33
, so careful consideration of the 
transporter probes should be undertaken to eliminate confounding variables due to lysosomal 
sequestration or vesicular elimination pathways
34,35
. 
This work demonstrates the utility of SCH as a viable screening tool for drug-induced PLD.  The 
studies performed include only two incubation time periods with PLD-inducing drugs: 10 minutes and 48 
hours.  Although these time points were ideal for evaluation of the impact of PLD on vectorial transport 
of taurocholate and rosuvastatin, a comprehensive evaluation of onset and offset would provide useful 
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information.  The time course for PLD induction could be established by utilizing serial LysoTracker Red 
imaging or measurement of a validated biomarker for PLD in the medium
36,37
.  For example, PLD-
inducing drugs could be added into the feeding medium of SCH for 48 hours and then removed from the 
feeding medium for another 48 hours.  Serial imaging of the cells or medium biomarker measurements 
every 24 hours in combination with a non-destructive measure of cell viability (e.g. LDH assay) may help 
provide a link between hepatic PLD and toxicity in addition to characterizing the drug-specific time 
course for lysosomal dysfunction onset and washout.  Intuitively, combination of these time course 
experiments with standard probe disposition studies (taurocholate and rosuvastatin) in vitro would aid in 
drug development by suggesting whether a change in hepatic transporter-mediated disposition is likely for 
a compound in development based on the proposed administration schedule in the clinic. 
 
Role of Multidrug Resistance-Associated Protein 4 (MRP4) in the Basolateral Efflux of Hepatically-
Derived Enalaprilat (Chapter 3) 
 The transport proteins responsible for the hepatic uptake and biliary excretion of enalapril and 
enalaprilat have been well described
11-14
, but the processes involved in basolateral efflux of enalaprilat 
have not been well-characterized.  Importantly, enalapril is hydrolyzed to the active form, enalaprilat, by 
hepatic carboxylesterases and must be fluxed across the basolateral membrane to exert its systemic 
pharmacologic effect
38
.  Additionally, enalapril is being investigated as an anti-fibrotic agent in patients 
with NASH
16
.  Enalaprilat is thought to exert its anti-fibrotic properties through direct inhibition of 
procollagen proteases, resulting in decreased collagen deposition and fibrosis formation
39
.  Therefore, 
understanding the mechanisms responsible for the hepatic disposition of enalaprilat following 
transformation may have important therapeutic implications in liver disease where alterations in efflux 
function may impact both systemic (blood pressure lowering effect) as well as hepatic (inhibition of 
intracellular proteases involved in fibrosis formation) efficacy.  Transport of enalapril and enalaprilat by 
MRP3 and MRP4 was assessed in membrane vesicles prepared from HEK293 cells transfected to express 
MRP3 or MRP4.  Enalaprilat was transported by MRP4; a modest trend towards inhibition of transport 
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was observed with rosuvastatin co-incubation whereas co-incubation with the potent pan-MRP inhibitor, 
MK-571, resulted in significant inhibition.  A novel protocol was developed to assess the basolateral 
efflux of enalaprilat from human SCH.  Since enalaprilat was not excreted into the bile compartment, 
enalaprilat intrinsic basolateral clearance (CLint, basolateral) was calculated as the product of the amount 
excreted across the basolateral membrane into the medium and the reciprocal of the hepatocyte cellular 
exposure over the incubation time.  Since the amount effluxed is corrected by the cellular exposure, 
inhibition of uptake by concomitantly administered MRP inhibitors does not affect the calculation of 
clearance.  Inhibition of enalaprilat CLint, basolateral in human SCH co-incubated with rosuvastatin or MK-
571 was similar to inhibition of enalaprilat MRP4-mediated transport observed in MRP4-expressing 
membrane vesicles co-incubated with rosuvastatin or MK-571; rosuvastatin resulted in a modest non-
significant inhibitory trend, whereas MK-571 resulted in statistically significant potent inhibition.  Further 
studies are required to determine whether changes in MRP4 hepatic expression or function, due to disease 
or drug-drug interactions, may alter both the hepatic and systemic exposure and pharmacodynamic effect 
of enalaprilat.  
Several strategies using the SCH model have been proposed to assess the basolateral efflux 
clearance of drugs and/or their derived metabolites
4,40-42
.  Unfortunately, when competing mechanisms for 
clearance exist (e.g. basolateral vs canalicular transport) simple calculation of clearance as mass excreted 
divided by cellular exposure is not accurate due to flux of the bile canalicular contents into the medium.  
Although mathematical modeling has been used successfully to deconvolute the net contributions of 
basolateral vs biliary efflux
40,42-44
, this approach requires a significant amount of data to optimize the 
model.  One distinct advantage with enalaprilat is the absence of biliary excretion in the model system, 
which allows for use of this abbreviated protocol to determine CLint, basolateral.  Further studies should be 
performed to test this abbreviated protocol for compounds that satisfy the following three criteria: 1) 
biliary excretion of the compound in SCH is negligible; 2) the compound, once effluxed from the 
hepatocyte, does not reenter the hepatocyte (i.e. the metabolite must be hepatically-derived); and 3) any 
further conversion from parent to metabolite after the loading phase is insignificant.  If these criteria are 
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not met, then mathematical modeling would be required to deconvolute the impact of basolateral vs 
biliary efflux and/or prolonged metabolite formation. 
Following oral administration in humans, enalapril is eliminated primarily as enalaprilat in the 
urine
38
, suggesting that hepatic basolateral efflux is the predominant elimination route from the liver with 
subsequent renal excretion.  Therefore, small changes in basolateral efflux function (e.g., MRP4) in vivo 
could have a large impact on hepatic, and potentially systemic, concentrations and exposure to this active 
metabolite
45,46
.  The current work demonstrates that MRP4 inhibition can decrease enalaprilat CLint, 
basolateral, but was not designed to provide evidence for the impact of increased protein function on hepatic 
exposure or systemic concentrations of enalaprilat.  Adaptation of previously developed protocols to 
induce localization of efflux proteins on the hepatic basolateral membrane may address this knowledge 
gap
47
.    Cyclic adenosine monophosphate (cAMP) is involved in signaling the translocation of many 
hepatic transport proteins including Ntcp, Mrp2, Mrp3, Bsep, and multidrug resistance protein (Mdr1 p-
glycoprotein and Mdr2 p-glycoprotein) from endosomal reserves to the basolateral or canalicular 
membrane
47-49
.  Assuming cAMP will result in increased trafficking of MRP4 to the basolateral plasma 
membrane, similar to other efflux transporters, treatment of human SCH with glucagon or a membrane 
permeable cAMP analogue, such as dibutyryl-adenosine 3’,5’-cyclic monophosphate, may result in 
increased MRP4 localization and function on the basolateral membrane
47
.  Utilizing this technique, 
functional MRP4 protein on the basolateral membrane could be acutely modulated.  Comparison of 
hepatocytes that exhibit increased functional MRP4 protein on the basolateral membrane with vehicle-
treated hepatocytes would allow both the cellular exposure and basolateral efflux to be calculated and 
compared.  With increased MRP4 protein expression on the basolateral membrane, it would be expected 
that hepatically-derived enalaprilat cellular exposure would decrease while the rate of basolateral efflux 
would increase if MRP4 was the predominant route of excretion from the hepatocyte.  Although in vitro 
studies should be performed first as a proof of concept, a clinical investigation of enalapril 
pharmacokinetic and pharmacodynamic response may provide valuable information regarding the impact 
of increased efflux protein expression in patients with inflammatory liver disease.  Two separate study 
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designs could be incorporated: 1) a simple pharmacokinetic/pharmacodynamic study comparing healthy 
subjects to patients with inflammatory liver disease (e.g. NASH), or 2) a large cohort epidemiologic study 
to compare the change in blood pressure in individuals with and without probable inflammatory liver 
disease treated with enalapril at hypertension diagnosis.  Notably, inclusion of two healthy subject control 
cohorts, normal weight and obese, may help to address the potential confounding factor of obesity in 
patients with NASH in these studies
50
.  Since MRP4 protein expression is up-regulated in inflammatory 
liver disease, these study designs would evaluate the impact of increased MRP4 expression on enalaprilat 
basolateral efflux and subsequent systemic pharmacodynamic effect.  Caution should be taken, however, 
noting that the results from these studies would reveal changes in the systemic disposition of enalaprilat, 
but not necessarily hepatic concentrations or effect.  Assuming the target for the anti-fibrotic effect of 
enalaprilat is in the hepatocyte, a combination of in vitro and in vivo studies, including modeling and 
simulation, would provide solid evidence to support or refute the hypothesis that increased MRP4-
mediated basolateral efflux will decrease hepatic exposure and pharmacodynamic effect of enalaprilat. 
    
Altered Morphine-Glucuronides Disposition in Patients with Non-Alcoholic Steatohepatitis 
(Chapter 4) 
Probe substrates to assess the clinical impact of hepatic transporter function in response to genetic 
variation or drug-drug interactions have been investigated previously for basolateral uptake and 
canalicular efflux transporters 
51-54
.  This work focused primarily on the impact of altered function of 
basolateral efflux transporters on the systemic disposition of a probe substrate.  Until recently, the 
importance of basolateral efflux in the hepatic and systemic disposition of drugs and hepatically-derived 
metabolites was underappreciated
40,43
.  The objective of using morphine glucuronides as a probe for 
MRP3 function was to assess whether the known increase in MRP3 protein expression in patients with 
NASH leads to an increase in function.  Utilizing mathematical modeling and simulation informed by 
protein expression data from human liver biopsies
55
, a comparative cohort study was designed and 
conducted to compare the systemic disposition of morphine glucuronides in healthy controls compared to 
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patients with NASH.  Consistent with increased MRP3 function, the presence of NASH led to a 
statistically significant increase in both maximum serum concentration (Cmax) and exposure (AUC0-last) of 
morphine glucuronides in patients with NASH compared to healthy controls.  This finding confirmed the 
important role of MRP3 in the systemic and hepatic disposition of morphine glucuronides, but future 
studies are needed to determine the implications for safety and efficacy of other drugs used in patients 
with NASH.  
 Morphine and its hepatically-derived glucuronide metabolites were selected as a phenotypic 
probe of MRP3 function in patients with NASH for several reasons: 1) morphine enters the hepatocyte via 
a combination of passive diffusion and active transport and should be unaffected by changes in uptake 
transporters known to be altered in NASH
56
, 2) hepatic expression of UGT2B7, which metabolizes 
morphine to morphine-3- and -6-glucuronide, is not altered in NASH
2,3,57,58
, and 3) MRP3 appears to be 
the only protein that transports the hepatically-derived morphine glucuronides into the blood
17,18
.  
Therefore, since expression of Mrp3 protein appears to positively correlate with efflux clearance of 
glucuronide conjugates, and decreased function polymorphisms in UGT2B7 appear to have minimal 
impact on systemic glucuronide concentrations
22,59
, systemic concentrations of morphine glucuronides 
may increase due to the increased MRP3 protein expression in patients with NASH compared to healthy 
subjects; the pharmacokinetics of parent morphine should be unaffected due to its ability to passively 
cross membrane barriers.   
 A physiologically-based pharmacokinetic model was developed to estimate the expected change 
in systemic morphine glucuronides pharmacokinetics in healthy subjects compared to patients with 
NASH.  Using a previously published model as the starting point, the model was optimized using data 
extracted from the literature
60-66
.  Morphine was assumed to exhibit flow-limited distribution to all tissues.  
The sum of both morphine glucuronides (morphine-6-glucuronide and morphine-3-glucuronide, hereafter 
referred to as morphine glucuronide) was assumed to be limited by a diffusional barrier in the liver 
compartment described by biliary and basolateral clearance parameters (CLMRP2 and CLMRP3, 
respectively). For simulation purposes, CLMRP3 was assumed to be increased by 3-fold in NASH patients 
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based on published protein expression data
55
.  These simulations indicated a 36% increase in morphine 
glucuronide Cmax in patients with NASH compared to healthy controls; no difference in morphine 
glucuronide AUC0-∞ was expected; a corresponding 56% decrease in hepatic exposure was predicted.  
Therefore, morphine glucuronide Cmax was chosen as the primary endpoint for the study and the sample 
size was estimated.  This methodology of developing an a priori model to inform study design, expected 
outcomes, primary endpoint selection, and sample size estimation highlights the utility of mathematical 
modeling and simulation to provide rational study design in drug development.  Additionally, a priori 
modeling and simulation revealed that in tandem with increased morphine glucuronide systemic 
concentrations, a concurrent decrease in hepatic concentrations and exposure would be expected. This 
approach would be particularly useful in early phase trials (Phase I and II) where in vitro data and disease 
state models could be leveraged to help avoid futile trial designs.   
 The experimental paradigm followed in this dissertation research could be applied to additional 
substrates with unique transporter-mediated clearance pathways and pharmacodynamic properties to 
better characterize the impact of altered transporter expression in NASH.  Substrates should be selected to 
evaluate basolateral and canalicular transporters other than MRP3 that allow either direct or indirect 
measurement of hepatic concentration or exposure.  Contrary to the current study with morphine, radio-
ligand labeled probes or magnetic resonance imaging probes would allow direct measurement of systemic 
and hepatic exposure in healthy subjects and patients with NASH
51,67-70
.   Where imaging agents are not 
available to assess transporter function, an indirect pharmacodynamic measure could be evaluated as a 
surrogate for hepatic concentrations.  Utilizing a surrogate pharmacodynamic marker for intrahepatic 
cellular concentrations would require three assumptions: 1) the pharmacodynamic effect of the chosen 
drug would be directly related to intracellular concentration, 2) a biomarker for the intracellular drug 
effect must be present in the systemic circulation, and 3) the disease process being investigated does not 
directly affect the pharmacodynamic effect of the chosen drug.  If these three assumptions are reasonable 
for the chosen drug, comparison of the systemic pharmacokinetics of both the drug and the circulating 
biomarker of intracellular concentration will provide a relative understanding of systemic and hepatic 
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disposition of the drug in diseased compared to healthy individuals.  Additionally, if the relationship 
between intracellular concentration and pharmacodynamic inhibition/activation profile of the target is 
well described, a mathematical modeling and simulation approach would provide additional information 
regarding expected hepatic intracellular concentrations.  These studies could provide further insight into 
the impact of NASH on hepatic transporter-mediated drug disposition and increase our understanding of 
how altered hepatic pharmacokinetics influences the pharmacodynamics of medications used in this 
population.  Another potential approach would be measurement of naturally occurring endogenous 
compounds that may be modulated by changes in hepatic and/or intestinal transport processes associated 
with NASH.  This metabolomics approach could provide additional insight into the interplay between 
altered hepatic homeostasis of endogenous molecules and vectorial transport of exogenous drugs.  Taken 
together, these datasets may increase our understanding of how the hepatic manifestations of NASH 
impact both transporter-mediated drug disposition and important inflammatory or disease-related 
signaling cascades.   
 The objective of this dissertation project was to develop preclinical and clinical tools to assess the 
impact of liver pathology on transport protein-mediated vectorial transport.  Decreased uptake or 
increased basolateral efflux may alter the systemic and hepatic exposure to drugs/metabolites and, in turn, 
change the pharmacodynamic profile of medications.  This research has made multiple contributions to 
the field of hepatic transport, which will enhance our ability to investigate future compounds in greater 
detail with improved efficiency.  These novel approaches can be employed to help predict altered drug 
disposition due to patient-specific factors such as disease, and enhance the design of safe and efficacious 
medications. 
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Figure 2.1 Mean Toxicity SEM
Treatment 1 2 3 4 5
AMD 10 µM 38.7 10.0 0.0 -4.0 -0.4 8.9 7.8
AMD 50 µM 56.7 61.2 27.0 27.8 - 43.2 9.2
CHQ 1 µM 26.4 65.0 0.0 4.8 -13.7 16.5 13.7
CHQ 10 µM 0.0 21.7 89.5 28.9 3.8 28.8 16.1
DES 1 µM -4.8 -2.5 13.8 - - 2.2 5.9
DES 10 µM 9.6 10.3 19.3 - - 13.1 3.1
DES 50 µM - - 72.3 33.6 58.7 54.9 11.3
AZI 1 µM - - 28.7 13.9 16.0 19.5 4.6
AZI 10 µM - - 48.0 23.3 29.0 33.5 7.5
AZI 50 µM - - 62.4 36.3 29.8 42.8 10.0
GTM 1 mM 52.2 46.7 1.0 5.2 - 26.3 13.5
Replicate
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Figure 2.4
Mean SEM Mean SEM
1 2 3 1 2 3
Control 31.4 28.0 27.1 28.8 1.3 4.8 5.9 3.5 4.7 0.7
AMD 50 µM 31.9 24.7 26.2 27.6 2.2 5.3 5.7 3.8 4.9 0.6
CHQ 10 µM 37.0 32.3 26.2 31.8 3.1 4.3 5.2 3.4 4.3 0.5
DES 50 µM 31.5 28.4 23.8 27.9 2.3 4.1 5.3 3.6 4.3 0.5
AZI 50 µM 29.8 23.5 22.1 25.2 2.4 4.0 4.5 3.8 4.1 0.2
GTM 1 mM 43.2 34.9 26.5 34.9 4.8 4.5 6.7 3.5 4.9 0.9
Mean SEM Mean SEM
1 2 3 1 2 3
Control 197.8 205.6 138.2 180.5 21.3 92.4 120.2 60.9 91.2 17.1
AMD 50 µM 173.8 173.8 135.1 160.9 12.9 84.1 103.4 57.6 81.7 13.3
CHQ 10 µM 194.6 196.5 153.3 181.5 14.1 88.3 113.4 51.7 84.5 17.9
DES 50 µM 135.3 144.6 108.0 129.3 11.0 60.5 77.4 42.6 60.2 10.1
AZI 50 µM 148.6 153.5 112.2 138.1 13.0 69.8 84.5 45.2 66.5 11.5
GTM 1 mM 218.9 235.7 152.2 202.3 25.5 116.3 141.4 66.3 108.0 22.1
[
3
H] Taurocholate Accumulation
Cells + Bile Cells
[
3
H] Rosuvastatin Accumulation
Replicate Replicate
Replicate Replicate
Cells + Bile Cells
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Figure 2.5
Mean SEM Mean SEM
1 2 3 4 5 6 7 1 2 3 4 5 6 7
Control 47.3 34.2 27.9 43.3 24.2 67.6 74.1 45.5 7.3 7.8 5.0 2.5 3.8 2.3 7.0 9.6 5.4 1.1
AMD 10 µM - - - 19.9 12.9 33.4 55.4 30.4 9.4 - - - 2.4 1.4 4.5 8.1 4.1 1.5
AMD 50 µM - - - - 2.5 8.2 12.0 7.6 2.8 - - - - 1.3 3.4 5.6 3.4 1.2
CHQ 1 µM - - - - 15.2 57.3 43.6 38.7 12.4 - - - - 1.6 7.3 7.5 5.5 1.9
CHQ 10 µM - - - - 7.4 21.7 16.1 15.1 4.2 - - - - 2.3 4.0 5.0 3.8 0.8
DES 1 µM 59.9 30.3 24.1 - - - - 38.1 11.0 7.5 5.3 4.0 - - - - 5.6 1.0
DES 10 µM 31.0 23.3 19.9 - - - - 24.7 3.3 4.2 3.6 1.9 - - - - 3.3 0.7
DES 50 µM 11.7 9.3 7.8 - - - - 9.6 1.1 4.3 3.1 3.4 - - - - 3.6 0.3
AZI 1 µM 42.8 10.0 21.5 - - - - 24.8 9.6 5.1 4.6 3.6 - - - - 4.4 0.4
AZI 10 µM 20.3 8.8 11.2 - - - - 13.4 3.5 3.8 3.1 3.1 - - - - 3.3 0.2
AZI 50 µM 10.3 7.0 8.9 - - - - 8.7 1.0 6.9 6.1 3.7 - - - - 5.6 0.9
GTM 1 mM - - - 47.6 - 62.0 65.4 58.3 5.4 - - - 4.5 - 7.9 9.5 7.3 1.5
Mean SEM Mean SEM
1 2 3 4 5 6 7 1 2 3 4 5 6 7
Control 243.8 182.4 221.3 88.8 94.6 234.1 142.2 172.5 24.6 94.8 86.1 58.3 33.3 45.7 123.0 75.0 73.7 11.6
AMD 10 µM - - - - 54.4 113.7 82.4 83.5 17.1 - - - - 16.8 40.4 37.2 31.5 7.4
AMD 50 µM - - - - 9.8 27.4 14.8 17.3 5.2 - - - - 5.9 8.6 8.6 7.7 0.9
CHQ 1 µM - - - - 78.1 192.8 108.5 126.5 34.3 - - - - 30.0 102.0 53.5 61.8 21.2
CHQ 10 µM - - - 34.4 45.2 93.4 54.6 56.9 12.8 - - - 7.3 14.2 35.9 31.9 22.3 6.9
DES 1 µM 212.8 142.3 181.5 - - - - 178.9 20.4 107.5 92.7 84.0 - - - - 94.7 6.9
DES 10 µM 190.1 130.7 142.8 - - - - 154.5 18.1 72.6 66.5 62.9 - - - - 67.3 2.8
DES 50 µM 40.3 33.0 21.8 - - - - 31.7 5.4 24.3 19.1 12.6 - - - - 18.7 3.4
AZI 1 µM 181.6 146.1 136.6 - - - - 154.8 13.7 64.4 66.2 56.1 - - - - 62.3 3.1
AZI 10 µM 86.4 64.6 72.8 - - - - 74.6 6.4 25.5 27.1 24.6 - - - - 25.7 0.8
AZI 50 µM 55.1 44.3 48.1 - - - - 49.2 3.2 33.1 22.7 17.8 - - - - 24.5 4.5
GTM 1 mM - - - 111.3 - 221.6 151.4 161.4 32.2 - - - 44.2 - 129.2 77.5 83.6 24.7
ReplicateReplicate
Cells
[
3
H] Taurocholate Accumulation
Cells + Bile
Cells + Bile
[
3
H] Rosuvastatin Accumulation
Cells
Replicate Replicate
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Figure 3.2
Replicate MOCK MRP3 MOCK MRP4
1 11.6 19.4 15.2 15.2
2 75.2 114.1 252.1 89.5
3 23.1 58.7 140.8 251.5
4 - - 75.1 0.0
Mean 36.6 64.1 120.8 89.0
SEM 19.6 27.5 50.7 57.6
Replicate MOCK MRP3 MOCK MRP4
1 21.9 11.5 3.9 17.0
2 13.7 173.0 223.5 703.8
3 169.0 5.3 72.0 388.3
4 - - 214.7 511.3
Mean 68.2 63.3 128.5 405.1
SEM 50.5 54.9 54.1 144.7
ATP-Dependent Uptake (pmol/mg protein)
Enalapril
MRP3 MRP4
ATP-Dependent Uptake (pmol/mg protein)
Enalaprilat
MRP3 MRP4
Figure 3.3
Mean SEM
1 2 3
Control 100 100 100 100
+50 µM MK-571 52.3 0 0 17.4 17.4
ATP-Dependent Uptake (% Control)
Replicate
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Figure 3.4
Mean SEM Mean SEM
1 2 3 1 2 3
[
3
H] Taurocholate 98.0 103.8 149.0 116.9 16.1 19.0 28.7 14.0 20.6 4.3
[
3
H] Rosuvastatin 49.0 74.0 87.0 70.0 11.2 32.0 39.0 57.0 42.7 7.4
Enalapril 1.3 1.7 - 1.5 0.2 (SD) 1.0 1.3 - 1.1 0.1 (SD)
Enalaprilat 5.0 9.6 - 7.3 2.3 (SD) 5.8 9.3 - 7.5 1.8 (SD)
Replicate Replicate
Accumulation (pmol/mg protein)
Cells + Bile Cells
Figure 3.5
Mean SEM
1 2 3
Control 100 100 100 100
+50 µM MK-571 16.9 30.6 51.1 32.9 9.9
Replicate
CLint,basolateral (% Control)
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Figure 4.1
Time Mean (nM) Upper 95% CI Lower 95% CI Mean (nM) Upper 95% CI Lower 95% CI
0 295.6 396.4 239.6 331.9 524.2 217.0
5 89.8 112.1 76.9 73.7 112.8 47.0
10 53.0 68.7 44.8 42.4 54.8 33.1
15 38.1 52.1 31.9 33.8 40.2 28.4
30 27.6 36.7 22.7 23.0 27.4 19.4
45 22.7 29.9 18.7 19.0 29.8 11.8
60 18.6 24.1 15.7 15.7 20.7 11.7
90 16.5 21.3 13.5 15.5 20.2 11.7
120 13.3 16.9 10.9 11.3 14.5 8.7
180 11.4 13.5 9.6
240
300
360
420
480
Time Mean (nM) Upper 95% CI Lower 95% CI Mean (nM) Upper 95% CI Lower 95% CI
0 16.9 33.3 8.1
5 89.4 118.1 74.0 7.3 35.9 -20.7
10 141.6 193.4 117.4 9.7 12.0 8.1
15 133.6 187.1 108.9 12.5 15.4 10.8
30 140.5 180.1 118.2 18.4 22.7 15.8
45 138.5 191.3 114.5 19.3 24.3 16.6
60 129.4 180.7 99.9 18.5 21.7 16.4
90 107.2 146.1 88.7 16.7 22.4 13.6
120 85.6 118.1 70.5 11.6 14.6 9.9
180 70.2 104.3 56.2 11.3 13.7 9.7
240 57.7 80.8 44.6
300 42.2 60.1 35.9
360 35.8 46.2 30.7
420 34.4 44.3 29.4
480 34.1 48.0 27.5
Time Mean (nM) Upper 95% CI Lower 95% CI Mean (nM) Upper 95% CI Lower 95% CI
0 21.3 65.3 -0.3
5 142.3 333.1 47.9 14.1 27.6 2.0
10 161.6 271.0 96.3 15.7 23.5 9.7
15 243.5 293.2 202.0 17.5 25.9 12.5
30 177.6 225.8 140.0 19.3 28.9 13.1
45 179.5 257.5 121.6 19.9 31.8 12.2
60 152.3 172.8 134.4 17.7 23.5 13.3
90 200.7 324.5 124.6 23.0 33.3 16.4
120 155.0 267.8 88.6 19.1 30.4 11.9
180 135.4 206.1 86.8 16.7 21.5 12.8
240 100.1 174.7 57.8 10.5 18.3 4.8
300 75.3 132.7 42.0
360 59.2 92.8 37.7
420 51.1 72.5 35.5
480 31.1 64.8 16.3
M Healthy M NASH
M3G Healthy
M6G NASHM3G NASH
M6G Healthy
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3
 
 
Figure 4.1
Time/Subject 1 2 3 4 5 6 7 8 9 10 11 12 13 14
0 242.6 357.3 219.7 364.5 389.0 210.6 385.6 209.5 236.7 177.3 654.0 213.9 283.2 508.8
5 79.7 57.7 138.8 91.1 110.0 94.1 46.7 70.5 69.8 94.3 129.8 145.2 119.5 75.7
10 36.1 40.9 60.3 47.3 77.1 69.3 43.3 23.0 37.4 75.7 93.3 81.0 65.5 44.4
15 31.8 20.4 56.8 19.2 71.8 47.3 34.5 15.3 31.5 57.5 59.9 59.9 43.8 38.2
30 24.5 20.1 27.6 22.1 59.9 36.1 27.9 11.6 21.6 28.1 48.6 26.6 26.8 34.2
45 22.3 11.6 25.3 27.1 45.9 38.7 21.5 13.6 16.6 22.0 34.9 20.9 16.4 23.3
60 14.0 8.4 17.5 14.7 28.2 27.1 17.9 9.9 17.7 25.5 29.9 15.8 22.2 29.6
90 20.5 13.4 13.4 26.1 21.1 14.1 12.1 17.6 30.8 14.0 10.1 15.4
120 9.8 19.7 17.7 8.8 13.5 10.7 20.4 10.5 12.9 14.5
180 11.5 11.2 9.6 9.7 15.8 10.7 12.5
240 10.4 10.3 11.5
300 11.4 10.6
360 8.3
420
480
Time/Subject 1 2 3 4 5 6 7 8 9 10 11 12 13 14
0 48.3 8.8 16.1 16.9 9.4 16.1 9.5 40.4
5 58.0 104.0 56.6 149.1 124.2 70.7 55.9 86.0 52.6 90.1 84.1 145.5 97.9 170.0
10 54.4 207.1 170.8 207.8 286.0 114.7 116.5 109.9 71.0 208.2 115.5 224.4 172.1 117.2
15 101.1 150.7 223.2 71.5 221.0 138.1 197.4 102.7 57.8 288.2 73.5 188.8 118.5 139.9
30 132.7 221.4 130.5 164.9 260.0 104.5 119.1 160.2 77.1 208.5 106.4 179.0 82.3 141.8
45 92.0 162.0 244.9 203.0 200.2 202.8 95.0 250.3 55.1 223.2 80.9 116.3 105.1 109.7
60 106.5 140.2 151.9 110.9 195.5 99.3 87.7 150.3 75.2 357.6 99.2 139.7 137.6 112.2
90 71.3 119.0 178.6 160.4 181.2 57.7 84.6 107.9 59.0 202.6 129.3 138.8 53.3 100.1
120 43.2 108.7 47.5 85.2 182.2 65.6 36.0 85.3 73.9 154.7 107.1 105.9 112.2 112.6
180 50.2 76.7 31.4 138.0 107.5 51.5 28.4 61.6 39.1 164.5 101.5 118.2 94.9 59.4
240 36.7 93.2 58.1 70.0 44.0 46.8 35.5 53.2 156.4 54.6 41.2 77.8 52.0 58.4
300 13.3 61.3 43.6 78.2 55.3 42.5 11.2 49.5 66.9 83.6 47.7 44.7 29.9 44.4
360 19.1 56.7 42.9 42.5 39.0 33.9 13.8 31.4 50.0 56.1 49.9 30.4 24.5 47.8
420 39.6 46.2 47.7 36.4 44.0 25.4 12.5 33.3 28.4 59.6 27.4 23.5 37.5 54.7
480 33.0 72.4 28.2 33.4 24.9 9.7 27.6 33.0 68.5 43.3 32.3 43.3 41.3
Time/Subject 1 2 3 4 5 6 7 8 9 10 11 12 13 14
0
5 5.4 9.8
10 6.4 13.8 6.7 8.6 9.8 8.2 9.7 9.1 12.3 16.9 8.3 10.7
15 14.7 12.8 10.8 7.6 15.4 17.4 18.7 8.7 10.7 16.3 8.1 18.2 9.0 15.0
30 27.8 27.3 18.4 13.2 24.3 25.3 19.7 16.3 13.2 14.3 16.1 26.2 9.4 18.3
45 21.4 14.0 20.8 24.5 26.9 33.5 21.0 29.0 7.2 19.9 17.0 20.6 14.5 15.9
60 21.6 14.0 17.6 13.0 25.1 16.6 20.5 15.3 14.4 28.4 18.6 24.9 17.0 19.4
90 21.2 9.9 16.1 16.0 28.2 17.4 14.4 13.7 9.8 16.1 36.3 20.5 8.5 24.0
120 10.9 9.6 7.5 10.5 20.3 15.5 5.6 8.9 15.8 14.6 13.7 16.9 11.0 10.5
180 12.2 6.7 11.4 16.1 10.3 8.9 11.3 13.4 15.4 11.1
240 6.9 5.7 8.5 14.4 14.1 6.4
300 8.8 6.1 16.6
360
420
480
M3G Healthy (nM)
M6G Healthy (nM)
M Healthy (nM)
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Figure 4.1
Time/Subject 1 2 3 4 5 6 7
0 365.6 609.8 472.4 488.5 264.8 274.4 118.6
5 56.6 77.4 54.0 146.5 85.5 98.5 40.6
10 33.3 46.3 44.2 56.8 53.1 50.5 23.6
15 29.4 40.0 26.1 39.2 27.7 41.4 36.4
30 23.7 26.4 18.7 25.7 22.8 29.3 17.0
45 12.3 24.0 17.5 37.0 11.6 29.5 13.7
60 19.2 13.5 17.7 13.8 22.3 10.7
90 20.5 12.7 14.1 14.9 21.5 11.9
120 9.7 8.6 11.5 11.5 16.8 11.4
180 10.2 15.1
240 9.7
300
360
420
480
Time/Subject 1 2 3 4 5 6 7
0 7.6 10.7 15.2 35.0 41.2 107.3 10.4
5 84.7 44.6 104.3 224.3 324.3 461.6 89.4
10 101.9 60.7 173.8 208.2 351.1 231.9 158.0
15 272.6 182.5 328.5 280.1 211.6 221.0 237.0
30 176.7 115.9 142.5 205.0 244.3 229.7 165.9
45 153.8 127.9 158.0 326.3 149.3 257.9 153.7
60 119.9 172.1 161.3 179.9 150.2 156.7 135.2
90 76.2 294.7 179.2 158.0 261.9 409.6 192.0
120 68.0 78.0 179.0 136.5 236.7 346.7 202.3
180 75.4 99.2 142.2 183.0 103.6 266.5 154.9
240 52.9 52.0 121.8 158.8 182.0 192.2 54.1
300 46.2 34.2 100.4 85.5 146.9 153.4 44.8
360 33.6 33.2 87.7 86.1 108.5 42.9 64.8
420 34.2 34.2 64.5 57.7 91.2 43.8 52.2
480 19.6 6.3 69.8 51.5 73.9 42.7 19.8
Time/Subject 1 2 3 4 5 6 7
0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
5 0.0 0.0 9.0 0.0 16.7 18.8 0.0
10 0.0 0.0 13.7 17.7 22.3 20.8 8.6
15 13.2 6.3 23.5 28.3 22.0 21.1 19.6
30 17.7 8.1 14.0 30.4 31.5 21.1 24.4
45 10.5 12.8 15.1 40.3 23.2 30.1 22.0
60 13.9 14.2 14.8 25.7 25.6 13.9 20.6
90 9.7 31.4 18.0 24.2 31.9 36.0 22.4
120 7.2 17.5 18.6 29.7 31.0 23.0
180 10.4 14.2 19.3 20.8 21.1 17.0
240 5.2 9.9 19.3 14.4 8.9
300 5.4 8.8 13.0
360 7.4
420 5.9483823
480
M NASH (nM)
M3G NASH (nM)
M6G NASH (nM)
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Figure 4.2
Subject Total Bile Acids (µM) Glycocholate (µM) Taurocholate (µM)
1 0.90 0.04 0.01
2 1.82 0.08 0.01
3 1.60 0.03 0.00
4 0.83 0.03 0.01
5 1.85 0.18 0.03
6 1.61 0.08 0.01
7 1.94 0.23 0.05
8 3.05 0.12 0.06
9 1.89 0.05 0.01
10 1.19 0.04 0.02
11 0.90 0.03 0.02
12 1.45 0.11 0.07
13 1.00 0.01 0.00
14 1.23 0.05 0.01
Mean 1.52 0.08 0.02
SD 0.59 0.06 0.02
1 3.26 0.08 0.03
2 1.03 0.05 0.02
3 10.15 0.63 0.26
4 6.30 0.45 0.52
5 1.18 0.05 0.01
6 2.38 0.21 0.06
7 1.96 0.24 0.02
Mean 3.75 0.24 0.13
SD 3.34 0.22 0.19
NASH
Healthy
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Figure 4.3
NAS+Fibrosis Predicted MG Cmax Predicted MG Cmax Upper Limit Predicted MG Cmax Lower Limit Predicted MG AUC Predicted MG AUC Upper Limit Predicted MG AUC Lower Limit
0 233.3 269.2 197.4 38.0 45.7 30.3
0 233.3 269.2 197.4 38.0 45.7 30.3
0 233.3 269.2 197.4 38.0 45.7 30.3
0 233.3 269.2 197.4 38.0 45.7 30.3
0 233.3 269.2 197.4 38.0 45.7 30.3
0 233.3 269.2 197.4 38.0 45.7 30.3
0 233.3 269.2 197.4 38.0 45.7 30.3
0 233.3 269.2 197.4 38.0 45.7 30.3
0 233.3 269.2 197.4 38.0 45.7 30.3
0 233.3 269.2 197.4 38.0 45.7 30.3
0 233.3 269.2 197.4 38.0 45.7 30.3
0 233.3 269.2 197.4 38.0 45.7 30.3
0 233.3 269.2 197.4 38.0 45.7 30.3
0 233.3 269.2 197.4 38.0 45.7 30.3
4 307.3 342.7 271.9 54.5 62.1 46.9
5 325.8 367.4 284.2 58.6 67.5 49.6
5 325.8 367.4 284.2 58.6 67.5 49.6
7 362.8 420.1 305.6 66.8 79.1 54.5
7 362.8 420.1 305.6 66.8 79.1 54.5
7 362.8 420.1 305.6 66.8 79.1 54.5
8 381.3 447.2 315.4 70.9 85.1 56.7
Maximum Concentration (Cmax; nM) Area Under the Concentration-Time Curve (AUC; µM*min)
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